<?xml version="1.0" ?><!DOCTYPE gene_cancer_corpus [
	<!ELEMENT gene_cancer_corpus (annotation_unit+)>	
	<!-- The `annotation_unit' element contains 1) an annotation unit as presented to the anotators and 2) the annotations made by the annotators.-->
	<!-- The elements `sentence', `gene', `expression_change_keyword_1', `expression_change_keyword_2' and `cancer_term' together represent an annotation unit as presented to the annotators.-->
	<!-- The `annotation' element contains the annotations made by the annotators, or the values of the four annotation concepts.-->
	<!ELEMENT annotation_unit (sentence, gene, expression_change_keyword_1, expression_change_keyword_2, cancer_term+, annotation)>
	<!ATTLIST annotation_unit id ID #REQUIRED
				  phase (pilot | p1 | p2 | p3) #REQUIRED
				  cancer_type (prostate | breast | ovarian) #REQUIRED >
	<!ELEMENT sentence (#PCDATA)>
	<!ATTLIST sentence pmid CDATA #REQUIRED >
	<!ELEMENT gene (#PCDATA)>
	<!ATTLIST gene range CDATA #REQUIRED >
	<!ELEMENT expression_change_keyword_1 (#PCDATA)>
	<!ATTLIST expression_change_keyword_1 range CDATA #REQUIRED type (None | Gene_expression) #REQUIRED>
	<!ELEMENT expression_change_keyword_2 (#PCDATA)>
	<!ATTLIST expression_change_keyword_2 range CDATA #REQUIRED type (Negative_regulation | Positive_regulation) #REQUIRED>
	<!ELEMENT cancer_term (#PCDATA)>
	<!ATTLIST cancer_term range CDATA #REQUIRED>
	<!ELEMENT annotation (CGE, CCS, IGE, PT)>
	<!ELEMENT CGE EMPTY>
	<!ATTLIST CGE value (increased | decreased) #REQUIRED>
	<!ELEMENT CCS EMPTY>
	<!ATTLIST CCS value (normalTOnormal | normalTOcancer | cancerTOcancer | cancerTOnormal | unidentifiable) #REQUIRED>
	<!ELEMENT IGE EMPTY>
	<!ATTLIST IGE value (up-regulated | down-regulated | unchanged | unidentifiable) #REQUIRED>
	<!ELEMENT PT EMPTY>
	<!ATTLIST PT value (causality | observation) #REQUIRED>
]><gene_cancer_corpus>
<annotation_unit cancer_type="prostate" id="au1" phase="pilot">
<sentence pmid="10945637.s12">Thus, FGF6 is increased in PIN and prostate cancer and can promote the proliferation of the transformed prostatic epithelial cells via paracrine and autocrine mechanisms.</sentence>
<gene range="6-9">FGF6</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="14-22" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="35-49">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au2" phase="pilot">
<sentence pmid="11722842.s0">Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.</sentence>
<gene range="93-97">MUC18</gene>
<expression_change_keyword_1 range="99-113" type="Gene_expression">over-expression</expression_change_keyword_1>
<expression_change_keyword_2 range="99-113" type="Positive_regulation">over-expression</expression_change_keyword_2>
<cancer_term range="118-132">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au3" phase="pilot">
<sentence pmid="11722842.s13">We therefore conclude that MUC18 expression is increased during prostate cancer initiation (high grade PIN) and progression to carcinoma, and in metastatic cell lines and metastatic carcinoma.</sentence>
<gene range="27-31">MUC18</gene>
<expression_change_keyword_1 range="33-42" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="47-55" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="64-78">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au4" phase="pilot">
<sentence pmid="11839683.s9">These results demonstrate that in a sequence-specific manner, RIalpha antisense, via efficient depletion of the growth stimulatory molecule RIalpha, induces growth inhibition, apoptosis, and phenotypic (cell morphology) changes, providing an innovative approach to combat hormone-insensitive prostate cancer cell growth.</sentence>
<gene range="112-146">growth stimulatory molecule RIalpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="95-103" type="Negative_regulation">depletion</expression_change_keyword_2>
<cancer_term range="292-306">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au5" phase="pilot">
<sentence pmid="12006585.s2">We have found that Cdc6 expression is down-regulated in prostate cancer as detected by semiquantitative reverse transcriptase-PCR of prostate cell lines and laser-captured microdissected prostate tissues.</sentence>
<gene range="19-22">Cdc6</gene>
<expression_change_keyword_1 range="24-33" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="38-51" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="56-70">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au6" phase="pilot">
<sentence pmid="12006585.s4">Furthermore, a 100-fold reduction in the transcription efficiency of the Cdc6 promoter-luciferase construct was noted in the metastatic PC3 cells compared with that in BPH-1 cells.</sentence>
<gene range="73-106">Cdc6 promoter-luciferase construct</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="24-32" type="Negative_regulation">reduction</expression_change_keyword_2>
<cancer_term range="136-138">PC3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au7" phase="pilot">
<sentence pmid="12409226.s7">Sustained increase of the c-myc gene product was detectable in PC-3 but not in DU-145 cells.</sentence>
<gene range="26-43">c-myc gene product</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="10-17" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="63-66">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au8" phase="pilot">
<sentence pmid="12409226.s8">Concurrently, we demonstrated BN-dependent activation of the transcription factor Elk-1 and significant increase of cell proliferation in both prostate cancer cell lines.</sentence>
<gene range="61-86">transcription factor Elk-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="43-52" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="143-157">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au9" phase="pilot">
<sentence pmid="12433721.s1">Electronic profiling of publicly available expressed sequence tag databases identified a gene, cysteine-rich secretoryprotein-3 (CRISP-3), that is up-regulated in prostate cancer, and of which the expression is relatively prostate-specific.</sentence>
<gene range="129-135">CRISP-3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="147-158" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="163-177">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au10" phase="pilot">
<sentence pmid="12569365.s4">Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%).</sentence>
<gene range="0-5">Cdc25B</gene>
<expression_change_keyword_1 range="21-33" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="21-33" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="44-58">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au11" phase="pilot">
<sentence pmid="12598323.s1">PTOV1 was recently identified as a novel gene and protein during a differential display screening for genes overexpressed in prostate cancer.</sentence>
<gene range="0-4">PTOV1</gene>
<expression_change_keyword_1 range="108-120" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="108-120" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="125-139">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au12" phase="pilot">
<sentence pmid="12598323.s3">By immunohistochemical analysis, we have found that PTOV1 is overexpressed in 71% of 38 prostate carcinomas and in 80% of samples with prostate intraepithelial neoplasia.</sentence>
<gene range="52-56">PTOV1</gene>
<expression_change_keyword_1 range="61-73" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="61-73" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="88-106">prostate carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au13" phase="pilot">
<sentence pmid="12618764.s0">MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.</sentence>
<gene range="0-3">MEK5</gene>
<expression_change_keyword_1 range="5-18" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="5-18" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="50-64">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au14" phase="pilot">
<sentence pmid="12875974.s2">The overexpression of Bax inhibitor-1 (BI-1) in prostate carcinoma and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses.</sentence>
<gene range="39-42">BI-1</gene>
<expression_change_keyword_1 range="4-17" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-17" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="71-85">prostate cancer</cancer_term>
<cancer_term range="48-65">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au15" phase="pilot">
<sentence pmid="12907652.s9">These observations suggest that U19 is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with prostate cancer progression.</sentence>
<gene range="147-149">U19</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="151-165" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="195-209">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au16" phase="pilot">
<sentence pmid="14744752.s5">First, a comprehensive serial immunohistochemical analysis of primary and metastatic prostate cancer samples showed increased stage-specific expression of IL-11Ralpha during disease progression.</sentence>
<gene range="155-165">IL-11Ralpha</gene>
<expression_change_keyword_1 range="141-150" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="116-124" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="85-99">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au17" phase="pilot">
<sentence pmid="14744778.s2">We have shown previously that although AP-2 is expressed highly in normal prostatic epithelium, its expression is lost in high-grade prostatic intraepithelial neoplasia and prostate cancer, suggesting that loss of AP-2 plays a role in prostate cancer development.</sentence>
<gene range="214-217">AP-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="206-209" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="173-187">prostate cancer</cancer_term>
<cancer_term range="235-249">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au18" phase="pilot">
<sentence pmid="14744778.s10">Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer.</sentence>
<gene range="56-59">AP-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="48-51" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="158-172">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au19" phase="pilot">
<sentence pmid="14766760.s7">The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or HIPK3 expression was found to restore this interaction and increased the sensitivity of DU 145 cells to Fas receptor-mediated apoptosis.</sentence>
<gene range="92-96">HIPK3</gene>
<expression_change_keyword_1 range="98-107" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="62-71" type="Negative_regulation">abrogation</expression_change_keyword_2>
<cancer_term range="180-185">DU 145</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au20" phase="pilot">
<sentence pmid="15026365.s14">In clinical prostate cancer specimens from patients with varying grades of disease, the stained tissue sections showed high levels of SREBP-1 protein compared with noncancerous prostate tissue.</sentence>
<gene range="134-148">SREBP-1 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="124-129" type="Positive_regulation">levels</expression_change_keyword_2>
<cancer_term range="12-26">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au21" phase="pilot">
<sentence pmid="15026365.s17">In summary, the LNCaP xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of SREBPs and their downstream effector genes during progression to androgen independence.</sentence>
<gene range="145-150">SREBPs</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="128-140" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="47-61">prostate cancer</cancer_term>
<cancer_term range="96-110">prostate cancer</cancer_term>
<cancer_term range="16-20">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au22" phase="pilot">
<sentence pmid="15833840.s1">An increase in the activity of mitogen-activated protein kinase (MAPK) has been correlated with the progression of prostate cancer to advanced disease in humans.</sentence>
<gene range="31-62">mitogen-activated protein kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="3-10" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="115-129">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au23" phase="pilot">
<sentence pmid="15833840.s3">Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression.</sentence>
<gene range="117-119">PSA</gene>
<expression_change_keyword_1 range="122-131" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="81-88" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="52-66">prostate cancer</cancer_term>
<cancer_term range="169-183">prostate cancer</cancer_term>
<cancer_term range="74-78">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au24" phase="pilot">
<sentence pmid="15833840.s3">Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression.</sentence>
<gene range="272-274">PSA</gene>
<expression_change_keyword_1 range="276-285" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="262-270" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="52-66">prostate cancer</cancer_term>
<cancer_term range="169-183">prostate cancer</cancer_term>
<cancer_term range="74-78">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au25" phase="pilot">
<sentence pmid="15837784.s0">Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.</sentence>
<gene range="19-29">ATM protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-14" type="Negative_regulation">Down-regulation</expression_change_keyword_2>
<cancer_term range="48-62">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au26" phase="pilot">
<sentence pmid="15897876.s7">CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions.</sentence>
<gene range="0-3">CBX7</gene>
<expression_change_keyword_1 range="5-18" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="5-18" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="23-27">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au27" phase="pilot">
<sentence pmid="16115918.s1">Cytochrome P450 1B1 (CYP1B1), a dioxin inducible member of the CYP supergene family, is overexpressed in various human malignancies including prostate cancer.</sentence>
<gene range="0-27">Cytochrome P450 1B1 (CYP1B1)</gene>
<expression_change_keyword_1 range="88-100" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="88-100" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="142-156">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au28" phase="pilot">
<sentence pmid="16424021.s0">Increased expression of osteopontin contributes to the progression of prostate cancer.</sentence>
<gene range="24-34">osteopontin</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="70-84">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au29" phase="pilot">
<sentence pmid="16601286.s0">Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.</sentence>
<gene range="24-117">type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3)</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="166-183">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au30" phase="pilot">
<sentence pmid="16601286.s13">We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma.</sentence>
<gene range="40-45">AKR1C3</gene>
<expression_change_keyword_1 range="26-35" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-24" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="73-90">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au31" phase="pilot">
<sentence pmid="16609016.s9">Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P &amp;lt; 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression.</sentence>
<gene range="51-55">RPL19</gene>
<expression_change_keyword_1 range="57-66" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="41-49" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="182-196">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au32" phase="pilot">
<sentence pmid="16818616.s6">Transfection-mediated WWOX overexpression in DU145 cells suppressed colony growth (P = 0.0012), and WWOX overexpression by infection with Ad-WWOX virus induced apoptosis through a caspase-dependent mechanism and suppressed cell growth.</sentence>
<gene range="100-103">WWOX</gene>
<expression_change_keyword_1 range="105-118" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="105-118" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="45-49">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au33" phase="pilot">
<sentence pmid="17003780.s7">Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.</sentence>
<gene range="39-43">Tiam1</gene>
<expression_change_keyword_1 range="45-58" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="45-58" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="184-198">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au34" phase="pilot">
<sentence pmid="17134822.s0">Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.</sentence>
<gene range="0-28">Polycomb-group oncogenes EZH2</gene>
<expression_change_keyword_1 range="51-63" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="51-63" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="68-82">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au35" phase="pilot">
<sentence pmid="17481580.s4">Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform gal8g were upregulated in LNCaP cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.</sentence>
<gene range="49-53">gal8e</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="105-115" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="120-124">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au36" phase="pilot">
<sentence pmid="17481580.s4">Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform gal8g were upregulated in LNCaP cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.</sentence>
<gene range="94-98">gal8g</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="105-115" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="120-124">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au37" phase="pilot">
<sentence pmid="17513602.s0">Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.</sentence>
<gene range="24-32">cyclin B1</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="45-59">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au38" phase="pilot">
<sentence pmid="17875724.s7">We present here for the first time that signal transducers and activators of transcription 3 (Stat3), which is constitutively activated in a wide variety of human cancers, including prostate cancer, interacts with PKCepsilon.</sentence>
<gene range="40-91">signal transducers and activators of transcription 3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="126-134" type="Positive_regulation">activated</expression_change_keyword_2>
<cancer_term range="182-196">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au39" phase="pilot">
<sentence pmid="17908958.s0">Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.</sentence>
<gene range="0-4">Smad3</gene>
<expression_change_keyword_1 range="9-21" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="9-21" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="41-55">prostate cancer</cancer_term>
<cancer_term range="97-111">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au40" phase="pilot">
<sentence pmid="18008330.s1">Clinical data showed that the levels of interleukin-4 (IL-4) are significantly elevated in serum of patients with ablation resistant prostate cancer.</sentence>
<gene range="40-52">interleukin-4</gene>
<expression_change_keyword_1 range="30-35" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="79-86" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="133-147">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au41" phase="pilot">
<sentence pmid="18008330.s9">Overexpression of IL-4 increases the sensitivity of androgen-sensitive LNCaP prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo.</sentence>
<gene range="18-21">IL-4</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="77-91">prostate cancer</cancer_term>
<cancer_term range="71-75">LNCaP</cancer_term>
<cancer_term range="162-166">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au42" phase="pilot">
<sentence pmid="18167127.s0">Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9.</sentence>
<gene range="8-12">BRCA2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-3" type="Negative_regulation">Loss</expression_change_keyword_2>
<cancer_term range="23-37">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au43" phase="pilot">
<sentence pmid="18167127.s6">Consistently, PI3-kinase inhibition with a dominant-negative mutant or MAPK/ERK activation with a gain-of-function mutant reduced MMP-9 levels and prevented migration and invasion in wild-type PC-3 cells.</sentence>
<gene range="14-23">PI3-kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="25-34" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="193-196">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au44" phase="p1">
<sentence pmid="11431361.s0">Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells.</sentence>
<gene range="0-20">Hyaluronan synthase 3</gene>
<expression_change_keyword_1 range="22-35" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="22-35" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="64-78">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au45" phase="p1">
<sentence pmid="16491480.s2">We have previously described the increased expression of two prostate-specific G-protein coupled receptors (PSGR and PSGR2) in human prostate cancer.</sentence>
<gene range="108-111">PSGR</gene>
<expression_change_keyword_1 range="43-52" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="33-41" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="133-147">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au46" phase="p1">
<sentence pmid="16491480.s2">We have previously described the increased expression of two prostate-specific G-protein coupled receptors (PSGR and PSGR2) in human prostate cancer.</sentence>
<gene range="117-121">PSGR2</gene>
<expression_change_keyword_1 range="43-52" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="33-41" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="133-147">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au47" phase="p1">
<sentence pmid="16491480.s9">AMACR was the best single marker of prostate cancer but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while PSGR and/or PSGR2 were substantially elevated.</sentence>
<gene range="144-147">PSGR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="181-188" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="36-50">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au48" phase="p1">
<sentence pmid="17426117.s3">Reduction of AR expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and LAPC4, significantly decreased AR-mediated transcription and cell growth.</sentence>
<gene range="13-14">AR</gene>
<expression_change_keyword_1 range="16-25" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Reduction</expression_change_keyword_2>
<cancer_term range="57-71">prostate cancer</cancer_term>
<cancer_term range="85-89">LNCaP</cancer_term>
<cancer_term range="95-99">LAPC4</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au49" phase="p1">
<sentence pmid="8612685.s0">Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells.</sentence>
<gene range="18-33">protein kinase C</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Negative_regulation">Downregulation</expression_change_keyword_2>
<cancer_term range="78-96">prostatic carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au50" phase="p1">
<sentence pmid="8612685.s7">PKC isozyme analysis revealed that chronic PDBu treatment caused downregulation of PKC-alpha and -epsilon in DU-145 cells.</sentence>
<gene range="83-104">PKC-alpha and -epsilon</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="65-78" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="109-114">DU-145</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au51" phase="p1">
<sentence pmid="12544353.s7">Antisense bcl-2 oligodeoxynucleotides decreased Bcl-2 protein levels and significantly inhibited PC-3 cell growth in a dose dependent manner.</sentence>
<gene range="48-60">Bcl-2 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="97-100">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au52" phase="p1">
<sentence pmid="16302272.s1">Experimental work in various prostate cancer models revealed that the androgen receptor is frequently upregulated and implicated in tumor progression.</sentence>
<gene range="70-86">androgen receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="102-112" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="29-43">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au53" phase="p1">
<sentence pmid="21320357.s4">EPCR expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and PC-3 cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells.</sentence>
<gene range="0-3">EPCR</gene>
<expression_change_keyword_1 range="5-14" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-30" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="89-94">DU-145</cancer_term>
<cancer_term range="186-190">LNCaP</cancer_term>
<cancer_term range="100-103">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au54" phase="p1">
<sentence pmid="15638997.s4">Response to bicalutamide in LNCaP cells was represented by downregulation of androgen-regulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and telomerase reverse transcriptase subunit.</sentence>
<gene range="121-123">p53</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="103-112" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="28-32">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au55" phase="p1">
<sentence pmid="15638997.s4">Response to bicalutamide in LNCaP cells was represented by downregulation of androgen-regulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and telomerase reverse transcriptase subunit.</sentence>
<gene range="262-264">MYC</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="189-202" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="28-32">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au56" phase="p1">
<sentence pmid="15638997.s4">Response to bicalutamide in LNCaP cells was represented by downregulation of androgen-regulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and telomerase reverse transcriptase subunit.</sentence>
<gene range="271-310">telomerase reverse transcriptase subunit</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="189-202" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="28-32">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au57" phase="p1">
<sentence pmid="15638997.s6">In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.</sentence>
<gene range="152-154">p53</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="134-143" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="103-107">LNCaP</cancer_term>
<cancer_term range="167-171">LNCaP</cancer_term>
<cancer_term range="258-262">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au58" phase="p1">
<sentence pmid="15638997.s6">In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the p53 pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive DU145 cells.</sentence>
<gene range="73-89">androgen receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="91-98" type="Negative_regulation">blockade</expression_change_keyword_2>
<cancer_term range="103-107">LNCaP</cancer_term>
<cancer_term range="167-171">LNCaP</cancer_term>
<cancer_term range="258-262">DU145</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au59" phase="p1">
<sentence pmid="19584279.s0">Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.</sentence>
<gene range="16-50">androgen receptor-regulated TMPRSS2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Reactivation</expression_change_keyword_2>
<cancer_term range="96-110">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au60" phase="p1">
<sentence pmid="19584279.s0">Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.</sentence>
<gene range="52-59">ERG gene</gene>
<expression_change_keyword_1 range="61-70" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Reactivation</expression_change_keyword_2>
<cancer_term range="96-110">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au61" phase="p1">
<sentence pmid="19584279.s5">Moreover, as observed in the clinical samples, ERG expression was fully restored in the VCaP xenografts that relapsed after castration, coincident with AR reactivation.</sentence>
<gene range="47-49">ERG</gene>
<expression_change_keyword_1 range="51-60" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="72-79" type="Positive_regulation">restored</expression_change_keyword_2>
<cancer_term range="88-91">VCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au62" phase="p1">
<sentence pmid="19584279.s5">Moreover, as observed in the clinical samples, ERG expression was fully restored in the VCaP xenografts that relapsed after castration, coincident with AR reactivation.</sentence>
<gene range="152-153">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="155-166" type="Positive_regulation">reactivation</expression_change_keyword_2>
<cancer_term range="88-91">VCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au63" phase="p1">
<sentence pmid="18358509.s4">We observed that re-expression of AR in the AR-negative cells PC3 decreases anchorage-independent growth and Matrigel invasiveness of PC3-AR cells where plasma membrane interaction between AR and EGFR led to an interference with downstream signalling and internalization of activated EGFR.</sentence>
<gene range="284-287">EGFR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="274-282" type="Positive_regulation">activated</expression_change_keyword_2>
<cancer_term range="62-64">PC3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au64" phase="p1">
<sentence pmid="16427044.s4">M12 cells, like many other human cancer cells, contain constitutively activated signal transducer and activator of transcription 3 (STAT3).</sentence>
<gene range="132-136">STAT3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="70-78" type="Positive_regulation">activated</expression_change_keyword_2>
<cancer_term range="0-2">M12</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au65" phase="p1">
<sentence pmid="16427044.s6">Strikingly, IFN-gamma-induced apoptosis and growth inhibition of M12 cells were associated with persistent suppression of the constitutive tyrosine-phosphorylated STAT3 (pY-STAT3).</sentence>
<gene range="163-167">STAT3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="107-117" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="65-67">M12</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au66" phase="p1">
<sentence pmid="20336778.s3">In this study, while demonstrating suppressed levels of Tm1 in the prostate cancer cell lines LNCaP, PC3, and DU-145 compared to normal prostate epithelial cell primary isolates (PrEC), a novel splice variant of the TPM2 gene was identified.</sentence>
<gene range="56-58">Tm1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-44" type="Negative_regulation">suppressed</expression_change_keyword_2>
<cancer_term range="67-81">prostate cancer</cancer_term>
<cancer_term range="110-115">DU-145</cancer_term>
<cancer_term range="94-98">LNCaP</cancer_term>
<cancer_term range="101-103">PC3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au67" phase="p1">
<sentence pmid="10931458.s14">These findings suggest that inhibition of COX-2 development may lead not only to inhibition of the proliferation and metastasis of prostate carcinoma but also to the inhibition of prostate carcinogenesis.</sentence>
<gene range="42-46">COX-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="28-37" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="131-148">prostate carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au68" phase="p1">
<sentence pmid="18349265.s4">Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.</sentence>
<gene range="65-76">PTH receptor</gene>
<expression_change_keyword_1 range="47-56" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="37-45" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="135-149">prostate cancer</cancer_term>
<cancer_term range="0-14">Prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au69" phase="p1">
<sentence pmid="18349265.s4">Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.</sentence>
<gene range="79-84">PTH-IR</gene>
<expression_change_keyword_1 range="47-56" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="37-45" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="135-149">prostate cancer</cancer_term>
<cancer_term range="0-14">Prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au70" phase="p1">
<sentence pmid="18349265.s4">Prostate cancer bony metastases show increased expression of the PTH receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.</sentence>
<gene range="91-93">PTH</gene>
<expression_change_keyword_1 range="47-56" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="37-45" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="135-149">prostate cancer</cancer_term>
<cancer_term range="0-14">Prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au71" phase="p1">
<sentence pmid="10216950.s8">A broad spectrum of tumor derived cell lines, from varied tissue sources and blood samples from patients having confirmed prostate carcinoma, all scored positive for expression of PTI-1, while corresponding normal tissues or blood samples were negative.</sentence>
<gene range="180-184">PTI-1</gene>
<expression_change_keyword_1 range="166-175" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="153-160" type="Positive_regulation">positive</expression_change_keyword_2>
<cancer_term range="122-139">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au72" phase="p1">
<sentence pmid="9586898.s11">A decrease in PSA level is associated with both survival and response in soft tissue lesions and should be incorporated into the response criteria and reporting of trials of cytotoxic agents in prostate cancer.</sentence>
<gene range="14-16">PSA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="2-9" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="194-208">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au73" phase="p1">
<sentence pmid="21064106.s0">miR 488* inhibits androgen receptor expression in prostate carcinoma cells.</sentence>
<gene range="18-34">androgen receptor</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="9-16" type="Negative_regulation">inhibits</expression_change_keyword_2>
<cancer_term range="50-67">prostate carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au74" phase="p1">
<sentence pmid="17409433.s3">NSAIDs exert their anti-inflammatory effects by inhibiting cyclooxygenase (COX) activity; however, evidence suggests that COX-independent mechanisms mediate decreased prostate cancer cell survival.</sentence>
<gene range="59-72">cyclooxygenase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="48-57" type="Negative_regulation">inhibiting</expression_change_keyword_2>
<cancer_term range="167-181">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au75" phase="p1">
<sentence pmid="17409433.s3">NSAIDs exert their anti-inflammatory effects by inhibiting cyclooxygenase (COX) activity; however, evidence suggests that COX-independent mechanisms mediate decreased prostate cancer cell survival.</sentence>
<gene range="75-77">COX</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="48-57" type="Negative_regulation">inhibiting</expression_change_keyword_2>
<cancer_term range="167-181">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au76" phase="p1">
<sentence pmid="17409433.s10">Hence, R-flurbiprofen and ibuprofen selectively induce p75(NTR)-dependent decreased survival of prostate cancer cells independently of COX inhibition.</sentence>
<gene range="135-137">COX</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="139-148" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="96-110">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au77" phase="p1">
<sentence pmid="11704864.s5">Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line LNCaP observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of NF-kappa B.</sentence>
<gene range="245-254">NF-kappa B</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="231-240" type="Negative_regulation">inhibitors</expression_change_keyword_2>
<cancer_term range="79-96">prostate carcinoma</cancer_term>
<cancer_term range="108-112">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au78" phase="p1">
<sentence pmid="11704864.s6">Concomitantly, bcl-2 p2 promoter studies in LNCaP cells show a 40-fold increase in promoter activity after stimulation with TNF-alpha in the absence of hormone.</sentence>
<gene range="124-132">TNF-alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="107-117" type="Positive_regulation">stimulation</expression_change_keyword_2>
<cancer_term range="44-48">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au79" phase="p1">
<sentence pmid="11704864.s5">Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line LNCaP observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of NF-kappa B.</sentence>
<gene range="60-64">Bcl-2</gene>
<expression_change_keyword_1 range="46-55" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="21-28" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="79-96">prostate carcinoma</cancer_term>
<cancer_term range="108-112">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au80" phase="p1">
<sentence pmid="19879420.s2">For example, some studies showed that CLU expression is increased in advanced stages of prostate cancer and that suppression of CLU expression sensitizes prostate cancer cells to chemotherapeutic drugs killing.</sentence>
<gene range="128-130">CLU</gene>
<expression_change_keyword_1 range="132-141" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="113-123" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="88-102">prostate cancer</cancer_term>
<cancer_term range="154-168">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="up-regulated"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au81" phase="p1">
<sentence pmid="19879420.s2">For example, some studies showed that CLU expression is increased in advanced stages of prostate cancer and that suppression of CLU expression sensitizes prostate cancer cells to chemotherapeutic drugs killing.</sentence>
<gene range="38-40">CLU</gene>
<expression_change_keyword_1 range="42-51" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="56-64" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="88-102">prostate cancer</cancer_term>
<cancer_term range="154-168">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au82" phase="p1">
<sentence pmid="19879420.s3">In contrast with the hypothesis that CLU is a positive modulator of prostate cancer, we and others have observed that CLU is downregulated during human prostate cancer progression.</sentence>
<gene range="118-120">CLU</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="125-137" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="68-82">prostate cancer</cancer_term>
<cancer_term range="152-166">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au83" phase="p1">
<sentence pmid="19879420.s4">Accordingly, a meta-analysis of available microarray data shows that CLU mRNA is significantly downregulated in prostate cancer tissue compared to normal prostate in 14 out of 15 independent studies.</sentence>
<gene range="69-76">CLU mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="95-107" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="112-126">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au84" phase="p1">
<sentence pmid="19879420.s6">Consistently, CLU expression was found to be significantly reduced in untreated and hormone-refractory human prostate carcinomas.</sentence>
<gene range="14-16">CLU</gene>
<expression_change_keyword_1 range="18-27" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="59-65" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="109-127">prostate carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au85" phase="p1">
<sentence pmid="21479359.s10">In PC-3 cells, adhesion molecule expression, analyzed by immunoblotting, was unaffected by LA, while a down-regulation of c-met (up to 28%) was observed after 24 h of treatment but which did not hold up over time (48-144 h).</sentence>
<gene range="122-126">c-met</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="103-117" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="3-6">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au86" phase="p1">
<sentence pmid="21479359.s11">Our findings demonstrate the efficacy of LA in upregulating E-cadherin, β- and γ-catenin in LNCaP cells.</sentence>
<gene range="60-69">E-cadherin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="47-58" type="Positive_regulation">upregulating</expression_change_keyword_2>
<cancer_term range="92-96">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au87" phase="p1">
<sentence pmid="21479359.s11">Our findings demonstrate the efficacy of LA in upregulating E-cadherin, β- and γ-catenin in LNCaP cells.</sentence>
<gene range="79-87">γ-catenin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="47-58" type="Positive_regulation">upregulating</expression_change_keyword_2>
<cancer_term range="92-96">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au88" phase="p1">
<sentence pmid="12603425.s3">In BPH samples there was a significant correlation between CD38 loss (mean 21% of acini) and HLA-DR up-regulation (mean 20%; P &amp;lt; 0.001).</sentence>
<gene range="93-98">HLA-DR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="100-112" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="3-5">BPH</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au89" phase="p1">
<sentence pmid="12603425.s4">Moreover, 76% of all CD38-negative acini in BPH had HLA-DR up-regulation in the same prostate epithelial cells, predominantly in atrophic and cystic glands, and in cells with retained secretions (74%).</sentence>
<gene range="52-57">HLA-DR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="59-71" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="44-46">BPH</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au90" phase="p1">
<sentence pmid="12603425.s8">The absence of CD38 and presence of HLA-DR expression in prostatic epithelium is consistent in BPH and tissue surrounding tumour, and strongly related to gland atrophy.</sentence>
<gene range="15-18">CD38</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-10" type="Negative_regulation">absence</expression_change_keyword_2>
<cancer_term range="95-97">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au91" phase="p1">
<sentence pmid="14665875.s1">The prostate cancer detection rate in patients with elevated prostate specific antigen (PSA) increases with extended needle biopsy protocols.</sentence>
<gene range="61-85">prostate specific antigen</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="52-59" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="4-18">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au92" phase="p1">
<sentence pmid="14665875.s1">The prostate cancer detection rate in patients with elevated prostate specific antigen (PSA) increases with extended needle biopsy protocols.</sentence>
<gene range="88-90">PSA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="52-59" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="4-18">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au93" phase="p1">
<sentence pmid="15193259.s1">R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPARgamma pathway.</sentence>
<gene range="198-206">cyclin D1</gene>
<expression_change_keyword_1 range="208-217" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="180-193" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="139-153">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au94" phase="p1">
<sentence pmid="17143532.s0">Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.</sentence>
<gene range="104-108">BRCA2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="88-99" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="45-59">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au95" phase="p1">
<sentence pmid="19483721.s0">Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.</sentence>
<gene range="15-18">PKIB</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpressing</expression_change_keyword_2>
<cancer_term range="23-37">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au96" phase="p1">
<sentence pmid="15647840.s8">DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.</sentence>
<gene range="205-207">E2F</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="190-200" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="129-133">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au97" phase="p1">
<sentence pmid="15647840.s8">DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.</sentence>
<gene range="163-173">E2F protein</gene>
<expression_change_keyword_1 range="175-184" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="151-158" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="129-133">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au98" phase="p1">
<sentence pmid="15647840.s8">DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of LNCaP cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.</sentence>
<gene range="12-24">E2F-1 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="56-64" type="Negative_regulation">inhibited</expression_change_keyword_2>
<cancer_term range="129-133">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au99" phase="p1">
<sentence pmid="21789713.s0">Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.</sentence>
<gene range="17-19">PKA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-12" type="Negative_regulation">blockade</expression_change_keyword_2>
<cancer_term range="89-103">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au100" phase="p1">
<sentence pmid="21789713.s0">Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.</sentence>
<gene range="25-29">NF-κB</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-12" type="Negative_regulation">blockade</expression_change_keyword_2>
<cancer_term range="89-103">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au101" phase="p1">
<sentence pmid="21789713.s7">Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing RLN2 levels in patients with benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p = 0.002).</sentence>
<gene range="242-245">RLN2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="264-274" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="181-215">prostatic intraepithelial neoplasia</cancer_term>
<cancer_term range="145-172">benign prostatic hyperplasia</cancer_term>
<cancer_term range="175-177">BPH</cancer_term>
<cancer_term range="286-288">BPH</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au102" phase="p1">
<sentence pmid="9116750.s6">In surgically excised adult human prostate tissues, localized accumulations of TGF-beta1 are associated with prostate cancer and benign prostatic hyperplasia (BPH).</sentence>
<gene range="79-87">TGF-beta1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="62-74" type="Positive_regulation">accumulations</expression_change_keyword_2>
<cancer_term range="129-156">benign prostatic hyperplasia</cancer_term>
<cancer_term range="109-123">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au103" phase="p1">
<sentence pmid="14749128.s2">In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.</sentence>
<gene range="140-149">HIF-1alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="126-135" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="9-23">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au104" phase="p1">
<sentence pmid="14749128.s2">In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.</sentence>
<gene range="45-47">ILK</gene>
<expression_change_keyword_1 range="49-58" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="32-40" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="9-23">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au105" phase="p1">
<sentence pmid="14749128.s2">In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.</sentence>
<gene range="140-149">HIF-1alpha</gene>
<expression_change_keyword_1 range="160-169" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="126-135" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="9-23">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au106" phase="p1">
<sentence pmid="14749128.s2">In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.</sentence>
<gene range="155-158">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="126-135" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="9-23">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au107" phase="p1">
<sentence pmid="14749128.s2">In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.</sentence>
<gene range="155-158">VEGF</gene>
<expression_change_keyword_1 range="160-169" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="126-135" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="9-23">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au108" phase="p1">
<sentence pmid="14749128.s2">In human prostate cancer cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.</sentence>
<gene range="89-91">ILK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="75-84" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="9-23">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au109" phase="p1">
<sentence pmid="14749128.s4">Inhibition of ILK activity also inhibits prostate tumor angiogenesis and suppresses tumor growth.</sentence>
<gene range="14-16">ILK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Negative_regulation">Inhibition</expression_change_keyword_2>
<cancer_term range="41-54">prostate tumor</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au110" phase="p1">
<sentence pmid="21125667.s0">GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer.</sentence>
<gene range="0-4">GRP78</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="6-18" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="116-130">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au111" phase="p1">
<sentence pmid="21125667.s10">In keeping with our clinical data, activation of AR by dihydrotestosterone (DHT) potently activated GRP78 expression in both LNCaP and LNCaP-CR cells.</sentence>
<gene range="100-104">GRP78</gene>
<expression_change_keyword_1 range="106-115" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="90-98" type="Positive_regulation">activated</expression_change_keyword_2>
<cancer_term range="125-129">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au112" phase="p1">
<sentence pmid="21125667.s10">In keeping with our clinical data, activation of AR by dihydrotestosterone (DHT) potently activated GRP78 expression in both LNCaP and LNCaP-CR cells.</sentence>
<gene range="49-50">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-44" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="125-129">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au113" phase="p1">
<sentence pmid="21125667.s14">Up-regulated expression of AR and GRP78 expression in untreated prostate cancer predicts a less favourable outcome.</sentence>
<gene range="27-28">AR</gene>
<expression_change_keyword_1 range="13-22" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Up-regulated</expression_change_keyword_2>
<cancer_term range="64-78">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au114" phase="p1">
<sentence pmid="15336984.s0">TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.</sentence>
<gene range="87-91">TRPV6</gene>
<expression_change_keyword_1 range="106-115" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="77-85" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="10-24">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au115" phase="p1">
<sentence pmid="21415100.s5">In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of DU145 cells with decreased function of store-operated Ca(2+) entry and reduced expression of Orai1 at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2.</sentence>
<gene range="232-236">Orai1</gene>
<expression_change_keyword_1 range="218-227" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="210-216" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="139-143">DU145</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au116" phase="p1">
<sentence pmid="19789311.s6">TSPO expression is increased in prostatic intraepithelial neoplasia, primary prostate cancer, and metastases compared with normal prostate tissue and benign prostatic hyperplasia.</sentence>
<gene range="0-3">TSPO</gene>
<expression_change_keyword_1 range="5-14" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-27" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="32-66">prostatic intraepithelial neoplasia</cancer_term>
<cancer_term range="150-177">benign prostatic hyperplasia</cancer_term>
<cancer_term range="77-91">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au117" phase="p1">
<sentence pmid="19789311.s10">These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.</sentence>
<gene range="33-36">TSPO</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="24-31" type="Negative_regulation">blocking</expression_change_keyword_2>
<cancer_term range="121-135">prostate cancer</cancer_term>
<cancer_term range="203-217">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au118" phase="p1">
<sentence pmid="14624913.s1">To evaluate retrospectively the effectiveness of transurethral resection of the prostate (TURP) in diagnosing prostate cancer in patients with obstructive voiding symptoms and a history of negative transrectal prostate biopsy but elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE).</sentence>
<gene range="266-268">PSA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="230-237" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="110-124">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au119" phase="p1">
<sentence pmid="21263452.s0">Increased levels of plasma haemoxygenase-1 in prostate cancer.</sentence>
<gene range="20-41">plasma haemoxygenase-1</gene>
<expression_change_keyword_1 range="10-15" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="46-60">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au120" phase="p1">
<sentence pmid="19212833.s2">PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.</sentence>
<gene range="0-10">PDLIM4 mRNA</gene>
<expression_change_keyword_1 range="16-33" type="Gene_expression">protein-expression</expression_change_keyword_1>
<expression_change_keyword_2 range="47-53" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="94-108">prostate cancer</cancer_term>
<cancer_term range="58-62">LNCaP</cancer_term>
<cancer_term range="65-69">LAPC4</cancer_term>
<cancer_term range="72-76">DU145</cancer_term>
<cancer_term range="79-83">CWR22</cancer_term>
<cancer_term range="90-92">PC3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au121" phase="p1">
<sentence pmid="19212833.s2">PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells.</sentence>
<gene range="0-10">PDLIM4 mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="47-53" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="94-108">prostate cancer</cancer_term>
<cancer_term range="58-62">LNCaP</cancer_term>
<cancer_term range="65-69">LAPC4</cancer_term>
<cancer_term range="72-76">DU145</cancer_term>
<cancer_term range="79-83">CWR22</cancer_term>
<cancer_term range="90-92">PC3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au122" phase="p1">
<sentence pmid="16299799.s0">Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.</sentence>
<gene range="18-22">PIM-1</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="52-69">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au123" phase="p1">
<sentence pmid="18281549.s0">Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.</sentence>
<gene range="123-128">Bcl-XL</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="85-98" type="Negative_regulation">down-regulates</expression_change_keyword_2>
<cancer_term range="65-79">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au124" phase="p1">
<sentence pmid="18281549.s0">Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.</sentence>
<gene range="134-141">survivin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="85-98" type="Negative_regulation">down-regulates</expression_change_keyword_2>
<cancer_term range="65-79">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au125" phase="p1">
<sentence pmid="20873592.s5">Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P &amp;lt; 0.05).</sentence>
<gene range="132-138">miR-182</gene>
<expression_change_keyword_1 range="109-119" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="99-107" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="14-16">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au126" phase="p1">
<sentence pmid="20873592.s5">Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P &amp;lt; 0.05).</sentence>
<gene range="144-150">miR-183</gene>
<expression_change_keyword_1 range="109-119" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="99-107" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="14-16">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au127" phase="p1">
<sentence pmid="20873592.s5">Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P &amp;lt; 0.05).</sentence>
<gene range="68-73">miR-98</gene>
<expression_change_keyword_1 range="53-63" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="43-51" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="14-16">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au128" phase="p1">
<sentence pmid="20873592.s5">Compared with BPH, the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P &amp;lt; 0.05).</sentence>
<gene range="124-129">miR-96</gene>
<expression_change_keyword_1 range="109-119" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="99-107" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="14-16">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au129" phase="p1">
<sentence pmid="16763719.s4">With the treatment of 9-cis RA, the NKX3.1 promoter activity was increased in reporter gene assay and NKX3.1 expression was enhanced at both mRNA and protein levels in LNCaP cells.</sentence>
<gene range="102-107">NKX3.1</gene>
<expression_change_keyword_1 range="109-118" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="124-131" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="168-172">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au130" phase="p1">
<sentence pmid="16763719.s4">With the treatment of 9-cis RA, the NKX3.1 promoter activity was increased in reporter gene assay and NKX3.1 expression was enhanced at both mRNA and protein levels in LNCaP cells.</sentence>
<gene range="36-50">NKX3.1 promoter</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="65-73" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="168-172">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au131" phase="p1">
<sentence pmid="16763719.s7">Our results demonstrated that 9-cis RA as a differentiating agent can arrest prostate cancer cells in G(1) phase and reduce cell mitosis, and upregulate the expression of human homeobox gene NKX3.1, which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate.</sentence>
<gene range="171-196">human homeobox gene NKX3.1</gene>
<expression_change_keyword_1 range="157-166" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="142-151" type="Positive_regulation">upregulate</expression_change_keyword_2>
<cancer_term range="77-91">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au132" phase="p1">
<sentence pmid="1458483.s9">Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence.</sentence>
<gene range="27-31">bcl-2</gene>
<expression_change_keyword_1 range="33-42" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="47-55" type="Positive_regulation">augmented</expression_change_keyword_2>
<cancer_term range="127-141">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au133" phase="p1">
<sentence pmid="15647830.s0">A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer.</sentence>
<gene range="44-81">ubiquitin carboxyl extension protein 1</gene>
<expression_change_keyword_1 range="86-98" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="86-98" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="103-117">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au134" phase="p1">
<sentence pmid="15647830.s7">Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper.</sentence>
<gene range="89-95">UBCEP-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="32-44" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="106-123">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au135" phase="p1">
<sentence pmid="15647830.s7">Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 (UBCEP-1) mRNA in prostate carcinoma cells compared to the normal glandular epithelium of the prostate proper.</sentence>
<gene range="49-86">ubiquitin carboxyl extension protein 1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="32-44" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="106-123">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au136" phase="p1">
<sentence pmid="15657352.s0">Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.</sentence>
<gene range="17-32">c-Jun-NH2-kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-12" type="Positive_regulation">Up-regulation</expression_change_keyword_2>
<cancer_term range="145-159">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au137" phase="p1">
<sentence pmid="8780381.s0">Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma.</sentence>
<gene range="19-34">beta 1C integrin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-14" type="Negative_regulation">Down-regulation</expression_change_keyword_2>
<cancer_term range="76-93">prostate carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au138" phase="p1">
<sentence pmid="8780381.s4">In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged.</sentence>
<gene range="52-66">beta 1C variant</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="85-98" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="16-38">prostate adenocarcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au139" phase="p1">
<sentence pmid="15017584.s6">Our findings indicate a significant reduction in p27Kip1 immunoreactivity in HGPIN (P&amp;lt;0.0001) and prostate cancer (P&amp;lt;0.0001) compared with the benign tissue.</sentence>
<gene range="49-55">p27Kip1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="36-44" type="Negative_regulation">reduction</expression_change_keyword_2>
<cancer_term range="101-115">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au140" phase="p1">
<sentence pmid="17363494.s5">Resveratrol- and EGCG-induced apoptosis is associated with a significant down-regulation of CK2 activity and protein expression in both the ALVA-41 and PC-3 cells.</sentence>
<gene range="92-94">CK2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="73-87" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="140-146">ALVA-41</cancer_term>
<cancer_term range="152-155">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au141" phase="p1">
<sentence pmid="17363494.s5">Resveratrol- and EGCG-induced apoptosis is associated with a significant down-regulation of CK2 activity and protein expression in both the ALVA-41 and PC-3 cells.</sentence>
<gene range="92-94">CK2</gene>
<expression_change_keyword_1 range="117-126" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="73-87" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="140-146">ALVA-41</cancer_term>
<cancer_term range="152-155">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au142" phase="p1">
<sentence pmid="17363494.s6">Overexpression of CK2alpha protected prostatic cancer cells against resveratrol- and EGCG-induced apoptosis.</sentence>
<gene range="18-25">CK2alpha</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="37-52">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au143" phase="p1">
<sentence pmid="12808114.s8">The frequencies of loss for areas known to be frequently deleted in prostate cancer, such as 6q, 8p, or 13q, were not different between the two groups.</sentence>
<gene range="93-94">6q</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="57-63" type="Negative_regulation">deleted</expression_change_keyword_2>
<cancer_term range="68-82">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au144" phase="p1">
<sentence pmid="11069386.s7">The study suggests that IGF-II has a role in regulating AR expression in prostate cancer cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression.</sentence>
<gene range="179-184">IGF-II</gene>
<expression_change_keyword_1 range="186-195" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="170-177" type="Negative_regulation">suppress</expression_change_keyword_2>
<cancer_term range="73-87">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au145" phase="p1">
<sentence pmid="18332867.s3">Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.</sentence>
<gene range="86-88">PSA</gene>
<expression_change_keyword_1 range="91-96" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="183-188">PWR-1E</cancer_term>
<cancer_term range="101-105">LNCaP</cancer_term>
<cancer_term range="118-122">LAPC4</cancer_term>
<cancer_term range="108-112">22Rv1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au146" phase="p1">
<sentence pmid="18332867.s3">Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.</sentence>
<gene range="59-83">prostate specific antigen</gene>
<expression_change_keyword_1 range="91-96" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="183-188">PWR-1E</cancer_term>
<cancer_term range="101-105">LNCaP</cancer_term>
<cancer_term range="118-122">LAPC4</cancer_term>
<cancer_term range="108-112">22Rv1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au147" phase="p1">
<sentence pmid="18332867.s3">Isosilybin B (10-90 microM) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.</sentence>
<gene range="52-53">AR</gene>
<expression_change_keyword_1 range="91-96" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="183-188">PWR-1E</cancer_term>
<cancer_term range="101-105">LNCaP</cancer_term>
<cancer_term range="118-122">LAPC4</cancer_term>
<cancer_term range="108-112">22Rv1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au148" phase="p1">
<sentence pmid="17203235.s0">Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.</sentence>
<gene range="104-110">BMPR-IB</gene>
<expression_change_keyword_1 range="42-51" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="25-36" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="134-148">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au149" phase="p1">
<sentence pmid="17203235.s0">Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.</sentence>
<gene range="60-101">bone morphogenetic protein (BMP) receptors</gene>
<expression_change_keyword_1 range="42-51" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="25-36" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="134-148">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au150" phase="p1">
<sentence pmid="17203235.s0">Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.</sentence>
<gene range="116-122">BMPR-II</gene>
<expression_change_keyword_1 range="42-51" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="25-36" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="134-148">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au151" phase="p1">
<sentence pmid="17203235.s12">In a murine prostate tumour model, infusion of recombinant HGF resulted in an increase in the levels of both BMPR-IB and BMPR-II transcript in prostate tumours.</sentence>
<gene range="121-138">BMPR-II transcript</gene>
<expression_change_keyword_1 range="94-99" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="78-85" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="143-158">prostate tumours</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au152" phase="p1">
<sentence pmid="17203235.s12">In a murine prostate tumour model, infusion of recombinant HGF resulted in an increase in the levels of both BMPR-IB and BMPR-II transcript in prostate tumours.</sentence>
<gene range="109-115">BMPR-IB</gene>
<expression_change_keyword_1 range="94-99" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="78-85" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="143-158">prostate tumours</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au153" phase="p1">
<sentence pmid="17203235.s14">In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.</sentence>
<gene range="54-89">bone morphogenetic protein receptors</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-30" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="116-130">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au154" phase="p1">
<sentence pmid="17203235.s14">In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.</sentence>
<gene range="104-110">BMPR-II</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-30" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="116-130">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au155" phase="p1">
<sentence pmid="17203235.s14">In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells, both in vitro and in vivo.</sentence>
<gene range="92-98">BMPR-IB</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-30" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="116-130">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au156" phase="p1">
<sentence pmid="19470787.s0">3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.</sentence>
<gene range="71-106">p38 mitogen-activated protein kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="22-30" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="119-133">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au157" phase="p1">
<sentence pmid="19470787.s5">Transfection of the PC-3 prostate cell line with a dominant-negative form of p75(NTR) before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75(NTR) levels and inhibition of survival.</sentence>
<gene range="218-220">NTR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="201-209" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="20-23">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au158" phase="p1">
<sentence pmid="19470787.s5">Transfection of the PC-3 prostate cell line with a dominant-negative form of p75(NTR) before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75(NTR) levels and inhibition of survival.</sentence>
<gene range="214-216">p75</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="201-209" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="20-23">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au159" phase="p1">
<sentence pmid="19470787.s6">Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of p75(NTR) by DIM in the PC-3 prostate cell line.</sentence>
<gene range="111-113">p75</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="98-106" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="134-137">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au160" phase="p1">
<sentence pmid="19470787.s6">Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of p75(NTR) by DIM in the PC-3 prostate cell line.</sentence>
<gene range="115-117">NTR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="98-106" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="134-137">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au161" phase="p1">
<sentence pmid="12414626.s0">Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.</sentence>
<gene range="14-45">mitogen-activated protein kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Positive_regulation">Activation</expression_change_keyword_2>
<cancer_term range="122-136">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au162" phase="p1">
<sentence pmid="12414626.s4">We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy.</sentence>
<gene range="45-82">mitogen-activated protein (MAP) kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-43" type="Positive_regulation">activated</expression_change_keyword_2>
<cancer_term range="87-101">prostate tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au163" phase="p1">
<sentence pmid="12414626.s4">We found a significant increase of activated mitogen-activated protein (MAP) kinase in prostate tumors from patients receiving HF during androgen ablation therapy.</sentence>
<gene range="45-82">mitogen-activated protein (MAP) kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="23-30" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="87-101">prostate tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au164" phase="p1">
<sentence pmid="7525636.s5">In the CM of BPH stromal cells, IGFBP-2 levels were dramatically reduced to less than 20% of normal (P &amp;lt; 0.001).</sentence>
<gene range="32-38">IGFBP-2</gene>
<expression_change_keyword_1 range="40-45" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="65-71" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="13-15">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au165" phase="p1">
<sentence pmid="7525636.s7">Northern blot analysis of mRNA from normal and BPH stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P &amp;lt; 0.001) and a 4-fold increase in IGFBP-5 mRNA (P &amp;lt; 0.01) in BPH compared to normal cells.</sentence>
<gene range="152-163">IGFBP-5 mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="140-147" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="47-49">BPH</cancer_term>
<cancer_term range="182-184">BPH</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au166" phase="p1">
<sentence pmid="7525636.s7">Northern blot analysis of mRNA from normal and BPH stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P &amp;lt; 0.001) and a 4-fold increase in IGFBP-5 mRNA (P &amp;lt; 0.01) in BPH compared to normal cells.</sentence>
<gene range="99-110">IGFBP-2 mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="87-94" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="47-49">BPH</cancer_term>
<cancer_term range="182-184">BPH</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au167" phase="p1">
<sentence pmid="15326487.s10">These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients.</sentence>
<gene range="117-128">SRD5A2 locus</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="91-99" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="133-147">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au168" phase="p1">
<sentence pmid="17712489.s0">Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells.</sentence>
<gene range="14-23">telomerase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Negative_regulation">Inhibition</expression_change_keyword_2>
<cancer_term range="157-171">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au169" phase="p1">
<sentence pmid="17712489.s15">hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells.</sentence>
<gene range="84-93">hTERT mRNA</gene>
<expression_change_keyword_1 range="107-116" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="65-78" type="Negative_regulation">downregulating</expression_change_keyword_2>
<cancer_term range="212-214">PC3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au170" phase="p1">
<sentence pmid="17712489.s15">hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the hTERT mRNA and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of PC3 cells.</sentence>
<gene range="84-93">hTERT mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="65-78" type="Negative_regulation">downregulating</expression_change_keyword_2>
<cancer_term range="212-214">PC3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au171" phase="p1">
<sentence pmid="16044418.s0">Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.</sentence>
<gene range="18-20">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Negative_regulation">Inhibition</expression_change_keyword_2>
<cancer_term range="168-182">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au172" phase="p1">
<sentence pmid="16044418.s0">Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.</sentence>
<gene range="23-38">cyclooxygenase-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Negative_regulation">Inhibition</expression_change_keyword_2>
<cancer_term range="168-182">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au173" phase="p1">
<sentence pmid="16044418.s5">Previous studies by us and others, with androgen-sensitive prostate cancer cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, COX-2, and MMP-9 in cells.</sentence>
<gene range="176-180">COX-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="142-151" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="59-73">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au174" phase="p1">
<sentence pmid="21861338.s8">R-(+) equol and S-(-) equol inhibited motility and invasion in PC3 and DU145 cells, while the most strong effect was observed in PC3 cells by R-(+) equol, which might regulated by the activation of estrogen receptor-alpha.</sentence>
<gene range="198-220">estrogen receptor-alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="184-193" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="71-75">DU145</cancer_term>
<cancer_term range="63-65">PC3</cancer_term>
<cancer_term range="129-131">PC3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au175" phase="p1">
<sentence pmid="18816901.s0">Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.</sentence>
<gene range="13-15">p27</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="137-151">prostate cancer</cancer_term>
<cancer_term range="132-135">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au176" phase="p1">
<sentence pmid="18816901.s0">Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.</sentence>
<gene range="17-20">kip1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="137-151">prostate cancer</cancer_term>
<cancer_term range="132-135">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au177" phase="p1">
<sentence pmid="18816901.s5">These results suggest that TMS may inhibit the cell cycle through induction of p27(kip1), leading to apoptotic cell death in PC-3 prostate cancer cells.</sentence>
<gene range="83-86">kip1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="66-74" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="130-144">prostate cancer</cancer_term>
<cancer_term range="125-128">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au178" phase="p1">
<sentence pmid="18816901.s5">These results suggest that TMS may inhibit the cell cycle through induction of p27(kip1), leading to apoptotic cell death in PC-3 prostate cancer cells.</sentence>
<gene range="79-81">p27</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="66-74" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="130-144">prostate cancer</cancer_term>
<cancer_term range="125-128">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au179" phase="p1">
<sentence pmid="14735192.s9">Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer.</sentence>
<gene range="52-55">EGFR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="57-66" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="98-112">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au180" phase="p1">
<sentence pmid="22043900.s4">We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.</sentence>
<gene range="93-95">DR3</gene>
<expression_change_keyword_1 range="23-32" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="102-110" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="115-117">PC3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au181" phase="p1">
<sentence pmid="22043900.s4">We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.</sentence>
<gene range="156-158">DR3</gene>
<expression_change_keyword_1 range="134-143" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="164-172" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="115-117">PC3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au182" phase="p1">
<sentence pmid="22043900.s4">We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.</sentence>
<gene range="37-90">tumour necrosis factor receptor 2 and death receptor 3</gene>
<expression_change_keyword_1 range="23-32" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="102-110" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="115-117">PC3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au183" phase="p1">
<sentence pmid="22043900.s4">We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.</sentence>
<gene range="148-150">FAS</gene>
<expression_change_keyword_1 range="134-143" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="164-172" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="115-117">PC3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au184" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="839-854">alpha 1-globulin</gene>
<expression_change_keyword_1 range="880-885" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="827-834" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au185" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="794-800">albumin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="782-789" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au186" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="567-593">alpha 1- and gamma-globulin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="555-562" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au187" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="806-821">alpha 2-globulin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="782-789" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au188" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="289-314">alpha 2- and beta-globulin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="264-271" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au189" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="839-854">alpha 1-globulin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="827-834" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au190" phase="p1">
<sentence pmid="91252.s3">Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with prostatic cancer prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.</sentence>
<gene range="515-521">albumin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="503-510" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="177-192">prostatic cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au191" phase="p1">
<sentence pmid="15368472.s0">Trefoil factor 3 is overexpressed in human prostate cancer.</sentence>
<gene range="0-15">Trefoil factor 3</gene>
<expression_change_keyword_1 range="20-32" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="20-32" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="43-57">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au192" phase="p1">
<sentence pmid="15368472.s3">Recent cDNA array analyses suggest that human intestinal trefoil factor 3 (TFF3) may be overexpressed in human prostate cancer.</sentence>
<gene range="40-72">human intestinal trefoil factor 3</gene>
<expression_change_keyword_1 range="88-100" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="88-100" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="111-125">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au193" phase="p1">
<sentence pmid="15368472.s3">Recent cDNA array analyses suggest that human intestinal trefoil factor 3 (TFF3) may be overexpressed in human prostate cancer.</sentence>
<gene range="75-78">TFF3</gene>
<expression_change_keyword_1 range="88-100" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="88-100" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="111-125">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au194" phase="p1">
<sentence pmid="15368472.s11">These studies validate that TFF3 is overexpressed in a subset of primary and metastic prostate cancers.</sentence>
<gene range="28-31">TFF3</gene>
<expression_change_keyword_1 range="36-48" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="36-48" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="86-101">prostate cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au195" phase="p1">
<sentence pmid="12095941.s12">Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.</sentence>
<gene range="110-113">Cx32</gene>
<expression_change_keyword_1 range="115-124" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="97-105" type="Negative_regulation">reduction</expression_change_keyword_2>
<cancer_term range="129-134">RWPE-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au196" phase="p1">
<sentence pmid="12095941.s12">Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.</sentence>
<gene range="59-62">Cx43</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="34-41" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="129-134">RWPE-1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au197" phase="p1">
<sentence pmid="12095941.s12">Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in Cx32 expression in RWPE-1 cells.</sentence>
<gene range="46-56">connexin 43</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="34-41" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="129-134">RWPE-1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au198" phase="p1">
<sentence pmid="14971644.s0">Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.</sentence>
<gene range="17-26">HIF-1alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="9-15" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="98-115">prostate carcinoma</cancer_term>
<cancer_term range="86-90">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au199" phase="p1">
<sentence pmid="14971644.s0">Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.</sentence>
<gene range="32-35">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="9-15" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="98-115">prostate carcinoma</cancer_term>
<cancer_term range="86-90">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au200" phase="p1">
<sentence pmid="14971644.s0">Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.</sentence>
<gene range="45-48">PI3K</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="9-15" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="98-115">prostate carcinoma</cancer_term>
<cancer_term range="86-90">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au201" phase="p1">
<sentence pmid="14971644.s0">Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.</sentence>
<gene range="51-53">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="9-15" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="98-115">prostate carcinoma</cancer_term>
<cancer_term range="86-90">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au202" phase="p1">
<sentence pmid="14971644.s5">Here we demonstrate that arsenite induces the expression of HIF-1alpha but not HIF-1beta subunit in DU145 human prostate carcinoma cells.</sentence>
<gene range="60-69">HIF-1alpha</gene>
<expression_change_keyword_1 range="46-55" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="34-40" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="112-129">prostate carcinoma</cancer_term>
<cancer_term range="100-104">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au203" phase="p1">
<sentence pmid="14971644.s5">Here we demonstrate that arsenite induces the expression of HIF-1alpha but not HIF-1beta subunit in DU145 human prostate carcinoma cells.</sentence>
<gene range="79-95">HIF-1beta subunit</gene>
<expression_change_keyword_1 range="46-55" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="34-40" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="112-129">prostate carcinoma</cancer_term>
<cancer_term range="100-104">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au204" phase="p1">
<sentence pmid="10428464.s0">The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells.</sentence>
<gene range="36-39">Drg1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-64" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="88-111">prostatic adenocarcinoma</cancer_term>
<cancer_term range="82-86">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au205" phase="p1">
<sentence pmid="1978301.s1">Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.</sentence>
<gene range="265-283">luteinizing hormone</gene>
<expression_change_keyword_1 range="6-11" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="60-69" type="Positive_regulation">increments</expression_change_keyword_2>
<cancer_term range="342-357">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au206" phase="p1">
<sentence pmid="1978301.s1">Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.</sentence>
<gene range="46-49">ACTH</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="60-69" type="Positive_regulation">increments</expression_change_keyword_2>
<cancer_term range="342-357">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au207" phase="p1">
<sentence pmid="1978301.s1">Basal levels and adrenocorticotropic hormone (ACTH)-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.</sentence>
<gene range="17-43">adrenocorticotropic hormone</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="60-69" type="Positive_regulation">increments</expression_change_keyword_2>
<cancer_term range="342-357">prostatic cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au208" phase="p1">
<sentence pmid="19706771.s3">The most prominent of these progressive changes is the up-regulation of AR that occurs in &amp;gt;90% of prostate cancers.</sentence>
<gene range="72-73">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="55-67" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="98-113">of prostate canc</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au209" phase="p1">
<sentence pmid="19706771.s8">These events result in increased accumulation of AR and thus enhanced growth of prostate cancer cells at low levels of androgen.</sentence>
<gene range="49-50">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="33-44" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="80-94">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au210" phase="p1">
<sentence pmid="21791629.s1">About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression.</sentence>
<gene range="71-73">ERG</gene>
<expression_change_keyword_1 range="75-88" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="75-88" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="13-28">prostate cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au211" phase="p1">
<sentence pmid="12359757.s0">Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.</sentence>
<gene range="30-33">HER2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-44" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="49-84">androgen-independent prostate cancer</cancer_term>
<cancer_term range="70-84">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au212" phase="p1">
<sentence pmid="7686495.s10">In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.</sentence>
<gene range="153-161">junB mRNA</gene>
<expression_change_keyword_1 range="139-148" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="54-62" type="Positive_regulation">stimulate</expression_change_keyword_2>
<cancer_term range="8-11">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au213" phase="p1">
<sentence pmid="7686495.s10">In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.</sentence>
<gene range="97-129">plasminogen activator inhibitor-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="68-76" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="8-11">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au214" phase="p1">
<sentence pmid="7686495.s10">In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses.</sentence>
<gene range="81-91">fibronectin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="68-76" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="8-11">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au215" phase="p1">
<sentence pmid="15947099.s12">Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer.</sentence>
<gene range="29-30">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="11-20" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="99-113">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au216" phase="p1">
<sentence pmid="15947099.s12">Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer.</sentence>
<gene range="29-30">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="11-20" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="99-113">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au217" phase="p1">
<sentence pmid="9582091.s0">Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype.</sentence>
<gene range="28-47">superoxide dismutase</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="64-81">prostate carcinoma</cancer_term>
<cancer_term range="52-56">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au218" phase="p1">
<sentence pmid="9582091.s3">DU145 human prostate carcinoma cells were transfected with the cDNA for manganese superoxide dismutase (MnSOD), and two clones overexpressing MnSOD activity were subsequently characterized by comparison with parental and plasmid control-transfected cells.</sentence>
<gene range="142-146">MnSOD</gene>
<expression_change_keyword_1 range="127-140" type="Gene_expression">overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="127-140" type="Positive_regulation">overexpressing</expression_change_keyword_2>
<cancer_term range="12-29">prostate carcinoma</cancer_term>
<cancer_term range="0-4">DU145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au219" phase="p1">
<sentence pmid="9582091.s9">Our results suggest novel mechanisms by which MnSOD overexpression may modulate the malignant phenotype, with potential applications in developing new therapies for prostate cancer.</sentence>
<gene range="46-50">MnSOD</gene>
<expression_change_keyword_1 range="52-65" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="52-65" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="165-179">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au220" phase="p1">
<sentence pmid="18490922.s5">Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice.</sentence>
<gene range="18-27">p45-sErbB3</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="47-61">prostate cancer</cancer_term>
<cancer_term range="73-76">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au221" phase="p1">
<sentence pmid="7511267.s3">Accumulation of p53 protein in the absence of detectable mutant p53 was recognized more often in prostate cancer than in any other tumor examined.</sentence>
<gene range="16-26">p53 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Accumulation</expression_change_keyword_2>
<cancer_term range="97-111">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au222" phase="p1">
<sentence pmid="22116304.s0">L-mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.</sentence>
<gene range="89-121">N-myc downstream regulated gene 1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="41-52" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="126-143">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au223" phase="p1">
<sentence pmid="22116304.s0">L-mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.</sentence>
<gene range="57-83">B-cell translocation gene 2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="41-52" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="126-143">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au224" phase="p1">
<sentence pmid="22116304.s7">Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1 α (HIF-1α) and induced Btg2 and Ndrg1 protein expression, but downregulated protein levels of cyclin A in both PC-3 and LNCaP cells.</sentence>
<gene range="126-138">Ndrg1 protein</gene>
<expression_change_keyword_1 range="140-149" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="109-115" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="214-218">LNCaP</cancer_term>
<cancer_term range="205-208">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au225" phase="p1">
<sentence pmid="22116304.s7">Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1 α (HIF-1α) and induced Btg2 and Ndrg1 protein expression, but downregulated protein levels of cyclin A in both PC-3 and LNCaP cells.</sentence>
<gene range="117-120">Btg2</gene>
<expression_change_keyword_1 range="140-149" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="109-115" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="214-218">LNCaP</cancer_term>
<cancer_term range="205-208">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au226" phase="p1">
<sentence pmid="22116304.s7">Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1 α (HIF-1α) and induced Btg2 and Ndrg1 protein expression, but downregulated protein levels of cyclin A in both PC-3 and LNCaP cells.</sentence>
<gene range="117-120">Btg2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="109-115" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="214-218">LNCaP</cancer_term>
<cancer_term range="205-208">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au227" phase="p1">
<sentence pmid="22116304.s8">L-mimosine treatment decreased cyclin D1 protein in PC-3 cells, but not in LNCaP cells.</sentence>
<gene range="31-39">cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="21-29" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="75-79">LNCaP</cancer_term>
<cancer_term range="52-55">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au228" phase="p1">
<sentence pmid="22116304.s9">Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced Btg2 and Ndrg1 protein expression in LNCaP cells.</sentence>
<gene range="72-75">Btg2</gene>
<expression_change_keyword_1 range="95-104" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="64-70" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="109-113">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au229" phase="p1">
<sentence pmid="22116304.s9">Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced Btg2 and Ndrg1 protein expression in LNCaP cells.</sentence>
<gene range="81-93">Ndrg1 protein</gene>
<expression_change_keyword_1 range="95-104" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="64-70" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="109-113">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au230" phase="p1">
<sentence pmid="22116304.s9">Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced Btg2 and Ndrg1 protein expression in LNCaP cells.</sentence>
<gene range="72-75">Btg2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="64-70" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="109-113">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au231" phase="p1">
<sentence pmid="22116304.s11">Knockdown of HIF-1α attenuated the increasing protein levels of both Btg2 and Ndrg1 by hypoxia or L-mimosine in LNCaP cells.</sentence>
<gene range="13-18">HIF-1α</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Knockdown</expression_change_keyword_2>
<cancer_term range="112-116">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au232" phase="p1">
<sentence pmid="22116304.s11">Knockdown of HIF-1α attenuated the increasing protein levels of both Btg2 and Ndrg1 by hypoxia or L-mimosine in LNCaP cells.</sentence>
<gene range="69-72">Btg2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-44" type="Positive_regulation">increasing</expression_change_keyword_2>
<cancer_term range="112-116">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au233" phase="p1">
<sentence pmid="22116304.s11">Knockdown of HIF-1α attenuated the increasing protein levels of both Btg2 and Ndrg1 by hypoxia or L-mimosine in LNCaP cells.</sentence>
<gene range="78-82">Ndrg1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-44" type="Positive_regulation">increasing</expression_change_keyword_2>
<cancer_term range="112-116">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au234" phase="p1">
<sentence pmid="22116304.s13">L-mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.</sentence>
<gene range="43-47">Ndrg1</gene>
<expression_change_keyword_1 range="20-29" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="11-18" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="108-125">prostate carcinoma</cancer_term>
<cancer_term range="102-106">LNCaP</cancer_term>
<cancer_term range="93-96">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au235" phase="p1">
<sentence pmid="22116304.s13">L-mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.</sentence>
<gene range="34-37">Btg2</gene>
<expression_change_keyword_1 range="20-29" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="11-18" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="108-125">prostate carcinoma</cancer_term>
<cancer_term range="102-106">LNCaP</cancer_term>
<cancer_term range="93-96">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au236" phase="p1">
<sentence pmid="19633975.s7">Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to PC-3 cells could reduce the protein expressions of MMP-2 and MMP-9.</sentence>
<gene range="142-146">MMP-9</gene>
<expression_change_keyword_1 range="117-127" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="98-103" type="Negative_regulation">reduce</expression_change_keyword_2>
<cancer_term range="81-84">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au237" phase="p1">
<sentence pmid="19633975.s7">Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to PC-3 cells could reduce the protein expressions of MMP-2 and MMP-9.</sentence>
<gene range="132-136">MMP-2</gene>
<expression_change_keyword_1 range="117-127" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="98-103" type="Negative_regulation">reduce</expression_change_keyword_2>
<cancer_term range="81-84">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au238" phase="p1">
<sentence pmid="19633975.s8">These results showed fisetin could inhibit the metastatic ability of PC-3 by reducing MMP-2 and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.</sentence>
<gene range="96-100">MMP-9</gene>
<expression_change_keyword_1 range="102-112" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="77-84" type="Negative_regulation">reducing</expression_change_keyword_2>
<cancer_term range="69-72">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au239" phase="p1">
<sentence pmid="19633975.s8">These results showed fisetin could inhibit the metastatic ability of PC-3 by reducing MMP-2 and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.</sentence>
<gene range="86-90">MMP-2</gene>
<expression_change_keyword_1 range="102-112" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="77-84" type="Negative_regulation">reducing</expression_change_keyword_2>
<cancer_term range="69-72">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au240" phase="p1">
<sentence pmid="16316409.s1">The expression of the p75 neurotrophin receptor (p75NTR) is diminished in epithelial cells during progression of prostate cancer in vivo and in vitro.</sentence>
<gene range="22-46">p75 neurotrophin receptor</gene>
<expression_change_keyword_1 range="4-13" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="60-69" type="Negative_regulation">diminished</expression_change_keyword_2>
<cancer_term range="113-127">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au241" phase="p1">
<sentence pmid="16316409.s1">The expression of the p75 neurotrophin receptor (p75NTR) is diminished in epithelial cells during progression of prostate cancer in vivo and in vitro.</sentence>
<gene range="49-54">p75NTR</gene>
<expression_change_keyword_1 range="4-13" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="60-69" type="Negative_regulation">diminished</expression_change_keyword_2>
<cancer_term range="113-127">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au242" phase="p1">
<sentence pmid="16316409.s12">Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.</sentence>
<gene range="232-239">RAR-beta</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="219-230" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="86-100">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au243" phase="p1">
<sentence pmid="16316409.s12">Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.</sentence>
<gene range="143-148">CRABPI</gene>
<expression_change_keyword_1 range="129-138" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="111-123" type="Positive_regulation">up-regulating</expression_change_keyword_2>
<cancer_term range="86-100">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au244" phase="p1">
<sentence pmid="19415690.s0">Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.</sentence>
<gene range="11-39">mitochondrial creatine kinase</gene>
<expression_change_keyword_1 range="44-56" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="44-56" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="166-180">prostate cancer</cancer_term>
<cancer_term range="103-107">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au245" phase="p1">
<sentence pmid="19415690.s8">uMtCK was up-regulated in AIPC cells and in human prostate cancer tissues at WHO grade III.</sentence>
<gene range="0-4">uMtCK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="10-21" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="50-64">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au246" phase="p1">
<sentence pmid="19415690.s12">Exogenous uMtCK in LNCaP cells surprisingly contributed to overproduction of ROS, activation of Akt signaling pathway and more aggressive phenotypes including androgen independence development.</sentence>
<gene range="77-79">ROS</gene>
<expression_change_keyword_1 range="59-72" type="Gene_expression">overproduction</expression_change_keyword_1>
<expression_change_keyword_2 range="44-54" type="Positive_regulation">contributed</expression_change_keyword_2>
<cancer_term range="19-23">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au247" phase="p1">
<sentence pmid="16049707.s0">Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.</sentence>
<gene range="119-121">p21</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="107-114" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="54-72">prostatic carcinoma</cancer_term>
<cancer_term range="81-84">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au248" phase="p1">
<sentence pmid="16049707.s0">Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.</sentence>
<gene range="127-168">hypophosphorylated retinoblastoma proteins</gene>
<expression_change_keyword_1 range="170-179" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="107-114" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="54-72">prostatic carcinoma</cancer_term>
<cancer_term range="81-84">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au249" phase="p1">
<sentence pmid="16049707.s0">Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.</sentence>
<gene range="119-121">p21</gene>
<expression_change_keyword_1 range="170-179" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="107-114" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="54-72">prostatic carcinoma</cancer_term>
<cancer_term range="81-84">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au250" phase="p1">
<sentence pmid="16049707.s0">Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.</sentence>
<gene range="127-168">hypophosphorylated retinoblastoma proteins</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="107-114" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="54-72">prostatic carcinoma</cancer_term>
<cancer_term range="81-84">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au251" phase="p1">
<sentence pmid="15790678.s5">Androgen-sensitive LNCaP prostate cancer cells engineered to stably overexpress CDK6 display increased expression of the prostate-specific antigen and enhanced growth in the presence of dihydrotestosterone.</sentence>
<gene range="80-83">CDK6</gene>
<expression_change_keyword_1 range="68-78" type="Gene_expression">overexpress</expression_change_keyword_1>
<expression_change_keyword_2 range="68-78" type="Positive_regulation">overexpress</expression_change_keyword_2>
<cancer_term range="25-39">prostate cancer</cancer_term>
<cancer_term range="19-23">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au252" phase="p1">
<sentence pmid="14971642.s0">Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells.</sentence>
<gene range="40-49">HIF-1alpha</gene>
<expression_change_keyword_1 range="51-60" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="9-15" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="65-79">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au253" phase="p1">
<sentence pmid="14971642.s0">Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells.</sentence>
<gene range="17-23">p70S6K1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="25-34" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="65-79">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au254" phase="p1">
<sentence pmid="14971642.s7">We have also shown that arsenite specifically induces HIF-1alpha, but not HIF-1beta, protein levels in prostate cancer cells in a mTOR-dependent manner.</sentence>
<gene range="54-63">HIF-1alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="46-52" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="103-117">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au255" phase="p1">
<sentence pmid="12771931.s0">Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.</sentence>
<gene range="117-131">I kappa B alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="133-141" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="58-72">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au256" phase="p1">
<sentence pmid="12771931.s4">Treatment of the androgen-independent human prostate cancer cells PC-3 with doxazosin resulted in a strong caspase-3 activation within 24 h, whereas tamsulosin, a sulphonamide-based alpha 1-adrenoceptor antagonist, had no significant apoptotic effect against prostate cancer cells.</sentence>
<gene range="107-115">caspase-3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="117-126" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="44-58">prostate cancer</cancer_term>
<cancer_term range="259-273">prostate cancer</cancer_term>
<cancer_term range="66-69">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au257" phase="p1">
<sentence pmid="12771931.s11">These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of TGF-beta1 signalling effectors and subsequently I kappa B alpha.</sentence>
<gene range="135-143">TGF-beta1</gene>
<expression_change_keyword_1 range="121-130" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="108-115" type="Positive_regulation">inducing</expression_change_keyword_2>
<cancer_term range="69-83">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au258" phase="p1">
<sentence pmid="19024511.s0">[Overexpression of human tumor metastasis-related gene TMSG-1 suppresses cell proliferation and invasion of a highly metastatic prostate cancer cell line PC-3M-1E8 in vitro].</sentence>
<gene range="19-60">human tumor metastasis-related gene TMSG-1</gene>
<expression_change_keyword_1 range="0-14" type="Gene_expression">[Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-14" type="Positive_regulation">[Overexpression</expression_change_keyword_2>
<cancer_term range="117-142">metastatic prostate cancer</cancer_term>
<cancer_term range="128-142">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au259" phase="p1">
<sentence pmid="17022003.s3">The compound investigated is present in a herbal preparation extracted from Boswellia serrata oleo-gum-resin, it inhibits the growth of chemotherapy-resistant human PC-3 prostate cancer cells in vitro and induces apoptosis as shown by activation of caspase 3 and the induction of DNA fragmentation.</sentence>
<gene range="249-257">caspase 3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="235-244" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="170-184">prostate cancer</cancer_term>
<cancer_term range="165-168">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au260" phase="p1">
<sentence pmid="14607217.s6">OC expression is elevated in prostate tumor cells and in prostate and bone stromal cells interdigitating with both localized and metastatic prostate epithelium.</sentence>
<gene range="0-1">OC</gene>
<expression_change_keyword_1 range="3-12" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-24" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="29-42">prostate tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au261" phase="p1">
<sentence pmid="20499410.s1">After glioma pathogenesis-related protein 1 (GLIPR1/Glipr1) was identified, the expression of GLIPR1 was shown to be down-regulated in human prostate cancer, owing in part to methylation in the regulatory region of this gene in prostate cancer cells.</sentence>
<gene range="94-99">GLIPR1</gene>
<expression_change_keyword_1 range="80-89" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="117-130" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="141-155">prostate cancer</cancer_term>
<cancer_term range="228-242">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au262" phase="p1">
<sentence pmid="15643450.s3">Angiogenic cytokines such as vascular endothelial growth factor (VEGF) have been identified in prostate cancer cells and tumours, and androgens appear to stimulate VEGF.</sentence>
<gene range="164-167">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="154-162" type="Positive_regulation">stimulate</expression_change_keyword_2>
<cancer_term range="95-109">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au263" phase="p1">
<sentence pmid="15720809.s0">Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.</sentence>
<gene range="18-35">12/15-lipoxygenase</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="85-99">prostate tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au264" phase="p1">
<sentence pmid="16734726.s1">Overexpression of the enhancer of zeste homolog 2 (EZH2) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of prostate cancer and several other cancers.</sentence>
<gene range="51-54">EZH2</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="172-186">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au265" phase="p1">
<sentence pmid="15982318.s2">We critically review the recent advances in prostate cancer immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in prostate cancer.</sentence>
<gene range="192-227">alpha-methylacyl coenzyme A racemase</gene>
<expression_change_keyword_1 range="174-187" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="174-187" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="44-58">prostate cancer</cancer_term>
<cancer_term range="240-254">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au266" phase="p1">
<sentence pmid="12507965.s2">The proportion of PSA-ACT is increased in prostate cancer (PCa), but immunologic determination of PSA-ACT is hampered by a background produced by nonspecific adsorption of ACT to the solid phase.</sentence>
<gene range="18-24">PSA-ACT</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="29-37" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="42-56">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au267" phase="p1">
<sentence pmid="21099103.s3">However, in this issue of the JCI, Sharma et al. show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease.</sentence>
<gene range="59-61">RB1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="63-66" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="93-107">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au268" phase="p1">
<sentence pmid="14517586.s0">Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.</sentence>
<gene range="15-28">chromogranin A</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-7" type="Positive_regulation">Elevated</expression_change_keyword_2>
<cancer_term range="154-168">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au269" phase="p1">
<sentence pmid="18076023.s6">The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.</sentence>
<gene range="57-65">ephrin-A5</gene>
<expression_change_keyword_1 range="34-43" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="24-32" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="124-128">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au270" phase="p1">
<sentence pmid="18076023.s6">The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.</sentence>
<gene range="68-80">fibronectin 1</gene>
<expression_change_keyword_1 range="34-43" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="24-32" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="124-128">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au271" phase="p1">
<sentence pmid="18076023.s6">The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.</sentence>
<gene range="48-54">ADAMTS1</gene>
<expression_change_keyword_1 range="34-43" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="24-32" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="124-128">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au272" phase="p1">
<sentence pmid="18076023.s6">The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.</sentence>
<gene range="163-166">VEGF</gene>
<expression_change_keyword_1 range="137-146" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="173-181" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="124-128">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au273" phase="p1">
<sentence pmid="18076023.s6">The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased.</sentence>
<gene range="87-98">neuropilin 1</gene>
<expression_change_keyword_1 range="34-43" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="24-32" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="124-128">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au274" phase="p1">
<sentence pmid="12539225.s0">Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.</sentence>
<gene range="24-51">bone morphogenetic protein-7</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="61-86">metastatic prostate cancer</cancer_term>
<cancer_term range="72-86">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au275" phase="p1">
<sentence pmid="10325519.s7">(3) Of the 2,272 men, 284 had elevated PSA levels and prostate carcinoma was detected in 62 men.</sentence>
<gene range="39-41">PSA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="30-37" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="54-71">prostate carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au276" phase="p1">
<sentence pmid="10325519.s11">In the first prospective study, 106 of 158 men with elevated PSA levels &amp;lt;10.0 ng/ml were further evaluated and 37 prostate carcinomas were detected.</sentence>
<gene range="61-63">PSA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="52-59" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="117-135">prostate carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au277" phase="p1">
<sentence pmid="15770517.s5">Overexpression of clusterin in LNCaP cells confers resistance to both androgen ablation and chemotherapy.</sentence>
<gene range="18-26">clusterin</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="31-35">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au278" phase="p1">
<sentence pmid="15533896.s3">In contrast to previous findings by others, PPAR-gamma ligands did not induce PPAR-gamma expression in EC or PC-3.</sentence>
<gene range="78-87">PPAR-gamma</gene>
<expression_change_keyword_1 range="89-98" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="71-76" type="Positive_regulation">induce</expression_change_keyword_2>
<cancer_term range="109-112">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au279" phase="p1">
<sentence pmid="15533896.s7">Low COX-2 expression in PC-3 was up-regulated by serum, and 15d-PGJ(2) blocked serum-induced COX-2 expression and activity in a dose-dependent manner.</sentence>
<gene range="93-97">COX-2</gene>
<expression_change_keyword_1 range="99-108" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="71-77" type="Negative_regulation">blocked</expression_change_keyword_2>
<cancer_term range="24-27">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au280" phase="p1">
<sentence pmid="15533896.s11">The present study showed that PPAR-gamma activation can be an important regulator of COX-2 in prostate cells and may be an important target for prostate cancer chemoprevention.</sentence>
<gene range="30-39">PPAR-gamma</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="41-50" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="144-158">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au281" phase="p2">
<sentence pmid="11774200.s3">Overexpression of HER2 has independent prognostic significance in early breast cancer and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied.</sentence>
<gene range="18-21">HER2</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="72-84">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au282" phase="p2">
<sentence pmid="9042197.s2">Loss of c-kit expression has been reported in 80-90% of breast cancer specimens, suggesting a possible role in the development of tumors.</sentence>
<gene range="8-12">c-kit</gene>
<expression_change_keyword_1 range="14-23" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-3" type="Negative_regulation">Loss</expression_change_keyword_2>
<cancer_term range="56-68">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au283" phase="p2">
<sentence pmid="20853062.s1">Triple-negative (TN) breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and HER2/neu amplification (HER2).</sentence>
<gene range="88-89">PR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="36-39" type="Negative_regulation">lack</expression_change_keyword_2>
<cancer_term range="21-34">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au284" phase="p2">
<sentence pmid="20853062.s1">Triple-negative (TN) breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and HER2/neu amplification (HER2).</sentence>
<gene range="60-61">ER</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="36-39" type="Negative_regulation">lack</expression_change_keyword_2>
<cancer_term range="21-34">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au285" phase="p2">
<sentence pmid="22364742.s6">Importantly, this signaling circuit is manifest in human cancer cells and in a mouse model of ErbB2-driven breast cancer, where IL6 loss significantly impairs tumorigenesis.</sentence>
<gene range="128-130">IL6</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="132-135" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="107-119">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au286" phase="p2">
<sentence pmid="12615709.s1">Treatment of MCF-7 cells with the peroxisome proliferator-activated receptor (PPAR) gamma agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-dependent decrease of cyclin D1 and estrogen receptor (ER) alpha proteins, and this was accompanied by decreased cell proliferation and G(1)-G(0)--&gt;S-phase progression.</sentence>
<gene range="226-242">estrogen receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="200-207" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="13-17">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au287" phase="p2">
<sentence pmid="12615709.s1">Treatment of MCF-7 cells with the peroxisome proliferator-activated receptor (PPAR) gamma agonists ciglitazone or 15-deoxy-Delta 12,14-prostaglandin J2 resulted in a concentration- and time-dependent decrease of cyclin D1 and estrogen receptor (ER) alpha proteins, and this was accompanied by decreased cell proliferation and G(1)-G(0)--&gt;S-phase progression.</sentence>
<gene range="212-220">cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="200-207" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="13-17">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au288" phase="p2">
<sentence pmid="11564899.s8">In conclusion, three consecutive microarray (CGH, cDNA and tissue) experiments revealed high-level amplification and overexpression of the FGFR2 in a breast cancer cell line, but only a low frequency of involvement in primary breast tumors.</sentence>
<gene range="139-143">FGFR2</gene>
<expression_change_keyword_1 range="117-130" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="117-130" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="226-238">breast tumors</cancer_term>
<cancer_term range="150-162">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au289" phase="p2">
<sentence pmid="12761490.s4">Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).</sentence>
<gene range="16-19">HER2</gene>
<expression_change_keyword_1 range="0-11" type="Gene_expression">Transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Transfection</expression_change_keyword_2>
<cancer_term range="29-41">breast cancer</cancer_term>
<cancer_term range="24-27">MCF7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au290" phase="p2">
<sentence pmid="12761490.s4">Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).</sentence>
<gene range="132-134">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="118-127" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="29-41">breast cancer</cancer_term>
<cancer_term range="24-27">MCF7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au291" phase="p2">
<sentence pmid="9010319.s1">MCF-7 (estrogen receptor positive--ER+) and MDA-MB-231 (estrogen receptor negative--ER-) are human breast cancer cell lines which express functional thyroid hormone receptors (c-erb A alpha1 and c-erb beta1) as indicated by stimulation of mitochondrial alpha-glycerophosphate dehydrogenase.</sentence>
<gene range="239-288">mitochondrial alpha-glycerophosphate dehydrogenase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="224-234" type="Positive_regulation">stimulation</expression_change_keyword_2>
<cancer_term range="99-111">breast cancer</cancer_term>
<cancer_term range="44-53">MDA-MB-231</cancer_term>
<cancer_term range="0-4">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au292" phase="p2">
<sentence pmid="9010319.s2">In MCF-7, mimicking E2, T3 stimulated growth in a dose-dependent (10(10) M - 10(-8) M) manner, induced the expression of progesterone receptor and growth factor TGFalpha mRNAs and inhibited that of TGFbeta mRNA; T3 also increased progesterone binding and LDH5 isozyme activities.</sentence>
<gene range="121-141">progesterone receptor</gene>
<expression_change_keyword_1 range="107-116" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="95-101" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au293" phase="p2">
<sentence pmid="9010319.s2">In MCF-7, mimicking E2, T3 stimulated growth in a dose-dependent (10(10) M - 10(-8) M) manner, induced the expression of progesterone receptor and growth factor TGFalpha mRNAs and inhibited that of TGFbeta mRNA; T3 also increased progesterone binding and LDH5 isozyme activities.</sentence>
<gene range="147-174">growth factor TGFalpha mRNAs</gene>
<expression_change_keyword_1 range="107-116" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="95-101" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au294" phase="p2">
<sentence pmid="9010319.s2">In MCF-7, mimicking E2, T3 stimulated growth in a dose-dependent (10(10) M - 10(-8) M) manner, induced the expression of progesterone receptor and growth factor TGFalpha mRNAs and inhibited that of TGFbeta mRNA; T3 also increased progesterone binding and LDH5 isozyme activities.</sentence>
<gene range="255-266">LDH5 isozyme</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="220-228" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au295" phase="p2">
<sentence pmid="9010319.s4">10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.</sentence>
<gene range="128-139">TGFbeta mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="119-126" type="Positive_regulation">restored</expression_change_keyword_2>
<cancer_term range="173-177">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au296" phase="p2">
<sentence pmid="9010319.s4">10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.</sentence>
<gene range="65-85">progesterone receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-63" type="Negative_regulation">suppressed</expression_change_keyword_2>
<cancer_term range="173-177">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au297" phase="p2">
<sentence pmid="9010319.s4">10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells.</sentence>
<gene range="91-103">TGFalpha mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="105-113" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="173-177">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au298" phase="p2">
<sentence pmid="11118434.s4">Expression of C2GnT1 is low or absent in around 50% of breast cancers, whereas expression of ST3Gal-I is consistently increased.</sentence>
<gene range="93-100">ST3Gal-I</gene>
<expression_change_keyword_1 range="79-88" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="118-126" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="55-68">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au299" phase="p2">
<sentence pmid="11118434.s9">Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of ST3Gal-I is increased as it is in breast cancer.</sentence>
<gene range="124-131">ST3Gal-I</gene>
<expression_change_keyword_1 range="110-119" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="136-144" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="158-170">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au300" phase="p2">
<sentence pmid="12422056.s1">HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy.</sentence>
<gene range="0-3">HER2</gene>
<expression_change_keyword_1 range="5-18" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="5-18" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="62-74">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au301" phase="p2">
<sentence pmid="15688367.s6">Overexpressing ID2 in the MDA-MB-468 breast cancer cell line generated a marked cytoplasmic localisation of the protein and reduced the invasive capacity of cells.</sentence>
<gene range="15-17">ID2</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpressing</expression_change_keyword_2>
<cancer_term range="37-49">breast cancer</cancer_term>
<cancer_term range="26-35">MDA-MB-468</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au302" phase="p2">
<sentence pmid="15113415.s1">The cellular retinol binding protein I gene (CRBP) is downregulated in a subset of human breast cancers and in MMTV-Myc induced mouse mammary tumors.</sentence>
<gene range="45-48">CRBP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-66" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="134-147">mammary tumors</cancer_term>
<cancer_term range="89-102">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au303" phase="p2">
<sentence pmid="15113415.s1">The cellular retinol binding protein I gene (CRBP) is downregulated in a subset of human breast cancers and in MMTV-Myc induced mouse mammary tumors.</sentence>
<gene range="4-42">cellular retinol binding protein I gene</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-66" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="134-147">mammary tumors</cancer_term>
<cancer_term range="89-102">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au304" phase="p2">
<sentence pmid="15113415.s2">Functional studies suggest that CRBP downregulation contributes to breast tumor progression.</sentence>
<gene range="32-35">CRBP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="37-50" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="67-78">breast tumor</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au305" phase="p2">
<sentence pmid="16464948.s8">The insLQ polymorphism increases LHR activity, thereby shortening breast cancer disease-free survival, probably by increasing estrogen exposure in female carriers.</sentence>
<gene range="33-35">LHR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="23-31" type="Positive_regulation">increases</expression_change_keyword_2>
<cancer_term range="66-78">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au306" phase="p2">
<sentence pmid="1436241.s4">IFN-alpha increased the cell surface expression of DR antigen only in ZR-75-1 cells.</sentence>
<gene range="51-60">DR antigen</gene>
<expression_change_keyword_1 range="37-46" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="10-18" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="70-76">ZR-75-1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au307" phase="p2">
<sentence pmid="1436241.s5">IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells.</sentence>
<gene range="103-119">HLA class II (DR)</gene>
<expression_change_keyword_1 range="121-130" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="11-17" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="81-90">MDA-MB-468</cancer_term>
<cancer_term range="62-68">ZR-75-1</cancer_term>
<cancer_term range="140-146">ZR-75-1</cancer_term>
<cancer_term range="71-75">BT-20</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au308" phase="p2">
<sentence pmid="1349318.s9">No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.</sentence>
<gene range="69-74">PTPase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="59-67" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="167-180">mammary tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au309" phase="p2">
<sentence pmid="1349318.s9">No statistically significant association was found between increased PTPase activity and either c-erbB-2 overexpression or grade and stage of disease in primary human mammary tumors.</sentence>
<gene range="96-103">c-erbB-2</gene>
<expression_change_keyword_1 range="105-118" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="105-118" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="167-180">mammary tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au310" phase="p2">
<sentence pmid="21643005.s12">Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of FASN in MCF-7 cells.</sentence>
<gene range="94-97">FASN</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="59-67" type="Positive_regulation">stimulate</expression_change_keyword_2>
<cancer_term range="102-106">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au311" phase="p2">
<sentence pmid="20504320.s8">In aggregate, these studies support the notion that TGF-beta plays an important role in both bone-and lung metastases of basal-like breast cancer, and that inhibiting TGF-beta signaling results in a therapeutic effect independently of the tissue-tropism of the metastatic cells.</sentence>
<gene range="167-174">TGF-beta</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="156-165" type="Negative_regulation">inhibiting</expression_change_keyword_2>
<cancer_term range="132-144">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au312" phase="p2">
<sentence pmid="19115233.s0">Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins.</sentence>
<gene range="8-17">profilin-1</gene>
<expression_change_keyword_1 range="19-28" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-3" type="Negative_regulation">Loss</expression_change_keyword_2>
<cancer_term range="39-51">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au313" phase="p2">
<sentence pmid="19115233.s2">Herein, we demonstrate that loss of Pfn1 expression leads to slower but more stable lamellipodial protrusion thereby enhancing the net protrusion rate and the overall motility of MDA-MB-231 breast cancer cells.</sentence>
<gene range="36-39">Pfn1</gene>
<expression_change_keyword_1 range="41-50" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="28-31" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="190-202">breast cancer</cancer_term>
<cancer_term range="179-188">MDA-MB-231</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au314" phase="p2">
<sentence pmid="19115233.s3">Interestingly, MDA-MB-231 cells showed dramatic enrichment of VASP at their leading edge when Pfn1 expression was downregulated and this observation was also reproducible in other cell types including human mammary epithelial cells and vascular endothelial cells.</sentence>
<gene range="94-97">Pfn1</gene>
<expression_change_keyword_1 range="99-108" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="114-126" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="15-24">MDA-MB-231</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au315" phase="p2">
<sentence pmid="19115233.s4">We further demonstrate that Pfn1 downregulation results in a hyper-motile phenotype of MDA-MB-231 cells in an Ena/VASP-dependent mechanism.</sentence>
<gene range="28-31">Pfn1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="33-46" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="87-96">MDA-MB-231</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au316" phase="p2">
<sentence pmid="7917361.s8">We conclude that c-erbB-2 protein overexpression assessed by IHC is a superior prognostic indicator in operable breast cancer compared to c-erbB-2 gene amplification analysed by the dot-blot technique.</sentence>
<gene range="17-32">c-erbB-2 protein</gene>
<expression_change_keyword_1 range="34-47" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="34-47" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="112-124">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au317" phase="p2">
<sentence pmid="7949208.s0">Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.</sentence>
<gene range="81-89">aromatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="67-76" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="103-115">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au318" phase="p2">
<sentence pmid="7949208.s6">The inhibition of aromatase activity by these imidazole derivatives as second line therapy for patients with hormone dependent breast cancer appears to be a favorable alternative form of hormone ablative therapy and holds considerable promise for the treatment of this malignancy.</sentence>
<gene range="18-26">aromatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-13" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="127-139">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au319" phase="p2">
<sentence pmid="12861063.s3">The analysis of E-cadherin glycoprotein expression is a powerful tool for distinguishing lobular from ductal carcinomas, because complete loss of E-cadherin expression occurs in most infiltrating lobular tumors and lobular carcinomas in situ, but not in ductal tumors.</sentence>
<gene range="146-155">E-cadherin</gene>
<expression_change_keyword_1 range="157-166" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="138-141" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="215-232">lobular carcinomas</cancer_term>
<cancer_term range="102-118">ductal carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au320" phase="p2">
<sentence pmid="11156389.s7">We show, for the first time in a transgenic mouse model, that mammary tumor progression is associated with the loss of ERalpha expression, as has been often observed in human breast cancers with important clinical significance.</sentence>
<gene range="119-125">ERalpha</gene>
<expression_change_keyword_1 range="127-136" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="111-114" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="175-188">breast cancers</cancer_term>
<cancer_term range="62-74">mammary tumor</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au321" phase="p2">
<sentence pmid="8080727.s2">A strong association has been observed between reduced expression of the nm23 gene and acquisition of metastatic behaviour in some tumour cells, including breast cancer and melanoma, but not in others, such as neuroblastoma and colon, cervical and thyroid cancers.</sentence>
<gene range="73-81">nm23 gene</gene>
<expression_change_keyword_1 range="55-64" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="47-53" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="155-167">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au322" phase="p2">
<sentence pmid="18181175.s3">Here, we show that overexpression of BIRC5 induces a high proliferation level in MCF-7 breast tumor cells.</sentence>
<gene range="37-41">BIRC5</gene>
<expression_change_keyword_1 range="19-32" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-32" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="87-98">breast tumor</cancer_term>
<cancer_term range="81-85">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au323" phase="p2">
<sentence pmid="16489002.s0">ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.</sentence>
<gene range="16-57">vascular endothelial growth factor protein</gene>
<expression_change_keyword_1 range="59-67" type="Gene_expression">synthesis</expression_change_keyword_1>
<expression_change_keyword_2 range="6-14" type="Positive_regulation">increases</expression_change_keyword_2>
<cancer_term range="194-206">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au324" phase="p2">
<sentence pmid="16489002.s1">ErbB2 overexpression in breast tumors results in increased metastasis and angiogenesis and reduced survival.</sentence>
<gene range="0-4">ErbB2</gene>
<expression_change_keyword_1 range="6-19" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="6-19" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="24-36">breast tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au325" phase="p2">
<sentence pmid="18066063.s3">Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.</sentence>
<gene range="73-76">Pten</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="31-42" type="Negative_regulation">inactivation</expression_change_keyword_2>
<cancer_term range="260-284">hereditary breast cancers</cancer_term>
<cancer_term range="115-128">mammary tumors</cancer_term>
<cancer_term range="271-284">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au326" phase="p2">
<sentence pmid="18066063.s3">Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.</sentence>
<gene range="156-159">PTEN</gene>
<expression_change_keyword_1 range="161-170" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="148-151" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="260-284">hereditary breast cancers</cancer_term>
<cancer_term range="115-128">mammary tumors</cancer_term>
<cancer_term range="271-284">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au327" phase="p2">
<sentence pmid="18945339.s13">HER-2 over-expression was observed in 18.1% of Tunisian breast carcinoma affecting female patients.</sentence>
<gene range="0-4">HER-2</gene>
<expression_change_keyword_1 range="6-20" type="Gene_expression">over-expression</expression_change_keyword_1>
<expression_change_keyword_2 range="6-20" type="Positive_regulation">over-expression</expression_change_keyword_2>
<cancer_term range="56-71">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au328" phase="p2">
<sentence pmid="18829495.s9">Here, we defined a new mechanism for IMC-C225 that cross-links integrins with EGFR, leading to activation of RhoA and inhibition of breast cancer cell invasion irrespective of the level of EGFR in the cells, thus providing a rationale for using IMC-C225 in the metastatic setting independent of the levels of EGFR.</sentence>
<gene range="109-112">RhoA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="95-104" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="132-144">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au329" phase="p2">
<sentence pmid="15313907.s3">Southern analysis of breast cancer profiling arrays revealed that 29 patients (group I) expressed an elevated LF, 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue.</sentence>
<gene range="154-155">LF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="144-152" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="21-33">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au330" phase="p2">
<sentence pmid="15894658.s9">This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.</sentence>
<gene range="160-163">SHBG</gene>
<expression_change_keyword_1 range="165-170" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="137-146" type="Positive_regulation">increasing</expression_change_keyword_2>
<cancer_term range="93-105">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au331" phase="p2">
<sentence pmid="16510571.s3">Activated STAT3 correlated with elevated cyclin D1 protein in primary breast tumors and breast cancer-derived cell lines.</sentence>
<gene range="10-14">STAT3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Activated</expression_change_keyword_2>
<cancer_term range="70-82">breast tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au332" phase="p2">
<sentence pmid="16510571.s3">Activated STAT3 correlated with elevated cyclin D1 protein in primary breast tumors and breast cancer-derived cell lines.</sentence>
<gene range="41-57">cyclin D1 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="32-39" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="70-82">breast tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au333" phase="p2">
<sentence pmid="16510571.s7">Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth.</sentence>
<gene range="26-34">cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="13-21" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="39-54">breast carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au334" phase="p2">
<sentence pmid="15359289.s1">The EphA2 receptor tyrosine kinase is frequently overexpressed in invasive breast cancer cells.</sentence>
<gene range="4-33">EphA2 receptor tyrosine kinase</gene>
<expression_change_keyword_1 range="49-61" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="49-61" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="66-87">invasive breast cancer</cancer_term>
<cancer_term range="75-87">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au335" phase="p2">
<sentence pmid="20525379.s12">AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.</sentence>
<gene range="85-92">survivin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="71-83" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="37-43">ZR-75-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au336" phase="p2">
<sentence pmid="20525379.s12">AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.</sentence>
<gene range="98-102">c-Myc</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="71-83" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="37-43">ZR-75-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au337" phase="p2">
<sentence pmid="20525379.s12">AGR2 knockdown induced cell death in ZR-75-1 and T47 D cells, and also downregulated survivin and c-Myc.</sentence>
<gene range="0-3">AGR2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-13" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="37-43">ZR-75-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au338" phase="p2">
<sentence pmid="11964084.s1">Increased cellular activity of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human breast cancer, thus suggesting an important role for PA in tumor progression.</sentence>
<gene range="31-53">ornithine decarboxylase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="200-212">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au339" phase="p2">
<sentence pmid="11964084.s1">Increased cellular activity of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human breast cancer, thus suggesting an important role for PA in tumor progression.</sentence>
<gene range="56-58">ODC</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="200-212">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au340" phase="p2">
<sentence pmid="11518717.s1">Hyperactivation of the insulin-like growth factor I receptor (IGF-IR) contributes to primary breast cancer development, but the role of the IGF-IR in tumor metastasis is unclear.</sentence>
<gene range="23-59">insulin-like growth factor I receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-14" type="Positive_regulation">Hyperactivation</expression_change_keyword_2>
<cancer_term range="93-105">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au341" phase="p2">
<sentence pmid="11518717.s1">Hyperactivation of the insulin-like growth factor I receptor (IGF-IR) contributes to primary breast cancer development, but the role of the IGF-IR in tumor metastasis is unclear.</sentence>
<gene range="62-67">IGF-IR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-14" type="Positive_regulation">Hyperactivation</expression_change_keyword_2>
<cancer_term range="93-105">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au342" phase="p2">
<sentence pmid="11518717.s3">We found that IGF-IR overexpression markedly stimulated aggregation in E-cad-positive MCF-7 breast cancer cells, but not in E-cad-negative MDA-MB-231 cells.</sentence>
<gene range="14-19">IGF-IR</gene>
<expression_change_keyword_1 range="21-34" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="21-34" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="92-104">breast cancer</cancer_term>
<cancer_term range="139-148">MDA-MB-231</cancer_term>
<cancer_term range="86-90">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au343" phase="p2">
<sentence pmid="2516715.s3">All three interferons and TPA enhanced the expression of the Mr 180,000 carcinoembryonic antigen (CEA) and CEA-related TAA recognized by monoclonal antibody B1.1 in both T47D and MCF-7 human breast carcinoma cell lines.</sentence>
<gene range="72-95">carcinoembryonic antigen</gene>
<expression_change_keyword_1 range="43-52" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="30-37" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="191-206">breast carcinoma</cancer_term>
<cancer_term range="179-183">MCF-7</cancer_term>
<cancer_term range="170-173">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au344" phase="p2">
<sentence pmid="2516715.s3">All three interferons and TPA enhanced the expression of the Mr 180,000 carcinoembryonic antigen (CEA) and CEA-related TAA recognized by monoclonal antibody B1.1 in both T47D and MCF-7 human breast carcinoma cell lines.</sentence>
<gene range="98-100">CEA</gene>
<expression_change_keyword_1 range="43-52" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="30-37" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="191-206">breast carcinoma</cancer_term>
<cancer_term range="179-183">MCF-7</cancer_term>
<cancer_term range="170-173">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au345" phase="p2">
<sentence pmid="2516715.s3">All three interferons and TPA enhanced the expression of the Mr 180,000 carcinoembryonic antigen (CEA) and CEA-related TAA recognized by monoclonal antibody B1.1 in both T47D and MCF-7 human breast carcinoma cell lines.</sentence>
<gene range="107-121">CEA-related TAA</gene>
<expression_change_keyword_1 range="43-52" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="30-37" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="191-206">breast carcinoma</cancer_term>
<cancer_term range="179-183">MCF-7</cancer_term>
<cancer_term range="170-173">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au346" phase="p2">
<sentence pmid="2516715.s5">In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and HLA-DR expression in T47D and MCF-7 cells.</sentence>
<gene range="131-136">HLA-DR</gene>
<expression_change_keyword_1 range="138-147" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="76-85" type="Positive_regulation">augmenting</expression_change_keyword_2>
<cancer_term range="161-165">MCF-7</cancer_term>
<cancer_term range="152-155">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au347" phase="p2">
<sentence pmid="19041697.s6">In addition, Cd enhanced DNA synthesis and pS2 mRNA levels in estrogen (10 pM estradiol) treated T47D cells.</sentence>
<gene range="43-50">pS2 mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="16-23" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="97-100">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au348" phase="p2">
<sentence pmid="15040833.s2">E2 but not ICI stimulated BMP-6 reporter activity in breast cancer cells, whereas the opposite was observed in osteoblast-like cells, associated with lack of AF-2 dependence of the response, and absent intranuclear localization of ERalpha, suggesting the involvement of a distinct ERalpha-dependent response mechanism in osteoblasts.</sentence>
<gene range="26-30">BMP-6</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="15-24" type="Positive_regulation">stimulated</expression_change_keyword_2>
<cancer_term range="53-65">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au349" phase="p2">
<sentence pmid="15040833.s6">E2, but not ICI, stimulated BMP-6 reporter activity by approximately 100% in MCF-7, T47-D cells, and HepG2 cells when transfected with ERalpha.</sentence>
<gene range="135-141">ERalpha</gene>
<expression_change_keyword_1 range="118-128" type="Gene_expression">transfected</expression_change_keyword_1>
<expression_change_keyword_2 range="118-128" type="Positive_regulation">transfected</expression_change_keyword_2>
<cancer_term range="77-81">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au350" phase="p2">
<sentence pmid="10998426.s1">We report that transfection of insulin-like growth factor-binding protein-3 (IGFBP-3) cDNA in human breast cancer cell lines expressing either mutant p53 (T47D) or wild-type p53 (MCF-7) induces apoptosis.</sentence>
<gene range="31-74">insulin-like growth factor-binding protein-3</gene>
<expression_change_keyword_1 range="15-26" type="Gene_expression">transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="15-26" type="Positive_regulation">transfection</expression_change_keyword_2>
<cancer_term range="100-112">breast cancer</cancer_term>
<cancer_term range="179-183">MCF-7</cancer_term>
<cancer_term range="155-158">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au351" phase="p2">
<sentence pmid="10998426.s1">We report that transfection of insulin-like growth factor-binding protein-3 (IGFBP-3) cDNA in human breast cancer cell lines expressing either mutant p53 (T47D) or wild-type p53 (MCF-7) induces apoptosis.</sentence>
<gene range="77-83">IGFBP-3</gene>
<expression_change_keyword_1 range="15-26" type="Gene_expression">transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="15-26" type="Positive_regulation">transfection</expression_change_keyword_2>
<cancer_term range="100-112">breast cancer</cancer_term>
<cancer_term range="179-183">MCF-7</cancer_term>
<cancer_term range="155-158">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au352" phase="p2">
<sentence pmid="10998426.s3">In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.</sentence>
<gene range="74-89">Bcl-x(L) protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="62-69" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au353" phase="p2">
<sentence pmid="10998426.s3">In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.</sentence>
<gene range="95-107">Bcl-2 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="62-69" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au354" phase="p2">
<sentence pmid="10998426.s3">In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.</sentence>
<gene range="25-27">Bad</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="13-20" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au355" phase="p2">
<sentence pmid="10998426.s3">In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.</sentence>
<gene range="25-27">Bad</gene>
<expression_change_keyword_1 range="45-54" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="13-20" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au356" phase="p2">
<sentence pmid="10998426.s3">In MCF-7, an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.</sentence>
<gene range="33-43">Bax protein</gene>
<expression_change_keyword_1 range="45-54" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="13-20" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="3-7">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au357" phase="p2">
<sentence pmid="10998426.s4">In T47D, Bax and Bad proteins were up-regulated; Bcl-2 protein is undetectable in these cells.</sentence>
<gene range="17-28">Bad proteins</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-46" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="3-6">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au358" phase="p2">
<sentence pmid="10998426.s4">In T47D, Bax and Bad proteins were up-regulated; Bcl-2 protein is undetectable in these cells.</sentence>
<gene range="9-11">Bax</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-46" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="3-6">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au359" phase="p2">
<sentence pmid="10998426.s8">Transfection of IGFBP-3 increased the radiosensitivity of T47D and increased IR-induced apoptosis but did not effect a rapid G(1) arrest.</sentence>
<gene range="16-22">IGFBP-3</gene>
<expression_change_keyword_1 range="0-11" type="Gene_expression">Transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Transfection</expression_change_keyword_2>
<cancer_term range="58-61">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au360" phase="p2">
<sentence pmid="17595766.s6">HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness.</sentence>
<gene range="12-14">Dgk</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="16-25" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="30-39">MDA-MB-231</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au361" phase="p2">
<sentence pmid="21070441.s0">Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.</sentence>
<gene range="72-80">Her-2/neu</gene>
<expression_change_keyword_1 range="57-70" type="Gene_expression">overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="57-70" type="Positive_regulation">overexpressing</expression_change_keyword_2>
<cancer_term range="43-55">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au362" phase="p2">
<sentence pmid="15609126.s0">Increased frequency of long androgen receptor CAG repeats in male breast cancers.</sentence>
<gene range="28-56">androgen receptor CAG repeats</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="61-79">male breast cancers</cancer_term>
<cancer_term range="66-79">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au363" phase="p2">
<sentence pmid="7814146.s10">Stimulation of SKBR3 cells and HCII RI#11 mouse mammary epithelial cells expressing the human erbB-2 with EGF led to an increase in scFv(FRP5)-ETA activity, showing that the EGF-induced activation of erbB-2 can potentiate the action of the erbB-2-directed toxin.</sentence>
<gene range="137-140">FRP5</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="120-127" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="15-19">SKBR3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au364" phase="p2">
<sentence pmid="7814146.s10">Stimulation of SKBR3 cells and HCII RI#11 mouse mammary epithelial cells expressing the human erbB-2 with EGF led to an increase in scFv(FRP5)-ETA activity, showing that the EGF-induced activation of erbB-2 can potentiate the action of the erbB-2-directed toxin.</sentence>
<gene range="200-205">erbB-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="186-195" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="15-19">SKBR3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au365" phase="p2">
<sentence pmid="7814146.s10">Stimulation of SKBR3 cells and HCII RI#11 mouse mammary epithelial cells expressing the human erbB-2 with EGF led to an increase in scFv(FRP5)-ETA activity, showing that the EGF-induced activation of erbB-2 can potentiate the action of the erbB-2-directed toxin.</sentence>
<gene range="132-135">scFv</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="120-127" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="15-19">SKBR3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au366" phase="p2">
<sentence pmid="17079470.s5">By using 5' deletion mutant constructs of MMP-2 promoter, we showed that deletion of the region containing activator protein-1 (AP-1) site caused the greatest reduction of MMP-2 promoter activity both in MKK6- and H-Ras-activated MCF10A cells, suggesting that the AP-1 binding site is critical for the MMP-2 promoter activation.</sentence>
<gene range="302-315">MMP-2 promoter</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="317-326" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="230-235">MCF10A</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au367" phase="p2">
<sentence pmid="17079470.s8">Activation of ATF2, which depended on p38 activity, was crucial for MMP-2 promoter activity as well as induction of invasive and migrative phenotypes in MCF10A cells.</sentence>
<gene range="14-17">ATF2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Positive_regulation">Activation</expression_change_keyword_2>
<cancer_term range="153-158">MCF10A</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au368" phase="p2">
<sentence pmid="10323669.s2">It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.</sentence>
<gene range="292-308">c-jun early genes</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="264-273" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="127-139">breast cancer</cancer_term>
<cancer_term range="217-229">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au369" phase="p2">
<sentence pmid="10323669.s2">It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.</sentence>
<gene range="282-286">c-fos</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="264-273" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="127-139">breast cancer</cancer_term>
<cancer_term range="217-229">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au370" phase="p2">
<sentence pmid="10323669.s2">It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in breast cancer cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.</sentence>
<gene range="72-114">Src/p21ras/mitogen-activated protein kinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="58-66" type="Positive_regulation">stimulate</expression_change_keyword_2>
<cancer_term range="127-139">breast cancer</cancer_term>
<cancer_term range="217-229">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au371" phase="p2">
<sentence pmid="2521857.s2">We now show that the MDA468 breast cancer cells express the mRNA for the EGF-like molecule, transforming growth factor-alpha (TGF-alpha), and demonstrate that TPA or EGF cause an accumulation of both EGF receptor and TGF-alpha mRNA.</sentence>
<gene range="217-230">TGF-alpha mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="179-190" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="28-40">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au372" phase="p2">
<sentence pmid="12824874.s2">It has, however, been reported that expression of connexin26 (Cx26) protein is induced in human ductal carcinomas of the breast and that its amount increases in proportion to the grade of malignancy.</sentence>
<gene range="50-74">connexin26 (Cx26) protein</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="79-85" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="96-112">ductal carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au373" phase="p2">
<sentence pmid="12824874.s9">Our results strongly suggest that the induction of Cx26 protein observed in human breast cancers, reported previously, may not be very relevant to the development of breast cancers, and that Cx26 can function as a tumor suppressor in breast cancer cells.</sentence>
<gene range="51-62">Cx26 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="82-95">breast cancers</cancer_term>
<cancer_term range="166-179">breast cancers</cancer_term>
<cancer_term range="234-246">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au374" phase="p2">
<sentence pmid="16145051.s5">These results support the hypothesis that EMSY overexpression can play a role in the genesis of human breast cancer.</sentence>
<gene range="42-45">EMSY</gene>
<expression_change_keyword_1 range="47-60" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="47-60" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="102-114">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au375" phase="p2">
<sentence pmid="16234819.s6">In this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in MCF-7 human breast cancer cells.</sentence>
<gene range="57-64">sVEGFR-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="148-160">breast cancer</cancer_term>
<cancer_term range="136-140">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au376" phase="p2">
<sentence pmid="16234819.s6">In this study we show that oestradiol decreased secreted sVEGFR-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in MCF-7 human breast cancer cells.</sentence>
<gene range="86-89">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="67-75" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="148-160">breast cancer</cancer_term>
<cancer_term range="136-140">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au377" phase="p2">
<sentence pmid="20535861.s2">The synergistic action of unopposed oestrogen and leptin, compounded by increasing insulin, cortisol and xeno-oestrogen exposure directly initiate, promote and exacerbate obesity, type 2 diabetes, uterine overgrowth, prostatic enlargement, prostate cancer and breast cancer.</sentence>
<gene range="83-89">insulin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="72-81" type="Positive_regulation">increasing</expression_change_keyword_2>
<cancer_term range="260-272">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au378" phase="p2">
<sentence pmid="16755107.s0">Activation of PI3K/Akt signaling and hormone resistance in breast cancer.</sentence>
<gene range="14-21">PI3K/Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Positive_regulation">Activation</expression_change_keyword_2>
<cancer_term range="59-71">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au379" phase="p2">
<sentence pmid="16755107.s2">Recent studies show that aberrant activation of Akt in breast carcinoma is associated with a poor prognosis and resistance to endocrine therapy and chemotherapy.</sentence>
<gene range="48-50">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="34-43" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="55-70">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au380" phase="p2">
<sentence pmid="16755107.s13">These findings therefore suggest that Akt activation induces endocrine resistance in metastatic breast cancer, irrespective of the kind of endocrine agents that were administered.</sentence>
<gene range="38-40">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="42-51" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="85-108">metastatic breast cancer</cancer_term>
<cancer_term range="96-108">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au381" phase="p2">
<sentence pmid="16755107.s14">Our findings indicate that the activation of Akt in the downstream pathway of HER2 plays an important role in resistance to endocrine therapy for breast cancer.</sentence>
<gene range="45-47">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="31-40" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="146-158">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au382" phase="p2">
<sentence pmid="16755107.s15">Our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.</sentence>
<gene range="156-158">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="142-151" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="96-108">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au383" phase="p2">
<sentence pmid="19432961.s13">Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.</sentence>
<gene range="172-179">miR-520g</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="158-170" type="Negative_regulation">downregulated</expression_change_keyword_2>
<cancer_term range="83-96">breast tumours</cancer_term>
<cancer_term range="298-310">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au384" phase="p2">
<sentence pmid="19432961.s13">Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.</sentence>
<gene range="109-115">miR-342</gene>
<expression_change_keyword_1 range="117-126" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="99-107" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="83-96">breast tumours</cancer_term>
<cancer_term range="298-310">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au385" phase="p2">
<sentence pmid="19432961.s13">Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.</sentence>
<gene range="24-30">miR-342</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Decreased</expression_change_keyword_2>
<cancer_term range="83-96">breast tumours</cancer_term>
<cancer_term range="298-310">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au386" phase="p2">
<sentence pmid="12459033.s2">In nuclear run-on assays, 17beta-estradiol (E2) increased the rate of Tf gene expression approximately 3-fold within 1 h after treatment and reporter gene activity was also induced in MCF-7 cells transfected with a construct containing a -3600 to +39 Tf gene promoter insert.</sentence>
<gene range="70-76">Tf gene</gene>
<expression_change_keyword_1 range="78-87" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="48-56" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="184-188">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au387" phase="p2">
<sentence pmid="21855113.s0">SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.</sentence>
<gene range="0-10">SCARA3 mRNA</gene>
<expression_change_keyword_1 range="15-27" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="15-27" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="64-79">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au388" phase="p2">
<sentence pmid="21855113.s1">Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.</sentence>
<gene range="38-43">SCARA3</gene>
<expression_change_keyword_1 range="73-85" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="73-85" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="150-165">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au389" phase="p2">
<sentence pmid="21855113.s1">Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.</sentence>
<gene range="0-35">Scavenger receptor class A, member 3</gene>
<expression_change_keyword_1 range="73-85" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="73-85" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="150-165">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au390" phase="p2">
<sentence pmid="22310293.s2">miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL).</sentence>
<gene range="0-4">miR-9</gene>
<expression_change_keyword_1 range="9-21" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="9-21" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="100-112">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au391" phase="p2">
<sentence pmid="17342334.s5">It was found that there were both significant overexpression of Wnt5A and underexpression of Wnt10B in the metastasis-derived finite life-span breast cancer cells when they were compared to the finite life-span normal and established normal and breast tumor cells.</sentence>
<gene range="64-68">Wnt5A</gene>
<expression_change_keyword_1 range="46-59" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="46-59" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="143-155">breast cancer</cancer_term>
<cancer_term range="245-256">breast tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au392" phase="p2">
<sentence pmid="21176537.s9">Compared with that of the vector control and naïve MCF7 cell group, there was a significant decrease of BCSG-1 protein expression in the four experimental groups by immuno-histochemistry staining (P&lt;0.01).</sentence>
<gene range="104-117">BCSG-1 protein</gene>
<expression_change_keyword_1 range="119-128" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="92-99" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="51-54">MCF7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au393" phase="p2">
<sentence pmid="21176537.s11">BCSG1-siRNA down-regulates the expression of BCSG1 and inhibits effectively growth of the transplaned human breast cancer cell line in nude mice.</sentence>
<gene range="45-49">BCSG1</gene>
<expression_change_keyword_1 range="31-40" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="12-25" type="Negative_regulation">down-regulates</expression_change_keyword_2>
<cancer_term range="108-120">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au394" phase="p2">
<sentence pmid="11891846.s1">We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block c-fms RNA and protein expression in some breast cancer cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).</sentence>
<gene range="115-123">c-fms RNA</gene>
<expression_change_keyword_1 range="137-146" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="109-113" type="Negative_regulation">block</expression_change_keyword_2>
<cancer_term range="156-168">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au395" phase="p2">
<sentence pmid="9472634.s4">In MDA-MB-231, TGF-beta1 had no effect on cell proliferation but increased uPA activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level.</sentence>
<gene range="92-104">PAI-1 antigen</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="65-73" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="3-12">MDA-MB-231</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au396" phase="p2">
<sentence pmid="9472634.s4">In MDA-MB-231, TGF-beta1 had no effect on cell proliferation but increased uPA activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level.</sentence>
<gene range="75-77">uPA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="65-73" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="3-12">MDA-MB-231</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au397" phase="p2">
<sentence pmid="9472634.s4">In MDA-MB-231, TGF-beta1 had no effect on cell proliferation but increased uPA activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level.</sentence>
<gene range="167-169">uPA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="129-137" type="Negative_regulation">inhibited</expression_change_keyword_2>
<cancer_term range="3-12">MDA-MB-231</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au398" phase="p2">
<sentence pmid="20622894.s7">The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest.</sentence>
<gene range="129-131">p21</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="113-124" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="49-61">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au399" phase="p2">
<sentence pmid="20711231.s1">The activation of receptor tyrosine kinases, particularly ErbB2, has an important role in the genesis of breast cancer.</sentence>
<gene range="58-62">ErbB2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-13" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="105-117">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au400" phase="p2">
<sentence pmid="20711231.s5">We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human breast tumor samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and Akt pathways.</sentence>
<gene range="355-357">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="329-338" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="106-117">breast tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au401" phase="p2">
<sentence pmid="20711231.s5">We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human breast tumor samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and Akt pathways.</sentence>
<gene range="347-349">Erk</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="329-338" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="106-117">breast tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au402" phase="p2">
<sentence pmid="20711231.s5">We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human breast tumor samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and Akt pathways.</sentence>
<gene range="66-68">Pak</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="52-61" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="106-117">breast tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au403" phase="p2">
<sentence pmid="20711231.s7">Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo.</sentence>
<gene range="134-136">Erk</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="116-129" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="25-37">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au404" phase="p2">
<sentence pmid="20711231.s7">Finally, ErbB2-amplified breast cancer cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and Akt signaling in vivo.</sentence>
<gene range="142-144">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="116-129" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="25-37">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au405" phase="p2">
<sentence pmid="21809344.s4">Runx2 expression in C4-2B PCa cells synergized with AR to promote PIP expression, whereas its knockdown in T47D BCa cells abrogated basal as well as hormone stimulated PIP expression.</sentence>
<gene range="66-68">PIP</gene>
<expression_change_keyword_1 range="70-79" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="58-64" type="Positive_regulation">promote</expression_change_keyword_2>
<cancer_term range="107-110">T47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au406" phase="p2">
<sentence pmid="12442345.s6">Similarly, neoadjuvant studies demonstrate that letrozole substantially inhibits aromatase activity in both malignant and nonmalignant breast tissues, and markedly suppresses endogenous estrogens within the breast cancers.</sentence>
<gene range="81-89">aromatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="72-79" type="Negative_regulation">inhibits</expression_change_keyword_2>
<cancer_term range="207-220">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au407" phase="p2">
<sentence pmid="9849446.s4">After a median follow-up of 65 months, an increase in TGF-beta 1 over 1 year was the only significant, independent predictor of a shorter survival free from secondary primary breast cancer.</sentence>
<gene range="54-63">TGF-beta 1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="42-49" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="175-187">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au408" phase="p2">
<sentence pmid="20302909.s0">Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.</sentence>
<gene range="0-25">Estrogen receptor alpha 46</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="30-36" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="61-73">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au409" phase="p2">
<sentence pmid="20302909.s3">We observed reduced protein expression of an N-terminally truncated ERalpha46 in endocrine-resistant LCC2, LCC9, and LY2 compared to MCF-7 breast cancer cells.</sentence>
<gene range="68-76">ERalpha46</gene>
<expression_change_keyword_1 range="28-37" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="12-18" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="139-151">breast cancer</cancer_term>
<cancer_term range="133-137">MCF-7</cancer_term>
<cancer_term range="117-119">LY2</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au410" phase="p2">
<sentence pmid="20302909.s4">Transfection of LCC9 and LY2 cells with hERalpha46 partially restored growth inhibition by TAM.</sentence>
<gene range="40-49">hERalpha46</gene>
<expression_change_keyword_1 range="0-11" type="Gene_expression">Transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Transfection</expression_change_keyword_2>
<cancer_term range="25-27">LY2</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au411" phase="p2">
<sentence pmid="20302909.s5">Overexpression of hERalpha46 in MCF-7 cells reduced estradiol (E(2))-stimulated endogenous pS2, cyclin D1, nuclear respiratory factor-1 (NRF-1), and progesterone receptor transcription.</sentence>
<gene range="18-27">hERalpha46</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="32-36">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au412" phase="p2">
<sentence pmid="20302909.s8">Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells.</sentence>
<gene range="36-40">PDCD4</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="47-53" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="94-98">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au413" phase="p2">
<sentence pmid="18294401.s0">Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer.</sentence>
<gene range="12-16">HER 2</gene>
<expression_change_keyword_1 range="18-31" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="18-31" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="72-84">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au414" phase="p2">
<sentence pmid="18294401.s1">Both obesity and over-expression of HER II are associated with poor prognosis of breast cancer.</sentence>
<gene range="36-41">HER II</gene>
<expression_change_keyword_1 range="17-31" type="Gene_expression">over-expression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-31" type="Positive_regulation">over-expression</expression_change_keyword_2>
<cancer_term range="81-93">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au415" phase="p2">
<sentence pmid="18294401.s3">The overexpression of HER II is also positively correlated with other markers of prognosis of breast cancer such as cathepsin expression.</sentence>
<gene range="22-27">HER II</gene>
<expression_change_keyword_1 range="4-17" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-17" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="94-106">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au416" phase="p2">
<sentence pmid="17317102.s4">One of these kinases, Erk5, has been found to reside in the nucleus of breast cancer cells that overexpress the ErbB2 receptor.</sentence>
<gene range="112-125">ErbB2 receptor</gene>
<expression_change_keyword_1 range="96-106" type="Gene_expression">overexpress</expression_change_keyword_1>
<expression_change_keyword_2 range="96-106" type="Positive_regulation">overexpress</expression_change_keyword_2>
<cancer_term range="71-83">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au417" phase="p2">
<sentence pmid="17317102.s6">In breast cancer cells overexpressing ErbB2, Erk5 dual phosphorylation required ErbB2 tyrosine kinase activity; however, Erk5 nuclear residency did not require ErbB2 activity.</sentence>
<gene range="38-42">ErbB2</gene>
<expression_change_keyword_1 range="23-36" type="Gene_expression">overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="23-36" type="Positive_regulation">overexpressing</expression_change_keyword_2>
<cancer_term range="3-15">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au418" phase="p2">
<sentence pmid="15020607.s1">In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer.</sentence>
<gene range="176-179">HER2</gene>
<expression_change_keyword_1 range="181-194" type="Gene_expression">overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="181-194" type="Positive_regulation">overexpressing</expression_change_keyword_2>
<cancer_term range="196-219">metastatic breast cancer</cancer_term>
<cancer_term range="207-219">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au419" phase="p2">
<sentence pmid="1985102.s0">The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta.</sentence>
<gene range="108-138">transforming growth factor beta</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="95-103" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="31-43">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au420" phase="p2">
<sentence pmid="1985102.s5">Furthermore, in four breast cancer cell lines, the extent of induction of TGF-beta correlated with intracellular levels of Gestodene binding site.</sentence>
<gene range="74-81">TGF-beta</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="61-69" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="21-33">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au421" phase="p2">
<sentence pmid="16501249.s3">Moreover, we examined the putative impact of p53 MspI 1798G&gt;A, which is completely linked to p53PIN3, a 16 bp insertion/duplication that has been associated with reduced p53 expression, on familial breast cancer risk.</sentence>
<gene range="170-172">p53</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="162-168" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="189-210">familial breast cancer</cancer_term>
<cancer_term range="198-210">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au422" phase="p2">
<sentence pmid="16809439.s5">From a clinical perspective, we suggest that if chemically stable FASN inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti-breast cancer actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.</sentence>
<gene range="192-195">FASN</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="197-206" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="465-477">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au423" phase="p2">
<sentence pmid="16809439.s5">From a clinical perspective, we suggest that if chemically stable FASN inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti-breast cancer actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.</sentence>
<gene range="353-356">FASN</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="341-348" type="Negative_regulation">blockade</expression_change_keyword_2>
<cancer_term range="465-477">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au424" phase="p2">
<sentence pmid="11550075.s4">Inhibition of aromatase is an important approach for reducing growth stimulatory effects of estrogens in hormone-dependent breast cancer.</sentence>
<gene range="14-22">aromatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Negative_regulation">Inhibition</expression_change_keyword_2>
<cancer_term range="123-135">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au425" phase="p2">
<sentence pmid="18060053.s0">Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.</sentence>
<gene range="37-40">Cdk2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="27-35" type="Positive_regulation">activates</expression_change_keyword_2>
<cancer_term range="86-98">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au426" phase="p2">
<sentence pmid="18270579.s0">Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.</sentence>
<gene range="13-18">ErbB-3</gene>
<expression_change_keyword_1 range="20-29" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="111-127">breast carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au427" phase="p2">
<sentence pmid="3524819.s4">These results indicate that the overexpression of H-ras in human breast tumors is not correlated with alteration of the protooncogene.</sentence>
<gene range="50-54">H-ras</gene>
<expression_change_keyword_1 range="32-45" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="32-45" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="65-77">breast tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au428" phase="p2">
<sentence pmid="3524819.s8">Correlation with clinicopathological data showed, however, that the loss of one H-ras-1 allele in breast carcinoma DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis.</sentence>
<gene range="80-93">H-ras-1 allele</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="68-71" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="98-113">breast carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au429" phase="p2">
<sentence pmid="2440556.s0">Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.</sentence>
<gene range="12-52">urokinase-type plasminogen activator gene</gene>
<expression_change_keyword_1 range="54-63" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-7" type="Positive_regulation">Increase</expression_change_keyword_2>
<cancer_term range="83-99">breast carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au430" phase="p2">
<sentence pmid="22037875.s0">Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.</sentence>
<gene range="38-46">cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="30-33" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="69-81">mammary tumor</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au431" phase="p2">
<sentence pmid="22037875.s4">The lack of Cyclin D1 was associated with a compensatory upregulation of Cyclin D3, which explains why the targeted downregulation of Cyclin D1 in established mammary tumors had no effect on cancer cell proliferation.</sentence>
<gene range="12-20">Cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-7" type="Negative_regulation">lack</expression_change_keyword_2>
<cancer_term range="159-172">mammary tumors</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au432" phase="p2">
<sentence pmid="22037875.s4">The lack of Cyclin D1 was associated with a compensatory upregulation of Cyclin D3, which explains why the targeted downregulation of Cyclin D1 in established mammary tumors had no effect on cancer cell proliferation.</sentence>
<gene range="134-142">Cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="116-129" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="159-172">mammary tumors</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au433" phase="p2">
<sentence pmid="22037875.s4">The lack of Cyclin D1 was associated with a compensatory upregulation of Cyclin D3, which explains why the targeted downregulation of Cyclin D1 in established mammary tumors had no effect on cancer cell proliferation.</sentence>
<gene range="73-81">Cyclin D3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="57-68" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="159-172">mammary tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au434" phase="p2">
<sentence pmid="22037875.s5">Cyclin D1 and D3 are overexpressed in human breast cancer cell lines and primary invasive breast cancers, and Cyclin D3 frequently exceeded the expression of Cyclin D1 in ErbB2-positive cases.</sentence>
<gene range="0-8">Cyclin D1</gene>
<expression_change_keyword_1 range="21-33" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="21-33" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="81-103">invasive breast cancers</cancer_term>
<cancer_term range="90-103">breast cancers</cancer_term>
<cancer_term range="44-56">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au435" phase="p2">
<sentence pmid="22037875.s7">Collectively, the results of this study suggest that only the combined inhibition of Cyclin D1 and D3 might be a suitable strategy for breast cancer prevention and therapy.</sentence>
<gene range="85-93">Cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="71-80" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="135-147">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au436" phase="p2">
<sentence pmid="12036928.s4">We had reported previously that although both BT474 and MKN7 cells overexpress ErbB2, only BT474 cells show an antiproliferative response to mAb 4D5 treatment.</sentence>
<gene range="79-83">ErbB2</gene>
<expression_change_keyword_1 range="67-77" type="Gene_expression">overexpress</expression_change_keyword_1>
<expression_change_keyword_2 range="67-77" type="Positive_regulation">overexpress</expression_change_keyword_2>
<cancer_term range="46-50">BT474</cancer_term>
<cancer_term range="91-95">BT474</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au437" phase="p2">
<sentence pmid="17145775.s1">The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation.</sentence>
<gene range="60-69">BCRP/ABCG2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="84-90" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="26-38">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au438" phase="p2">
<sentence pmid="17145775.s1">The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation.</sentence>
<gene range="4-57">multidrug transporter breast cancer resistance protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="84-90" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="26-38">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au439" phase="p2">
<sentence pmid="12231537.s1">Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma.</sentence>
<gene range="0-5">Maspin</gene>
<expression_change_keyword_1 range="101-113" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="101-113" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="80-95">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au440" phase="p2">
<sentence pmid="12231537.s1">Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma.</sentence>
<gene range="0-5">Maspin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="62-75" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="80-95">breast carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au441" phase="p2">
<sentence pmid="7913408.s8">Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.</sentence>
<gene range="104-117">P-glycoprotein</gene>
<expression_change_keyword_1 range="86-99" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="86-99" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="22-37">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au442" phase="p2">
<sentence pmid="15072561.s2">In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERalpha expression in a dose-dependent manner.</sentence>
<gene range="103-109">ERalpha</gene>
<expression_change_keyword_1 range="111-120" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="93-101" type="Negative_regulation">decreases</expression_change_keyword_2>
<cancer_term range="11-23">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au443" phase="p2">
<sentence pmid="21983172.s6">We also observed a reduction of UBR1 protein levels in geldanamycin-treated mouse embryonic fibroblasts and human breast cancer cells, suggesting that UBR1 is an Hsp90 client.</sentence>
<gene range="32-43">UBR1 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="19-27" type="Negative_regulation">reduction</expression_change_keyword_2>
<cancer_term range="114-126">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au444" phase="p2">
<sentence pmid="9816210.s5">One of the best examples of a correlation between high levels of a protease in a primary tumor and poor prognosis is urokinase plasminogen activation in breast cancer.</sentence>
<gene range="117-137">urokinase plasminogen</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="139-148" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="153-165">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au445" phase="p2">
<sentence pmid="16954434.s1">Oestrogen receptor-alpha (ERalpha) is an important prognostic marker in breast cancer and endocrine therapies are designed to inhibit or prevent ERalpha activity.</sentence>
<gene range="145-151">ERalpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="137-143" type="Negative_regulation">prevent</expression_change_keyword_2>
<cancer_term range="72-84">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="up-regulated"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au446" phase="p2">
<sentence pmid="18373644.s0">IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.</sentence>
<gene range="11-16">IGFBP5</gene>
<expression_change_keyword_1 range="18-31" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="18-31" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="81-97">breast carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au447" phase="p2">
<sentence pmid="18373644.s0">IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.</sentence>
<gene range="0-5">IGFBP2</gene>
<expression_change_keyword_1 range="18-31" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="18-31" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="81-97">breast carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au448" phase="p2">
<sentence pmid="18373644.s2">Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.</sentence>
<gene range="18-23">IGFBP2</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="147-159">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au449" phase="p2">
<sentence pmid="18373644.s2">Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.</sentence>
<gene range="29-34">IGFBP5</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="147-159">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au450" phase="p2">
<sentence pmid="10449619.s0">Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.</sentence>
<gene range="13-35">thymidine phosphorylase</gene>
<expression_change_keyword_1 range="37-46" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="143-155">mammary tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au451" phase="p2">
<sentence pmid="10449619.s3">In the present study, we confirmed that the administration of cytostatics used for breast cancer treatment, such as taxanes and cyclophosphamide (CPA), up-regulated the tumor level of dThdPase in mammary tumor models as well.</sentence>
<gene range="184-191">dThdPase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="152-163" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="196-208">mammary tumor</cancer_term>
<cancer_term range="83-95">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au452" phase="p2">
<sentence pmid="10449619.s6">The preferential up-regulation of PyNPase activity in the tumor by CPA administration was also confirmed in mice bearing a syngeneic murine mammary adenocarcinoma, A755.</sentence>
<gene range="34-40">PyNPase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="17-29" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="140-161">mammary adenocarcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au453" phase="p2">
<sentence pmid="3298786.s3">Enhanced Ha-ras expression was documented in 66% of breast and 100% of colon carcinomas as compared with their normal counterparts, with levels in breast carcinomas ranging from 10.1 to 50.4 pg ras p21/micrograms protein and those in colon carcinomas ranging from 18.4 to 51.7 pg ras p21/micrograms protein.</sentence>
<gene range="9-14">Ha-ras</gene>
<expression_change_keyword_1 range="16-25" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-7" type="Positive_regulation">Enhanced</expression_change_keyword_2>
<cancer_term range="147-163">breast carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au454" phase="p2">
<sentence pmid="17726528.s11">Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression.</sentence>
<gene range="85-89">ABCB6</gene>
<expression_change_keyword_1 range="91-100" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="77-83" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="57-69">breast cancer</cancer_term>
<cancer_term range="52-55">MCF7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au455" phase="p2">
<sentence pmid="17726528.s11">Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression.</sentence>
<gene range="116-120">ABCB7</gene>
<expression_change_keyword_1 range="122-131" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="106-114" type="Negative_regulation">repressed</expression_change_keyword_2>
<cancer_term range="57-69">breast cancer</cancer_term>
<cancer_term range="52-55">MCF7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au456" phase="p2">
<sentence pmid="20305816.s7">Using multiple primer sets and controls, we found that neither mature BORIS transcripts nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in MCF-7 cells following 5-aza-2'-deoxycytidine treatment.</sentence>
<gene range="211-227">BORIS transcripts</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="236-242" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="247-251">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au457" phase="p2">
<sentence pmid="7840509.s6">The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of breast cancer in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.</sentence>
<gene range="480-503">epithelial growth factor</gene>
<expression_change_keyword_1 range="466-475" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="447-457" type="Positive_regulation">stimulation</expression_change_keyword_2>
<cancer_term range="163-175">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au458" phase="p2">
<sentence pmid="7840509.s6">The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of breast cancer in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.</sentence>
<gene range="506-508">EGF</gene>
<expression_change_keyword_1 range="466-475" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="447-457" type="Positive_regulation">stimulation</expression_change_keyword_2>
<cancer_term range="163-175">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au459" phase="p2">
<sentence pmid="11839580.s5">Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and &lt;0.001).</sentence>
<gene range="84-91">ER-alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="77-82" type="Positive_regulation">higher</expression_change_keyword_2>
<cancer_term range="34-46">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au460" phase="p2">
<sentence pmid="11839580.s5">Those patients that progressed to breast cancer (cases) showed significantly higher ER-alpha [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and &lt;0.001).</sentence>
<gene range="84-91">ER-alpha</gene>
<expression_change_keyword_1 range="233-242" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="77-82" type="Positive_regulation">higher</expression_change_keyword_2>
<cancer_term range="34-46">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au461" phase="p2">
<sentence pmid="18702457.s5">Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast (MDA-MB-468) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.</sentence>
<gene range="162-164">IKK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="147-154" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="104-113">MDA-MB-468</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au462" phase="p2">
<sentence pmid="18702457.s5">Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast (MDA-MB-468) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.</sentence>
<gene range="373-384">IKK/NFkappaB</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="359-368" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="104-113">MDA-MB-468</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au463" phase="p2">
<sentence pmid="19087284.s12">Our findings show, for the first time, that DC is a natural tumor promoter by elevating Flk-1 and decreasing ceramide-mediated apoptosis of breast cancer progenitor cells.</sentence>
<gene range="88-92">Flk-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="78-86" type="Positive_regulation">elevating</expression_change_keyword_2>
<cancer_term range="140-152">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au464" phase="p2">
<sentence pmid="1317462.s0">Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.</sentence>
<gene range="16-48">p53 tumor suppressor gene protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Accumulation</expression_change_keyword_2>
<cancer_term range="89-102">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au465" phase="p2">
<sentence pmid="1317462.s1">Mutations of the tumor suppressor gene p53 have been identified in breast cancer cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of p53 protein accumulation.</sentence>
<gene range="175-185">p53 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="187-198" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="102-118">breast carcinomas</cancer_term>
<cancer_term range="67-79">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au466" phase="p2">
<sentence pmid="15075673.s4">In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR.</sentence>
<gene range="102-113">maspin genes</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="70-82" type="Positive_regulation">re-activation</expression_change_keyword_2>
<cancer_term range="14-29">breast carcinoma</cancer_term>
<cancer_term range="3-12">MDA-MB-231</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au467" phase="p2">
<sentence pmid="15075673.s4">In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR.</sentence>
<gene range="87-96">E-cadherin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="70-82" type="Positive_regulation">re-activation</expression_change_keyword_2>
<cancer_term range="14-29">breast carcinoma</cancer_term>
<cancer_term range="3-12">MDA-MB-231</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au468" phase="p2">
<sentence pmid="16176813.s6">While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.</sentence>
<gene range="20-24">Bcl-2</gene>
<expression_change_keyword_1 range="6-15" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="55-63" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="161-173">mammary tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au469" phase="p2">
<sentence pmid="16176813.s6">While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.</sentence>
<gene range="27-31">Bcl-X</gene>
<expression_change_keyword_1 range="6-15" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="55-63" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="161-173">mammary tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au470" phase="p2">
<sentence pmid="16176813.s6">While expression of Bcl-2, Bcl-X(L), Hsp 70 and 90 was increased, expression of Bax and caspases 8 and 3 was significantly lower in both human as well as canine mammary tumor tissues compared to corresponding adjacent tissues.</sentence>
<gene range="37-42">Hsp 70</gene>
<expression_change_keyword_1 range="6-15" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="55-63" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="161-173">mammary tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au471" phase="p2">
<sentence pmid="9857236.s7">In conclusion, physiological elevation of the bFGF during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal breast cancer patients.</sentence>
<gene range="46-49">bFGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="29-37" type="Positive_regulation">elevation</expression_change_keyword_2>
<cancer_term range="179-191">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au472" phase="p2">
<sentence pmid="9857236.s7">In conclusion, physiological elevation of the bFGF during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal breast cancer patients.</sentence>
<gene range="156-159">bFGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="139-147" type="Positive_regulation">elevation</expression_change_keyword_2>
<cancer_term range="179-191">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au473" phase="p2">
<sentence pmid="16643892.s1">Many advanced human tumors including breast cancer overproduce plasmin that is known to promote angiogenesis and metastasis.</sentence>
<gene range="63-69">plasmin</gene>
<expression_change_keyword_1 range="51-61" type="Gene_expression">overproduce</expression_change_keyword_1>
<expression_change_keyword_2 range="51-61" type="Positive_regulation">overproduce</expression_change_keyword_2>
<cancer_term range="37-49">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au474" phase="p2">
<sentence pmid="16643892.s8">MDA-MB231 cell membranes induced plasmin generation in a time-dependent manner while those from MCF-7 cells failed to convert plasminogen to plasmin.</sentence>
<gene range="33-39">plasmin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="25-31" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="0-8">MDA-MB231</cancer_term>
<cancer_term range="96-100">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au475" phase="p2">
<sentence pmid="20635137.s0">GRB7 protein over-expression and clinical outcome in breast cancer.</sentence>
<gene range="0-11">GRB7 protein</gene>
<expression_change_keyword_1 range="13-27" type="Gene_expression">over-expression</expression_change_keyword_1>
<expression_change_keyword_2 range="13-27" type="Positive_regulation">over-expression</expression_change_keyword_2>
<cancer_term range="53-65">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au476" phase="p2">
<sentence pmid="20635137.s14">GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.</sentence>
<gene range="0-11">GRB7 protein</gene>
<expression_change_keyword_1 range="13-27" type="Gene_expression">over-expression</expression_change_keyword_1>
<expression_change_keyword_2 range="13-27" type="Positive_regulation">over-expression</expression_change_keyword_2>
<cancer_term range="82-94">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au477" phase="p2">
<sentence pmid="9654650.s10">All of the test compounds (10 nM) substantially inhibited estrogen sulfatase activity of intact MDA-MB-231 cells.</sentence>
<gene range="58-75">estrogen sulfatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="48-56" type="Negative_regulation">inhibited</expression_change_keyword_2>
<cancer_term range="96-105">MDA-MB-231</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au478" phase="p2">
<sentence pmid="9654650.s14">Our data indicate the utility of the new compounds for inhibition of breast cancer cell estrone sulfatase activity.</sentence>
<gene range="69-104">breast cancer cell estrone sulfatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="55-64" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="69-81">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au479" phase="p2">
<sentence pmid="22179838.s2">Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays.</sentence>
<gene range="53-57">SCRIB</gene>
<expression_change_keyword_1 range="39-48" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="30-37" type="Negative_regulation">reducing</expression_change_keyword_2>
<cancer_term range="118-130">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au480" phase="p2">
<sentence pmid="10885804.s10">We found that the functional disruption of IGF-1R markedly influences breast cancer metastasis in nude mice by suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels.</sentence>
<gene range="43-48">IGF-1R</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="29-38" type="Negative_regulation">disruption</expression_change_keyword_2>
<cancer_term range="70-82">breast cancer</cancer_term>
<cancer_term range="170-182">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au481" phase="p2">
<sentence pmid="9092801.s4">
In T-47D cells, PRG1 mRNA was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h.</sentence>
<gene range="16-24">PRG1 mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-60" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="3-7">T-47D</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au482" phase="p2">
<sentence pmid="21607411.s1">Both elevated protein-tyrosine kinase activity of pp60(c-src) and the association of its high activity with a short disease-free period have been reported in patients with human breast cancer.</sentence>
<gene range="50-60">pp60(c-src)</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-12" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="178-190">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au483" phase="p2">
<sentence pmid="21607411.s5">
In 60% of breast cancers, the pp60(c-src) level was increased, the reaction intensity was elevated, and a positive reaction was seen in cytoplasma and in the nuclear area.</sentence>
<gene range="30-40">pp60(c-src)</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="52-60" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="10-23">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au484" phase="p2">
<sentence pmid="20736065.s0">Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.</sentence>
<gene range="24-67">human 3β-hydroxysteroid dehydrogenase type 1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="10-19" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="98-110">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au485" phase="p2">
<sentence pmid="20630060.s14">We showed that treatment of MCF-7 and triple-negative MDA-MB-231 human breast cancer cells with a GnRH-II antagonist results in apoptotic cell death in vitro via activation of stress-activated MAPK p38 and loss of mitochondrial membrane potential.</sentence>
<gene range="198-200">p38</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="162-171" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="71-83">breast cancer</cancer_term>
<cancer_term range="54-63">MDA-MB-231</cancer_term>
<cancer_term range="28-32">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au486" phase="p2">
<sentence pmid="20630060.s15">In addition, we showed GnRH-II antagonist-induced activation of caspase-3 in MDA-MB-231 human breast cancer cells.</sentence>
<gene range="64-72">caspase-3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="50-59" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="94-106">breast cancer</cancer_term>
<cancer_term range="77-86">MDA-MB-231</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au487" phase="p2">
<sentence pmid="20390342.s0">CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.</sentence>
<gene range="0-28">CTEN (C-terminal tensin-like)</gene>
<expression_change_keyword_1 range="48-60" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="48-60" type="Gene_expression">overexpressed</expression_change_keyword_2>
<cancer_term range="65-89">invasive breast carcinoma</cancer_term>
<cancer_term range="74-89">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au488" phase="p2">
<sentence pmid="17608728.s0">The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.</sentence>
<gene range="145-193">retinoic acid receptor-beta tumor-suppressor gene</gene>
<expression_change_keyword_1 range="127-136" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="112-121" type="Positive_regulation">reactivate</expression_change_keyword_2>
<cancer_term range="198-210">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au489" phase="p2">
<sentence pmid="17608728.s4">Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces RAR-beta2, but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and MDA-MB-453 human breast cancer cells.</sentence>
<gene range="75-83">RAR-beta2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="67-73" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="175-187">breast cancer</cancer_term>
<cancer_term range="143-152">MDA-MB-468</cancer_term>
<cancer_term range="158-167">MDA-MB-453</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au490" phase="p2">
<sentence pmid="16630134.s0">MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers.</sentence>
<gene range="0-3">MTA1</gene>
<expression_change_keyword_1 range="5-18" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="5-18" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="88-101">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au491" phase="p2">
<sentence pmid="21247495.s1">Osteopontin (OPN) is a secreted phosphoprotein often overexpressed at high levels in the blood and primary tumors of breast cancer patients.</sentence>
<gene range="0-10">Osteopontin</gene>
<expression_change_keyword_1 range="53-65" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="53-65" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="117-129">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au492" phase="p2">
<sentence pmid="7438115.s6">These findings support the assumption that induction of PGR by estrogen in human breast cancer is mediated by a mechanism involving nuclear receptors.</sentence>
<gene range="56-58">PGR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="43-51" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="81-93">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au493" phase="p2">
<sentence pmid="14629195.s0">Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.</sentence>
<gene range="10-12">Src</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Activated</expression_change_keyword_2>
<cancer_term range="83-95">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au494" phase="p2">
<sentence pmid="14629195.s0">Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.</sentence>
<gene range="47-61">alpha2-integrin</gene>
<expression_change_keyword_1 range="63-72" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="14-22" type="Positive_regulation">increases</expression_change_keyword_2>
<cancer_term range="83-95">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au495" phase="p2">
<sentence pmid="14629195.s4">We have shown that overexpression of an activated form of the Src tyrosine kinase suppressed the loss of adhesion induced by dominant-negative; adenoviral FAK-CD and decreased the apoptotic response in BT474 and MCF-7 breast cancer cell lines.</sentence>
<gene range="62-80">Src tyrosine kinase</gene>
<expression_change_keyword_1 range="19-32" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="19-32" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="218-230">breast cancer</cancer_term>
<cancer_term range="212-216">MCF-7</cancer_term>
<cancer_term range="202-206">BT474</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au496" phase="p2">
<sentence pmid="14629195.s6">We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.</sentence>
<gene range="103-117">alpha2-integrin</gene>
<expression_change_keyword_1 range="89-98" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="75-83" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="55-67">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au497" phase="p2">
<sentence pmid="14629195.s6">We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.</sentence>
<gene range="146-160">alpha2-integrin</gene>
<expression_change_keyword_1 range="128-141" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="128-141" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="55-67">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au498" phase="p2">
<sentence pmid="14629195.s6">We have also shown that expression of activated Src in breast cancer cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.</sentence>
<gene range="48-50">Src</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="38-46" type="Positive_regulation">activated</expression_change_keyword_2>
<cancer_term range="55-67">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au499" phase="p2">
<sentence pmid="7947821.s4">Cell-surface expression of galectin-3 was reduced following treatment of viable T47D human breast carcinoma cells with gelatinase A.</sentence>
<gene range="27-36">galectin-3</gene>
<expression_change_keyword_1 range="13-22" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="42-48" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="91-106">breast carcinoma</cancer_term>
<cancer_term range="80-83">T47D</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au500" phase="p2">
<sentence pmid="20495363.s11">Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for breast cancer patients that lack stromal Cav-1 expression.</sentence>
<gene range="186-190">Cav-1</gene>
<expression_change_keyword_1 range="192-201" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="173-176" type="Negative_regulation">lack</expression_change_keyword_2>
<cancer_term range="145-157">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au501" phase="p2">
<sentence pmid="15138597.s0">Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients.</sentence>
<gene range="47-52">leptin</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="54-61" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="90-102">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au502" phase="p2">
<sentence pmid="15138597.s0">Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients.</sentence>
<gene range="47-52">leptin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-61" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="90-102">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au503" phase="p2">
<sentence pmid="15138597.s8">Patients with breast cancer showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and PGR associated with increased leptin levels.</sentence>
<gene range="140-142">PGR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="107-114" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="14-26">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au504" phase="p2">
<sentence pmid="15138597.s8">Patients with breast cancer showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and PGR associated with increased leptin levels.</sentence>
<gene range="170-175">leptin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="160-168" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="14-26">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au505" phase="p2">
<sentence pmid="19995430.s13">We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation.</sentence>
<gene range="137-141">CUL4A</gene>
<expression_change_keyword_1 range="119-132" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="119-132" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="92-105">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au506" phase="p2">
<sentence pmid="17872978.s0">Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility.</sentence>
<gene range="0-41">Myosin II co-chaperone general cell UNC-45</gene>
<expression_change_keyword_1 range="43-56" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="43-56" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="77-90">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au507" phase="p2">
<sentence pmid="17872978.s6">Elevation of GC UNC-45 levels by ectopic expression enhanced the rate of ovarian cancer cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels.</sentence>
<gene range="13-21">GC UNC-45</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Elevation</expression_change_keyword_2>
<cancer_term range="73-86">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au508" phase="p2">
<sentence pmid="17872978.s6">Elevation of GC UNC-45 levels by ectopic expression enhanced the rate of ovarian cancer cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels.</sentence>
<gene range="135-143">GC UNC-45</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="122-130" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="73-86">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au509" phase="p2">
<sentence pmid="17872978.s9">Knockdown of GC UNC-45 reduced the spreading ability of ovarian cancer cells whereas it was enhanced by GC UNC-45 overexpression.</sentence>
<gene range="13-21">GC UNC-45</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Knockdown</expression_change_keyword_2>
<cancer_term range="56-69">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au510" phase="p2">
<sentence pmid="17872978.s9">Knockdown of GC UNC-45 reduced the spreading ability of ovarian cancer cells whereas it was enhanced by GC UNC-45 overexpression.</sentence>
<gene range="104-112">GC UNC-45</gene>
<expression_change_keyword_1 range="114-127" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="114-127" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="56-69">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au511" phase="p2">
<sentence pmid="17872978.s10">In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis.</sentence>
<gene range="42-58">GC UNC-45 protein</gene>
<expression_change_keyword_1 range="60-69" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="33-40" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="74-90">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au512" phase="p2">
<sentence pmid="19438741.s8">In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness.</sentence>
<gene range="71-74">MRP1</gene>
<expression_change_keyword_1 range="53-66" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="53-66" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="37-50">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au513" phase="p2">
<sentence pmid="19048115.s0">Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.</sentence>
<gene range="17-19">NF1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="22-28" type="Negative_regulation">defects</expression_change_keyword_2>
<cancer_term range="50-74">ovarian serous carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au514" phase="p2">
<sentence pmid="19048115.s0">Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.</sentence>
<gene range="0-14">Neurofibromin 1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="22-28" type="Negative_regulation">defects</expression_change_keyword_2>
<cancer_term range="50-74">ovarian serous carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au515" phase="p2">
<sentence pmid="20075391.s4">We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt.</sentence>
<gene range="268-270">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="249-263" type="Positive_regulation">hyperactivation</expression_change_keyword_2>
<cancer_term range="208-225">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au516" phase="p2">
<sentence pmid="12481432.s10">Overall, these results implicate inhibition of DNA-PK as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant ovarian cancer.</sentence>
<gene range="47-52">DNA-PK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="33-42" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="178-191">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au517" phase="p2">
<sentence pmid="14694444.s0">Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells.</sentence>
<gene range="22-26">BRCA1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="10-17" type="Negative_regulation">blocking</expression_change_keyword_2>
<cancer_term range="88-101">ovarian cancer</cancer_term>
<cancer_term range="83-86">BG-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au518" phase="p2">
<sentence pmid="14694444.s1">Previous studies have shown that reduction in BRCA1 mRNA and protein can result in increased proliferation of BG-1 ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells.</sentence>
<gene range="46-55">BRCA1 mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="33-41" type="Negative_regulation">reduction</expression_change_keyword_2>
<cancer_term range="115-128">ovarian cancer</cancer_term>
<cancer_term range="110-113">BG-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au519" phase="p2">
<sentence pmid="20309881.s0">Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition.</sentence>
<gene range="8-11">MKK4</gene>
<expression_change_keyword_1 range="13-22" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-3" type="Negative_regulation">Loss</expression_change_keyword_2>
<cancer_term range="27-40">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au520" phase="p2">
<sentence pmid="20309881.s5">MKK4 gene knockdown in MDAH 2774 cells over-expressing MKK4 increased invasion activity.</sentence>
<gene range="55-58">MKK4</gene>
<expression_change_keyword_1 range="39-53" type="Gene_expression">over-expressing</expression_change_keyword_1>
<expression_change_keyword_2 range="39-53" type="Positive_regulation">over-expressing</expression_change_keyword_2>
<cancer_term range="23-31">MDAH 2774</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au521" phase="p2">
<sentence pmid="20309881.s7">Interestingly, we found that MKK4 upregulation caused downregulation of phosphorylated NF-κB and Twist, as well as upregulation of E-cadherin, in TOVG-21G and SKOV3 cells.</sentence>
<gene range="29-32">MKK4</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="34-45" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="159-163">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au522" phase="p2">
<sentence pmid="20309881.s7">Interestingly, we found that MKK4 upregulation caused downregulation of phosphorylated NF-κB and Twist, as well as upregulation of E-cadherin, in TOVG-21G and SKOV3 cells.</sentence>
<gene range="131-140">E-cadherin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="115-126" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="159-163">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au523" phase="p2">
<sentence pmid="20309881.s10">This promotes Twist over-expression, resulting in E-cadherin downregulation that induces EMT in ovarian cancer.</sentence>
<gene range="50-59">E-cadherin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="61-74" type="Negative_regulation">downregulation</expression_change_keyword_2>
<cancer_term range="96-109">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au524" phase="p2">
<sentence pmid="11150789.s6">
From these 23 patients, 18 pts were referred for suspected recurrence of ovarian carcinoma: occult recurrence (OR) defined by an increase in serum CA-125 levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts).</sentence>
<gene range="147-152">CA-125</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="129-136" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="73-89">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au525" phase="p2">
<sentence pmid="17470361.s6">We also found that: (1) luciferase activity mediated by the VEGF reporter containing a mutation of the HIF-1 binding site was much lower than that of the reporter containing a wild-type HIF-1 binding site in ovarian cancer cells, thus confirming that HIF-1 is a major transcriptional regulator of VEGF expression; and that (2) CDDP greatly inhibited VEGF reporter activity containing the wild-type but not the mutant HIF-1 binding site.</sentence>
<gene range="350-353">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="340-348" type="Negative_regulation">inhibited</expression_change_keyword_2>
<cancer_term range="208-221">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au526" phase="p2">
<sentence pmid="17470361.s11">These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation.</sentence>
<gene range="119-122">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="140-149" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="73-86">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au527" phase="p2">
<sentence pmid="11753647.s3">Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2&lt;10(-6)).</sentence>
<gene range="58-67">ERCC1 mRNA</gene>
<expression_change_keyword_1 range="69-78" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="48-56" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="105-118">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au528" phase="p2">
<sentence pmid="16230405.s3">We report that elevated expression of LPAAT-beta was associated with reduced survival in ovarian cancer and earlier progression of disease in ovarian and endometrial cancer.</sentence>
<gene range="38-47">LPAAT-beta</gene>
<expression_change_keyword_1 range="24-33" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="15-22" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="89-102">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au529" phase="p2">
<sentence pmid="16230405.s5">Inhibition of LPAAT-beta also enhanced the survival of mice bearing ovarian tumor xenografts.</sentence>
<gene range="14-23">LPAAT-beta</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Negative_regulation">Inhibition</expression_change_keyword_2>
<cancer_term range="68-80">ovarian tumor</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au530" phase="p2">
<sentence pmid="20505730.s7">Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours.</sentence>
<gene range="22-25">CD95</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="14-17" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="46-59">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au531" phase="p2">
<sentence pmid="11926891.s10">Osteopontin levels in plasma were significantly higher (P&lt;.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).</sentence>
<gene range="0-10">Osteopontin</gene>
<expression_change_keyword_1 range="12-17" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="48-53" type="Positive_regulation">higher</expression_change_keyword_2>
<cancer_term range="84-108">epithelial ovarian cancer</cancer_term>
<cancer_term range="95-108">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au532" phase="p2">
<sentence pmid="15297183.s6">Under normoxic conditions, treatment of both ovarian cancer cell lines with dmPGE(2) resulted in a significant increase in VEGF expression but had no effect on HIF-1alpha.</sentence>
<gene range="123-126">VEGF</gene>
<expression_change_keyword_1 range="128-137" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="111-118" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="45-58">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au533" phase="p2">
<sentence pmid="12576450.s11">Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.</sentence>
<gene range="14-17">Id-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="19-28" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="82-95">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au534" phase="p2">
<sentence pmid="15867372.s1">The overexpression of the colony-stimulating factor-1(CSF-1) by epithelial ovarian cancer cells enhances invasiveness and metastatic properties, contributing to the poor prognosis of the patients.</sentence>
<gene range="26-52">colony-stimulating factor-1</gene>
<expression_change_keyword_1 range="4-17" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-17" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="64-88">epithelial ovarian cancer</cancer_term>
<cancer_term range="75-88">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au535" phase="p2">
<sentence pmid="15867372.s1">The overexpression of the colony-stimulating factor-1(CSF-1) by epithelial ovarian cancer cells enhances invasiveness and metastatic properties, contributing to the poor prognosis of the patients.</sentence>
<gene range="54-58">CSF-1</gene>
<expression_change_keyword_1 range="4-17" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-17" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="64-88">epithelial ovarian cancer</cancer_term>
<cancer_term range="75-88">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au536" phase="p2">
<sentence pmid="15867372.s4">CSF-1 overexpression in Hey cells was found to associate with increased invasiveness, motility, urokinase activity, and virulence of tumorigenicity, compared with NOSE.1 cells, which expressed little CSF-1.</sentence>
<gene range="0-4">CSF-1</gene>
<expression_change_keyword_1 range="6-19" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="6-19" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="24-26">Hey</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au537" phase="p2">
<sentence pmid="15867372.s11">These data suggest that GAPDH binding to CSF-1 ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in ovarian cancer.</sentence>
<gene range="158-162">CSF-1</gene>
<expression_change_keyword_1 range="164-177" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="164-177" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="223-236">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au538" phase="p2">
<sentence pmid="17352242.s8">The MMP-9 levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to SKOV-3 cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation.</sentence>
<gene range="4-8">MMP-9</gene>
<expression_change_keyword_1 range="10-15" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="17-25" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="111-116">SKOV-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au539" phase="p2">
<sentence pmid="20878528.s8">In the parental HEY cell line, additional treatment with the PPARγ ligands led to an increased protein expression of DR5 and a further decline of XIAP expression.</sentence>
<gene range="117-119">DR5</gene>
<expression_change_keyword_1 range="103-112" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="85-93" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="16-18">HEY</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au540" phase="p2">
<sentence pmid="18208621.s2">Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers.</sentence>
<gene range="154-160">BRCA1/2</gene>
<expression_change_keyword_1 range="140-149" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="130-138" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="165-179">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au541" phase="p2">
<sentence pmid="18208621.s5">Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1.</sentence>
<gene range="104-108">BRCA1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="96-99" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="22-39">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au542" phase="p2">
<sentence pmid="15382080.s11">KTI treatment may also be beneficial for ovarian cancer patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of uPA expression.</sentence>
<gene range="247-249">uPA</gene>
<expression_change_keyword_1 range="251-260" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="232-242" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="41-54">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au543" phase="p2">
<sentence pmid="12006545.s11">These results indicate that high PTEN expression enhances the sensitivity of ovarian cancer cells to irinotecan and the induction of apoptosis and the suppression of topoisomerase I activity in cancer cells are suggested as possible mechanisms attributable to high PTEN expression.</sentence>
<gene range="166-180">topoisomerase I</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="151-161" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="77-90">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au544" phase="p2">
<sentence pmid="16299254.s13">The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.</sentence>
<gene range="87-90">VEGF</gene>
<expression_change_keyword_1 range="101-110" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="42-49" type="Negative_regulation">inhibits</expression_change_keyword_2>
<cancer_term range="129-145">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au545" phase="p2">
<sentence pmid="16299254.s13">The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.</sentence>
<gene range="184-187">VEGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="173-178" type="Negative_regulation">blocks</expression_change_keyword_2>
<cancer_term range="129-145">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au546" phase="p2">
<sentence pmid="16299254.s13">The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.</sentence>
<gene range="51-84">vascular endothelial growth factor</gene>
<expression_change_keyword_1 range="101-110" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="42-49" type="Negative_regulation">inhibits</expression_change_keyword_2>
<cancer_term range="129-145">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au547" phase="p2">
<sentence pmid="21695196.s0">Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.</sentence>
<gene range="57-62">HYAL-1</gene>
<expression_change_keyword_1 range="26-35" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-24" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="68-92">epithelial ovarian cancer</cancer_term>
<cancer_term range="79-92">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au548" phase="p2">
<sentence pmid="21695196.s0">Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.</sentence>
<gene range="40-54">hyaluronidase-1</gene>
<expression_change_keyword_1 range="26-35" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-24" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="68-92">epithelial ovarian cancer</cancer_term>
<cancer_term range="79-92">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au549" phase="p2">
<sentence pmid="12759391.s1">Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells.</sentence>
<gene range="166-199">vascular endothelial growth factor</gene>
<expression_change_keyword_1 range="152-161" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="137-146" type="Positive_regulation">increasing</expression_change_keyword_2>
<cancer_term range="109-132">malignant ovarian tumors</cancer_term>
<cancer_term range="119-132">ovarian tumors</cancer_term>
<cancer_term range="211-224">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au550" phase="p2">
<sentence pmid="12759391.s1">Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells.</sentence>
<gene range="202-205">VEGF</gene>
<expression_change_keyword_1 range="152-161" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="137-146" type="Positive_regulation">increasing</expression_change_keyword_2>
<cancer_term range="109-132">malignant ovarian tumors</cancer_term>
<cancer_term range="119-132">ovarian tumors</cancer_term>
<cancer_term range="211-224">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au551" phase="p2">
<sentence pmid="12759391.s5">Four of six cancer cell lines, including OVCAR-3, overexpressed cyclin D1 protein relative to levels in IOSE-29 cells.</sentence>
<gene range="64-80">cyclin D1 protein</gene>
<expression_change_keyword_1 range="50-62" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="50-62" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="41-47">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au552" phase="p2">
<sentence pmid="12759391.s6">LPA treatment increased cyclin D1 protein in a dose- and time-dependent manner in OVCAR-3 cells but not in IOSE-29 cells.</sentence>
<gene range="24-40">cyclin D1 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="14-22" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="82-88">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au553" phase="p2">
<sentence pmid="12759391.s11">In addition to the previously characterized indirect mechanism that increases angiogenesis via VEGF, LPA may directly increase the level of cyclin D1 in ovarian cancer cells, increasing their proliferation.</sentence>
<gene range="140-148">cyclin D1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="118-125" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="153-166">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au554" phase="p2">
<sentence pmid="11280739.s6">Cisplatin decreased XIAP protein levels and induced Akt cleavage and apoptosis in chemosensitive, but not in resistant, ovarian cancer cells.</sentence>
<gene range="20-31">XIAP protein</gene>
<expression_change_keyword_1 range="33-38" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="10-18" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="120-133">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au555" phase="p2">
<sentence pmid="11280739.s11">In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein.</sentence>
<gene range="74-77">XIAP</gene>
<expression_change_keyword_1 range="79-92" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="79-92" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="16-22">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au556" phase="p2">
<sentence pmid="15806153.s4">Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level.</sentence>
<gene range="125-128">PR-A</gene>
<expression_change_keyword_1 range="156-165" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="117-120" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="13-16">HOSE</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au557" phase="p2">
<sentence pmid="15806153.s4">Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level.</sentence>
<gene range="125-128">PR-A</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="117-120" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="13-16">HOSE</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au558" phase="p2">
<sentence pmid="15806153.s4">Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level.</sentence>
<gene range="134-142">PR-B mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="117-120" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="13-16">HOSE</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au559" phase="p2">
<sentence pmid="15806153.s4">Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level.</sentence>
<gene range="134-142">PR-B mRNA</gene>
<expression_change_keyword_1 range="156-165" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="117-120" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="13-16">HOSE</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au560" phase="p2">
<sentence pmid="22142513.s1">The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues.</sentence>
<gene range="43-47">PDCD6</gene>
<expression_change_keyword_1 range="4-13" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="65-78" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="105-118">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au561" phase="p2">
<sentence pmid="22142513.s1">The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues.</sentence>
<gene range="18-40">programmed cell death 6</gene>
<expression_change_keyword_1 range="4-13" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="65-78" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="105-118">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au562" phase="p2">
<sentence pmid="19423340.s2">The drug-resistant cell lines include ovarian cancer cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing class III beta-tubulin, A2780TC1 and A2780TC3.</sentence>
<gene range="140-161">class III beta-tubulin</gene>
<expression_change_keyword_1 range="125-138" type="Gene_expression">overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="125-138" type="Positive_regulation">overexpressing</expression_change_keyword_2>
<cancer_term range="38-51">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au563" phase="p2">
<sentence pmid="17690890.s1">Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers.</sentence>
<gene range="71-74">EGFR</gene>
<expression_change_keyword_1 range="15-28" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="15-28" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="181-195">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au564" phase="p2">
<sentence pmid="17690890.s1">Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers.</sentence>
<gene range="37-68">epidermal growth factor receptor</gene>
<expression_change_keyword_1 range="15-28" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="15-28" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="181-195">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au565" phase="p2">
<sentence pmid="19097929.s6">Increased KLF6-SV1 expression is associated with poor prognosis in prostate, lung, and ovarian cancer.</sentence>
<gene range="10-17">KLF6-SV1</gene>
<expression_change_keyword_1 range="19-28" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="87-100">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au566" phase="p2">
<sentence pmid="8431895.s4">The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers.</sentence>
<gene range="579-587">HER-2/neu</gene>
<expression_change_keyword_1 range="551-564" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="551-564" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="681-695">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au567" phase="p2">
<sentence pmid="8431895.s4">The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers.</sentence>
<gene range="569-576">c-erbB-2</gene>
<expression_change_keyword_1 range="551-564" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="551-564" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="681-695">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au568" phase="p2">
<sentence pmid="16086871.s8">pshRNA-Survivin could reduce the expression of Survivin gene, and induce apoptosis of SKOV3 and SKOV3/ADM cells.</sentence>
<gene range="47-59">Survivin gene</gene>
<expression_change_keyword_1 range="33-42" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="22-27" type="Negative_regulation">reduce</expression_change_keyword_2>
<cancer_term range="86-90">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au569" phase="p2">
<sentence pmid="19638582.s4">Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth.</sentence>
<gene range="246-247">Hh</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="235-244" type="Positive_regulation">activating</expression_change_keyword_2>
<cancer_term range="184-197">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au570" phase="p2">
<sentence pmid="19419758.s1">We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers.</sentence>
<gene range="30-35">TCEAL7</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="104-117" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="138-163">epithelial ovarian cancers</cancer_term>
<cancer_term range="149-163">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au571" phase="p2">
<sentence pmid="19419758.s1">We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers.</sentence>
<gene range="38-83">transcription elongation factor A (SII)-like 7</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="104-117" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="138-163">epithelial ovarian cancers</cancer_term>
<cancer_term range="149-163">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au572" phase="p2">
<sentence pmid="17045920.s0">Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells.</sentence>
<gene range="169-171">AKT</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="155-164" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="194-207">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au573" phase="p2">
<sentence pmid="17045920.s0">Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells.</sentence>
<gene range="177-183">P70S6K1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="155-164" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="194-207">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au574" phase="p2">
<sentence pmid="17045920.s1">The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer.</sentence>
<gene range="52-55">EGFR</gene>
<expression_change_keyword_1 range="75-87" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="75-87" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="124-137">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au575" phase="p2">
<sentence pmid="17045920.s1">The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer.</sentence>
<gene range="4-26">epidermal growth factor</gene>
<expression_change_keyword_1 range="75-87" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="75-87" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="124-137">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au576" phase="p2">
<sentence pmid="17045920.s1">The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer.</sentence>
<gene range="29-31">EGF</gene>
<expression_change_keyword_1 range="75-87" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="75-87" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="124-137">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au577" phase="p2">
<sentence pmid="17045920.s1">The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer.</sentence>
<gene range="38-49">EGF receptor</gene>
<expression_change_keyword_1 range="75-87" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="75-87" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="124-137">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au578" phase="p2">
<sentence pmid="17045920.s9">This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells.</sentence>
<gene range="141-147">p70S6K1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="119-128" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="158-171">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au579" phase="p2">
<sentence pmid="17045920.s9">This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells.</sentence>
<gene range="133-135">AKT</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="119-128" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="158-171">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au580" phase="p2">
<sentence pmid="10419053.s1">Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes.</sentence>
<gene range="0-26">Human folate receptor alpha</gene>
<expression_change_keyword_1 range="86-98" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="86-98" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="103-119">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au581" phase="p2">
<sentence pmid="10419053.s1">Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes.</sentence>
<gene range="29-35">FRalpha</gene>
<expression_change_keyword_1 range="86-98" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="86-98" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="103-119">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au582" phase="p2">
<sentence pmid="7696178.s0">Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.</sentence>
<gene range="45-53">CIP1/WAF1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="38-43" type="Positive_regulation">induce</expression_change_keyword_2>
<cancer_term range="100-113">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au583" phase="p2">
<sentence pmid="7696178.s10">OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1.</sentence>
<gene range="96-99">CIP1</gene>
<expression_change_keyword_1 range="101-110" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="88-94" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="0-6">OVCA420</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au584" phase="p2">
<sentence pmid="17118344.s8">Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven.</sentence>
<gene range="128-131">CHK2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="133-142" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="22-35">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au585" phase="p2">
<sentence pmid="19649288.s5">GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed hTERT expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts.</sentence>
<gene range="59-63">hTERT</gene>
<expression_change_keyword_1 range="65-74" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="48-57" type="Negative_regulation">suppressed</expression_change_keyword_2>
<cancer_term range="181-194">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au586" phase="p2">
<sentence pmid="15913739.s8">Single-chain antibody-mediated inhibition of Bcl-2 in SKOV3 cells was associated with increased growth rates and more rapid cell cycle progression.</sentence>
<gene range="45-49">Bcl-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="31-40" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="54-58">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au587" phase="p2">
<sentence pmid="15913739.s9">Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis.</sentence>
<gene range="133-137">Bcl-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="119-128" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="96-100">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au588" phase="p2">
<sentence pmid="18723500.s8">The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin.</sentence>
<gene range="34-37">FASN</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="39-48" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="74-87">ovarian cancer</cancer_term>
<cancer_term range="67-72">SKOV-3</cancer_term>
<cancer_term range="124-128">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au589" phase="p2">
<sentence pmid="14739059.s7">Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary.</sentence>
<gene range="160-166">inhibin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="145-152" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="111-134">ovarian germ cell tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au590" phase="p2">
<sentence pmid="14563607.s2">The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum CA 125 level, mimicking disseminated ovarian carcinoma.</sentence>
<gene range="198-203">CA 125</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="183-190" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="235-251">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au591" phase="p2">
<sentence pmid="19876919.s7">Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts.</sentence>
<gene range="0-3">Pak1</gene>
<expression_change_keyword_1 range="29-41" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="29-41" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="97-111">ovarian cancers</cancer_term>
<cancer_term range="46-59">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au592" phase="p2">
<sentence pmid="19876919.s7">Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts.</sentence>
<gene range="6-11">p-Pak1</gene>
<expression_change_keyword_1 range="29-41" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="29-41" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="97-111">ovarian cancers</cancer_term>
<cancer_term range="46-59">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au593" phase="p2">
<sentence pmid="19876919.s7">Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts.</sentence>
<gene range="17-22">p-Pak2</gene>
<expression_change_keyword_1 range="29-41" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="29-41" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="97-111">ovarian cancers</cancer_term>
<cancer_term range="46-59">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au594" phase="p2">
<sentence pmid="19876919.s14">Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.</sentence>
<gene range="20-23">Pak1</gene>
<expression_change_keyword_1 range="25-38" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="25-38" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="49-62">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au595" phase="p2">
<sentence pmid="19876919.s14">Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.</sentence>
<gene range="143-145">p38</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="133-141" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="49-62">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au596" phase="p2">
<sentence pmid="18436522.s0">Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice.</sentence>
<gene range="115-155">vesicular stomatitis virus matrix protein</gene>
<expression_change_keyword_1 range="103-113" type="Gene_expression">transferred</expression_change_keyword_1>
<expression_change_keyword_2 range="103-113" type="Positive_regulation">transferred</expression_change_keyword_2>
<cancer_term range="50-63">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au597" phase="p2">
<sentence pmid="16370564.s0">Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.</sentence>
<gene range="102-107">CA-125</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="93-100" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="35-54">benign struma ovarii</cancer_term>
<cancer_term range="42-54">struma ovarii</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au598" phase="p2">
<sentence pmid="21340838.s1">Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2).</sentence>
<gene range="39-55">c-erbB-2 oncogene</gene>
<expression_change_keyword_1 range="17-30" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-30" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="154-168">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au599" phase="p2">
<sentence pmid="20036116.s3">The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice.</sentence>
<gene range="4-7">HER2</gene>
<expression_change_keyword_1 range="9-22" type="Gene_expression">overexpressing</expression_change_keyword_1>
<expression_change_keyword_2 range="9-22" type="Positive_regulation">overexpressing</expression_change_keyword_2>
<cancer_term range="37-50">ovarian tumour</cancer_term>
<cancer_term range="30-35">SKOV-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au600" phase="p2">
<sentence pmid="14701673.s9">Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the Fas ligand promoter in Caov-3 cells.</sentence>
<gene range="96-114">Fas ligand promoter</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="68-74" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="119-124">Caov-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au601" phase="p2">
<sentence pmid="12855632.s0">Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.</sentence>
<gene range="38-46">claudin-4</gene>
<expression_change_keyword_1 range="63-75" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="63-75" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="106-125">ovarian cystadenomas</cancer_term>
<cancer_term range="80-93">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au602" phase="p2">
<sentence pmid="12855632.s0">Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.</sentence>
<gene range="24-32">claudin-3</gene>
<expression_change_keyword_1 range="63-75" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="63-75" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="106-125">ovarian cystadenomas</cancer_term>
<cancer_term range="80-93">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au603" phase="p2">
<sentence pmid="12855632.s8">Although expressed at low levels in some normal human tissues, including the ovary, CLDN3 and CLDN4 are highly up-regulated in epithelial ovarian cancers of all subtypes.</sentence>
<gene range="94-98">CLDN4</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="111-122" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="127-152">epithelial ovarian cancers</cancer_term>
<cancer_term range="138-152">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au604" phase="p2">
<sentence pmid="12855632.s8">Although expressed at low levels in some normal human tissues, including the ovary, CLDN3 and CLDN4 are highly up-regulated in epithelial ovarian cancers of all subtypes.</sentence>
<gene range="84-88">CLDN3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="111-122" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="127-152">epithelial ovarian cancers</cancer_term>
<cancer_term range="138-152">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au605" phase="p2">
<sentence pmid="12855632.s12">These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease.</sentence>
<gene range="24-28">CLDN3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="55-66" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="71-84">ovarian tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au606" phase="p2">
<sentence pmid="12855632.s12">These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease.</sentence>
<gene range="34-38">CLDN4</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="55-66" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="71-84">ovarian tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au607" phase="p2">
<sentence pmid="12684414.s0">Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.</sentence>
<gene range="33-63">centrosome kinase BTAK/Aurora-A</gene>
<expression_change_keyword_1 range="15-28" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="15-28" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="74-87">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au608" phase="p2">
<sentence pmid="12684414.s0">Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.</sentence>
<gene range="33-63">centrosome kinase BTAK/Aurora-A</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-9" type="Positive_regulation">Activation</expression_change_keyword_2>
<cancer_term range="74-87">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au609" phase="p2">
<sentence pmid="18349819.s2">We have previously shown that the E3 ubiquitin ligase, EDD, a regulator of DNA damage responses, is amplified and overexpressed in serous ovarian carcinoma.</sentence>
<gene range="55-57">EDD</gene>
<expression_change_keyword_1 range="114-126" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="114-126" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="138-154">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au610" phase="p2">
<sentence pmid="18349819.s5">Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.</sentence>
<gene range="258-260">EDD</gene>
<expression_change_keyword_1 range="262-271" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="245-253" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="91-104">ovarian cancer</cancer_term>
<cancer_term range="199-212">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au611" phase="p2">
<sentence pmid="11601039.s7">In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P &lt; 0.01), the incidence of the abnormal value was 100%.</sentence>
<gene range="48-50">IAP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="63-71" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="31-41">ovary tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au612" phase="p2">
<sentence pmid="8672936.s0">[Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course].</sentence>
<gene range="19-29">p53 protein</gene>
<expression_change_keyword_1 range="0-14" type="Gene_expression">[Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-14" type="Positive_regulation">[Overexpression</expression_change_keyword_2>
<cancer_term range="34-51">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au613" phase="p2">
<sentence pmid="8672936.s1">The accumulation of p53 protein was analysed immunohistochemically in ovarian cancer and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients.</sentence>
<gene range="20-30">p53 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-15" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="70-83">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au614" phase="p2">
<sentence pmid="21957230.s11">Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death.</sentence>
<gene range="10-16">p130cas</gene>
<expression_change_keyword_1 range="18-27" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="79-95">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au615" phase="p2">
<sentence pmid="18386461.s0">Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer.</sentence>
<gene range="18-45">follicle stimulating hormone</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="51-59" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="120-133">ovarian cancer</cancer_term>
<cancer_term range="64-76">ovarian tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au616" phase="p2">
<sentence pmid="14516936.s3">BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types.</sentence>
<gene range="0-4">BRCA1</gene>
<expression_change_keyword_1 range="6-15" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="20-28" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="91-105">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au617" phase="p2">
<sentence pmid="17673518.s3">Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.</sentence>
<gene range="25-27">EGF</gene>
<expression_change_keyword_1 range="80-92" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="80-92" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="126-139">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au618" phase="p2">
<sentence pmid="17673518.s3">Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.</sentence>
<gene range="34-57">hepatocyte growth factor</gene>
<expression_change_keyword_1 range="80-92" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="80-92" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="126-139">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au619" phase="p2">
<sentence pmid="17673518.s3">Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.</sentence>
<gene range="0-22">Epidermal growth factor</gene>
<expression_change_keyword_1 range="80-92" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="80-92" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="126-139">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au620" phase="p2">
<sentence pmid="17673518.s3">Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways.</sentence>
<gene range="60-62">HGF</gene>
<expression_change_keyword_1 range="80-92" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="80-92" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="126-139">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au621" phase="p2">
<sentence pmid="11877386.s10">According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.</sentence>
<gene range="212-224">BRCA1 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="196-203" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="258-272">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au622" phase="p2">
<sentence pmid="1358427.s1">Amplification or overexpression of the c-erbB-2 gene have been reported to correlate with poor patient prognosis in human breast, gastric, and ovarian cancer.</sentence>
<gene range="39-51">c-erbB-2 gene</gene>
<expression_change_keyword_1 range="17-30" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="17-30" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="143-156">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au623" phase="p2">
<sentence pmid="10408832.s7">We propose that, in the ovarian tumour microenvironment, interaction between tumour cells and fibroblasts may enhance fibroblast production of the proMMP-2 and TIMP-2.</sentence>
<gene range="147-154">proMMP-2</gene>
<expression_change_keyword_1 range="129-138" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="110-116" type="Positive_regulation">enhance</expression_change_keyword_2>
<cancer_term range="24-37">ovarian tumour</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au624" phase="p2">
<sentence pmid="10408832.s7">We propose that, in the ovarian tumour microenvironment, interaction between tumour cells and fibroblasts may enhance fibroblast production of the proMMP-2 and TIMP-2.</sentence>
<gene range="160-165">TIMP-2</gene>
<expression_change_keyword_1 range="129-138" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="110-116" type="Positive_regulation">enhance</expression_change_keyword_2>
<cancer_term range="24-37">ovarian tumour</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au625" phase="p2">
<sentence pmid="10408832.s8">Collagen I, also present in the ovarian tumours, then induces these fibroblasts to activate proMMP-2 even in the presence of TIMP-2.</sentence>
<gene range="92-99">proMMP-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="83-90" type="Positive_regulation">activate</expression_change_keyword_2>
<cancer_term range="32-46">ovarian tumours</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au626" phase="p2">
<sentence pmid="19181441.s1">We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.</sentence>
<gene range="64-67">FSHR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="70-78" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="132-156">ovarian epithelial tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au627" phase="p2">
<sentence pmid="19181441.s1">We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.</sentence>
<gene range="50-61">FSH receptor</gene>
<expression_change_keyword_1 range="30-39" type="Gene_expression">expressing</expression_change_keyword_1>
<expression_change_keyword_2 range="70-78" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="132-156">ovarian epithelial tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au628" phase="p2">
<sentence pmid="19181441.s1">We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.</sentence>
<gene range="64-67">FSHR</gene>
<expression_change_keyword_1 range="30-39" type="Gene_expression">expressing</expression_change_keyword_1>
<expression_change_keyword_2 range="70-78" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="132-156">ovarian epithelial tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au629" phase="p2">
<sentence pmid="16217764.s4">IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p&lt;0.04) and sera (p&lt;0.05) from patients with ovarian cancer.</sentence>
<gene range="0-4">IL-18</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="44-51" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="116-129">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au630" phase="p2">
<sentence pmid="16217764.s4">IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p&lt;0.04) and sera (p&lt;0.05) from patients with ovarian cancer.</sentence>
<gene range="10-23">FGF-2 proteins</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="44-51" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="116-129">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au631" phase="p2">
<sentence pmid="10342830.s17">In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.</sentence>
<gene range="164-170">activin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="149-159" type="Positive_regulation">up-regulate</expression_change_keyword_2>
<cancer_term range="24-26">PA1</cancer_term>
<cancer_term range="135-137">PA1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au632" phase="p2">
<sentence pmid="10342830.s17">In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.</sentence>
<gene range="109-115">activin</gene>
<expression_change_keyword_1 range="117-130" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="117-130" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="24-26">PA1</cancer_term>
<cancer_term range="135-137">PA1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au633" phase="p2">
<sentence pmid="7763262.s3">Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells.</sentence>
<gene range="12-21">IL-1 alpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-7" type="Negative_regulation">Blocking</expression_change_keyword_2>
<cancer_term range="35-39">HOC-7</cancer_term>
<cancer_term range="244-248">HOC-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au634" phase="p2">
<sentence pmid="11026599.s5">These results indicate that long-term NF treatment induces ovarian tumors in mice, possibly by continuous stimulation with gonadotropins such as LH via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism.</sentence>
<gene range="145-146">LH</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="106-116" type="Positive_regulation">stimulation</expression_change_keyword_2>
<cancer_term range="59-72">ovarian tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au635" phase="p2">
<sentence pmid="1696386.s2">Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: OVCAR-3 cancer cell line showed elevated amplification of c-Ki-ras, as compared to the human fibroblast cell line FS4 and normal ovarian tissues.</sentence>
<gene range="156-163">c-Ki-ras</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="130-137" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="98-104">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au636" phase="p2">
<sentence pmid="17409410.s0">Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.</sentence>
<gene range="0-3">Six1</gene>
<expression_change_keyword_1 range="5-18" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="5-18" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="23-39">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au637" phase="p2">
<sentence pmid="17409410.s2">Here, we show that the developmental regulator Six1 is overexpressed in ovarian carcinoma cell lines (OCC) compared with normal ovarian surface epithelium.</sentence>
<gene range="47-50">Six1</gene>
<expression_change_keyword_1 range="55-67" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="55-67" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="72-88">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au638" phase="p2">
<sentence pmid="17409410.s4">In addition, Six1 overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, and Six1 knockdown in the TRAIL-resistant SKOV3 ovarian carcinoma line dramatically sensitizes the cells to TRAIL.</sentence>
<gene range="146-149">Six1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="151-159" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="190-206">ovarian carcinoma</cancer_term>
<cancer_term range="184-188">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au639" phase="p2">
<sentence pmid="17409410.s4">In addition, Six1 overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, and Six1 knockdown in the TRAIL-resistant SKOV3 ovarian carcinoma line dramatically sensitizes the cells to TRAIL.</sentence>
<gene range="13-16">Six1</gene>
<expression_change_keyword_1 range="18-31" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="18-31" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="190-206">ovarian carcinoma</cancer_term>
<cancer_term range="184-188">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au640" phase="p2">
<sentence pmid="17409410.s6">Six1 was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) ovarian carcinomas examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors.</sentence>
<gene range="0-3">Six1</gene>
<expression_change_keyword_1 range="9-21" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="9-21" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="110-127">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au641" phase="p2">
<sentence pmid="17276501.s2">We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin.</sentence>
<gene range="133-135">ERK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="125-128" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="77-93">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au642" phase="p2">
<sentence pmid="11032026.s0">Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression.</sentence>
<gene range="18-27">caveolin-1</gene>
<expression_change_keyword_1 range="29-38" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Negative_regulation">Downmodulation</expression_change_keyword_2>
<cancer_term range="49-65">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au643" phase="p2">
<sentence pmid="11032026.s0">Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression.</sentence>
<gene range="90-110">alpha-folate receptor</gene>
<expression_change_keyword_1 range="112-125" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="112-125" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="49-65">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au644" phase="p2">
<sentence pmid="11032026.s5">SKOV3, but not two alphaFR-negative non-ovarian cell lines, exhibited down-regulation of cav-1 expression following stable alphaFR cDNA transfection.</sentence>
<gene range="123-134">alphaFR cDNA</gene>
<expression_change_keyword_1 range="136-147" type="Gene_expression">transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="136-147" type="Positive_regulation">transfection</expression_change_keyword_2>
<cancer_term range="0-4">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au645" phase="p2">
<sentence pmid="11032026.s5">SKOV3, but not two alphaFR-negative non-ovarian cell lines, exhibited down-regulation of cav-1 expression following stable alphaFR cDNA transfection.</sentence>
<gene range="89-93">cav-1</gene>
<expression_change_keyword_1 range="95-104" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="70-84" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="0-4">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au646" phase="p2">
<sentence pmid="11032026.s6">Conversely, cav-1 transfection in IGROV1 cells led to downregulated alphaFR expression, together with formation of caveolar structures and reduction of growth capability.</sentence>
<gene range="12-16">cav-1</gene>
<expression_change_keyword_1 range="18-29" type="Gene_expression">transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="18-29" type="Positive_regulation">transfection</expression_change_keyword_2>
<cancer_term range="34-39">IGROV1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au647" phase="p2">
<sentence pmid="11032026.s7">Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.</sentence>
<gene range="10-14">cav-1</gene>
<expression_change_keyword_1 range="16-25" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="31-37" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="42-47">IGROV1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au648" phase="p2">
<sentence pmid="11032026.s7">Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.</sentence>
<gene range="130-136">alphaFR</gene>
<expression_change_keyword_1 range="138-147" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="117-128" type="Negative_regulation">downmodulate</expression_change_keyword_2>
<cancer_term range="42-47">IGROV1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au649" phase="p2">
<sentence pmid="11032026.s7">Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.</sentence>
<gene range="10-14">cav-1</gene>
<expression_change_keyword_1 range="16-25" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="31-37" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="42-47">IGROV1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au650" phase="p2">
<sentence pmid="22027746.s12">Attenuating hypoxia-inducible factor (HIF)-1α expression via small interference RNA resulted in a significantly decreased hCG expression in OVCAR-3, which indicated that the effect of hypoxia on hCG expression was mediated through HIF-1α.</sentence>
<gene range="122-124">hCG</gene>
<expression_change_keyword_1 range="126-135" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="112-120" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="140-146">OVCAR-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au651" phase="p2">
<sentence pmid="22027746.s14">Expression level of vascular marker and HIF-1α in OVCAR-3 increased in response to hCG treatment in a dose-dependent manner.</sentence>
<gene range="40-45">HIF-1α</gene>
<expression_change_keyword_1 range="0-9" type="Gene_expression">Expression</expression_change_keyword_1>
<expression_change_keyword_2 range="58-66" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="50-56">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au652" phase="p2">
<sentence pmid="20657552.s4">Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer.</sentence>
<gene range="24-28">CD146</gene>
<expression_change_keyword_1 range="10-19" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Increased</expression_change_keyword_2>
<cancer_term range="167-180">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au653" phase="p2">
<sentence pmid="9458352.s4">IL-1 and CDDP treatment induced p53 protein in NIH:OVCAR-3 tumor cells.</sentence>
<gene range="32-42">p53 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="24-30" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="51-57">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au654" phase="p2">
<sentence pmid="9458352.s6">Taken together, these studies suggest that IL-1 may kill ovarian NIH:OVCAR-3 tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating c-myc gene and inducing p53-dependent apoptosis.</sentence>
<gene range="155-164">c-myc gene</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="139-153" type="Negative_regulation">down-regulating</expression_change_keyword_2>
<cancer_term range="69-75">OVCAR-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au655" phase="p2">
<sentence pmid="7913408.s8">Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.</sentence>
<gene range="104-117">P-glycoprotein</gene>
<expression_change_keyword_1 range="86-99" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="86-99" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="0-16">Ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au656" phase="p2">
<sentence pmid="21539834.s3">Cyclin E is overexpressed in breast, lung, skin, gastrointestinal, cervical, and ovarian cancers.</sentence>
<gene range="0-7">Cyclin E</gene>
<expression_change_keyword_1 range="12-24" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="12-24" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="81-95">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au657" phase="p2">
<sentence pmid="17285121.s7">MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and activation of caspase-9 and -3 cleavage.</sentence>
<gene range="127-129">p53</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="131-142" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="97-101">A2780</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au658" phase="p2">
<sentence pmid="1541865.s3">The levels of TAT and FDP were significantly higher in patients with ovarian cancer compared to the control group (both: p less than 0.01), and these levels were higher than in other gynecological malignancies.</sentence>
<gene range="14-16">TAT</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="45-50" type="Positive_regulation">higher</expression_change_keyword_2>
<cancer_term range="69-82">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au659" phase="p2">
<sentence pmid="1541865.s5">TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer.</sentence>
<gene range="0-2">TAT</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="17-25" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="202-215">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au660" phase="p2">
<sentence pmid="1541865.s5">TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer.</sentence>
<gene range="8-10">FDP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="17-25" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="202-215">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au661" phase="p2">
<sentence pmid="17331422.s5">Transfection of HER-2 siRNA was conducted with lipofectamine 2000 in ovarian carcinoma cell line SKOV3.</sentence>
<gene range="16-26">HER-2 siRNA</gene>
<expression_change_keyword_1 range="0-11" type="Gene_expression">Transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Transfection</expression_change_keyword_2>
<cancer_term range="69-85">ovarian carcinoma</cancer_term>
<cancer_term range="97-101">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au662" phase="p2">
<sentence pmid="12792888.s9">Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas.</sentence>
<gene range="10-16">p21Cip1</gene>
<expression_change_keyword_1 range="18-27" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Decreased</expression_change_keyword_2>
<cancer_term range="83-105">ovarian adenocarcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au663" phase="p2">
<sentence pmid="14743504.s0">Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.</sentence>
<gene range="154-163">BRCA1 gene</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="142-145" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="76-92">ovarian neoplasms</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au664" phase="p2">
<sentence pmid="14743504.s15">These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology.</sentence>
<gene range="50-62">BRCA1 protein</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="28-34" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="178-195">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au665" phase="p2">
<sentence pmid="14743504.s15">These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology.</sentence>
<gene range="113-122">BRCA1 gene</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="28-34" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="178-195">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au666" phase="p2">
<sentence pmid="20718682.s5">Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of &quot;struma pearl&quot; should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.</sentence>
<gene range="28-40">thyroglobulin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="19-26" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="229-254">malignant ovarian teratoma</cancer_term>
<cancer_term range="239-254">ovarian teratoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au667" phase="p2">
<sentence pmid="19486012.s6">ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression.</sentence>
<gene range="178-181">CDH1</gene>
<expression_change_keyword_1 range="183-192" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="166-173" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="116-137">ovarian adenocarcinoma</cancer_term>
<cancer_term range="139-143">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au668" phase="p2">
<sentence pmid="19486012.s6">ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression.</sentence>
<gene range="98-101">ZEB2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="103-111" type="Negative_regulation">knockdown</expression_change_keyword_2>
<cancer_term range="116-137">ovarian adenocarcinoma</cancer_term>
<cancer_term range="139-143">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au669" phase="p2">
<sentence pmid="9891239.s2">p53 overexpression, identified by immunohistochemistry, and p53 mutations, identified by single-strand conformational polymorphism (SSCP) and DNA sequencing, have been described in ovarian cancers.</sentence>
<gene range="0-2">p53</gene>
<expression_change_keyword_1 range="4-17" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-17" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="181-195">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au670" phase="p2">
<sentence pmid="9891239.s3">p53 overexpression has been correlated with poor outcome for women with ovarian cancer in some studies.</sentence>
<gene range="0-2">p53</gene>
<expression_change_keyword_1 range="4-17" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-17" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="72-85">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au671" phase="p2">
<sentence pmid="15520877.s14">No correlation could be seen between the histology of the ovarian tumours and the elevation of MMP-2/9 activity.</sentence>
<gene range="95-101">MMP-2/9</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="82-90" type="Positive_regulation">elevation</expression_change_keyword_2>
<cancer_term range="58-72">ovarian tumours</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au672" phase="p2">
<sentence pmid="15520877.s15">More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease.</sentence>
<gene range="29-33">MMP-9</gene>
<expression_change_keyword_1 range="35-44" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="95-102" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="174-187">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au673" phase="p2">
<sentence pmid="21119365.s6">Angiopoietin-1 and Ang-2 levels were significantly elevated in serum samples of patients with ovarian carcinoma compared with healthy controls (P = 0.0005 and P &lt; 0.0005, respectively).</sentence>
<gene range="19-23">Ang-2</gene>
<expression_change_keyword_1 range="25-30" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="51-58" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="94-110">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au674" phase="p2">
<sentence pmid="21119365.s6">Angiopoietin-1 and Ang-2 levels were significantly elevated in serum samples of patients with ovarian carcinoma compared with healthy controls (P = 0.0005 and P &lt; 0.0005, respectively).</sentence>
<gene range="0-13">Angiopoietin-1</gene>
<expression_change_keyword_1 range="25-30" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="51-58" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="94-110">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au675" phase="p2">
<sentence pmid="21119365.s7">In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P &lt; 0.0005) or borderline ovarian tumors (P = 0.011).</sentence>
<gene range="13-17">Ang-2</gene>
<expression_change_keyword_1 range="19-24" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="45-50" type="Positive_regulation">higher</expression_change_keyword_2>
<cancer_term range="138-162">borderline ovarian tumors</cancer_term>
<cancer_term range="69-85">ovarian carcinoma</cancer_term>
<cancer_term range="149-162">ovarian tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au676" phase="p2">
<sentence pmid="22001143.s19">Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy.</sentence>
<gene range="114-130">androgen receptor</gene>
<expression_change_keyword_1 range="132-141" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="143-151" type="Negative_regulation">decreases</expression_change_keyword_2>
<cancer_term range="41-54">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au677" phase="p2">
<sentence pmid="11014575.s0">Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.</sentence>
<gene range="176-177">Tn</gene>
<expression_change_keyword_1 range="201-210" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="163-174" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="121-148">epithelial ovarian carcinoma</cancer_term>
<cancer_term range="132-148">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au678" phase="p2">
<sentence pmid="11014575.s0">Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.</sentence>
<gene range="183-199">Sialyl Tn antigen</gene>
<expression_change_keyword_1 range="201-210" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="163-174" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="121-148">epithelial ovarian carcinoma</cancer_term>
<cancer_term range="132-148">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au679" phase="p2">
<sentence pmid="11014575.s10">Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.</sentence>
<gene range="66-74">Sialyl Tn</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="42-54" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="0-16">Ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au680" phase="p2">
<sentence pmid="11014575.s10">Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.</sentence>
<gene range="59-60">Tn</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="42-54" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="0-16">Ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au681" phase="p2">
<sentence pmid="21436696.s5">Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59% ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%).</sentence>
<gene range="72-81">TSLC1 gene</gene>
<expression_change_keyword_1 range="54-63" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="37-40" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="103-120">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au682" phase="p2">
<sentence pmid="21436696.s6">In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008).</sentence>
<gene range="33-37">TSLC1</gene>
<expression_change_keyword_1 range="39-48" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="23-31" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="3-20">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au683" phase="p2">
<sentence pmid="21436696.s7">By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P &lt; 0.001).</sentence>
<gene range="273-277">TSLC1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="263-271" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="39-55">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au684" phase="p2">
<sentence pmid="21436696.s7">By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P &lt; 0.001).</sentence>
<gene range="76-88">TSLC1 protein</gene>
<expression_change_keyword_1 range="90-99" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="66-74" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="39-55">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au685" phase="p2">
<sentence pmid="21436696.s9">Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma.</sentence>
<gene range="36-45">TSLC1 gene</gene>
<expression_change_keyword_1 range="18-27" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Decreased</expression_change_keyword_2>
<cancer_term range="110-126">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au686" phase="p2">
<sentence pmid="21300758.s1">Src is an attractive target because it is overexpressed in a number of malignancies, including ovarian cancer.</sentence>
<gene range="0-2">Src</gene>
<expression_change_keyword_1 range="42-54" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="42-54" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="95-108">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au687" phase="p2">
<sentence pmid="14961570.s0">Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.</sentence>
<gene range="116-121">ERK1/2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="84-90" type="Negative_regulation">reduces</expression_change_keyword_2>
<cancer_term range="159-172">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au688" phase="p2">
<sentence pmid="21789787.s5">NTN1 was found overexpressed in 76% of ovarian cancer specimens (13/17) as compared to normal (0/10, p&lt;0.004)and benign (1/8, p&lt;0.008) samples.</sentence>
<gene range="0-3">NTN1</gene>
<expression_change_keyword_1 range="15-27" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="15-27" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="39-52">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au689" phase="p2">
<sentence pmid="21789787.s8">Here,we demonstrated that NTN1 may be involved in ovarian cancer as the expression of NTN1 mRNA is strongly upregulated in ovarian malignant tumors but not in benign tumors.</sentence>
<gene range="86-94">NTN1 mRNA</gene>
<expression_change_keyword_1 range="72-81" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="108-118" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="50-63">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au690" phase="p2">
<sentence pmid="21789787.s9">The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer.</sentence>
<gene range="24-27">NTN1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="14-22" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="141-154">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au691" phase="p2">
<sentence pmid="20388850.s5">Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and GRB7v were frequently upregulated in ovarian cancer samples.</sentence>
<gene range="86-90">GRB7v</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="108-118" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="123-136">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au692" phase="p2">
<sentence pmid="20388850.s5">Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and GRB7v were frequently upregulated in ovarian cancer samples.</sentence>
<gene range="77-80">GRB7</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="108-118" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="123-136">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au693" phase="p2">
<sentence pmid="20388850.s6">The overexpressed GRB7 (P = 0.009) and GRB7v (P = 0.017) were significantly correlated with high-grade ovarian cancer.</sentence>
<gene range="18-21">GRB7</gene>
<expression_change_keyword_1 range="4-16" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="4-16" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="103-116">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au694" phase="p2">
<sentence pmid="20388850.s7">Immunohistochemical analysis on ovarian cancer tissue array confirmed that the upregulated GRB7 was significantly correlated with high-grade ovarian cancer (P = 0.001).</sentence>
<gene range="91-94">GRB7</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="79-89" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="32-45">ovarian cancer</cancer_term>
<cancer_term range="141-154">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au695" phase="p2">
<sentence pmid="20388850.s11">Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells.</sentence>
<gene range="45-48">GRB7</gene>
<expression_change_keyword_1 range="31-43" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="31-43" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="190-203">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au696" phase="p2">
<sentence pmid="20388850.s11">Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells.</sentence>
<gene range="54-58">GRB7v</gene>
<expression_change_keyword_1 range="31-43" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="31-43" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="190-203">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au697" phase="p2">
<sentence pmid="15523695.s0">Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.</sentence>
<gene range="78-90">progelatinase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="64-73" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="40-53">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au698" phase="p2">
<sentence pmid="15523695.s4">We report that MMP-7 is overexpressed in ovarian cancer cell lines and EOC surgical specimens.</sentence>
<gene range="15-19">MMP-7</gene>
<expression_change_keyword_1 range="24-36" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="24-36" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="41-54">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au699" phase="p2">
<sentence pmid="15523695.s5">DOV13 cells incubated with active rhMMP-7 significantly increased cellular invasion and proMMP-2 activation.</sentence>
<gene range="88-95">proMMP-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="97-106" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="0-4">DOV13</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au700" phase="p2">
<sentence pmid="15523695.s8">TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of proMMP-2 and the increased invasion of DOV13 cells promoted by rhMMP-7.</sentence>
<gene range="76-83">proMMP-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="62-71" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="115-119">DOV13</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au701" phase="p2">
<sentence pmid="8600090.s9">This decrease in the UTP and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of BG-1 cells.</sentence>
<gene range="21-23">UTP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-12" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="119-122">BG-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au702" phase="p2">
<sentence pmid="8600090.s9">This decrease in the UTP and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of BG-1 cells.</sentence>
<gene range="29-31">CTP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-12" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="119-122">BG-1</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au703" phase="p2">
<sentence pmid="16584837.s0">Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.</sentence>
<gene range="23-26">AKT2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="9-18" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="72-85">ovarian cancer</cancer_term>
<cancer_term range="147-160">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au704" phase="p2">
<sentence pmid="16584837.s0">Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.</sentence>
<gene range="131-133">AKT</gene>
<expression_change_keyword_1 range="117-126" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="107-115" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="72-85">ovarian cancer</cancer_term>
<cancer_term range="147-160">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au705" phase="p2">
<sentence pmid="2910450.s8">Despite these differences, ovarian carcinoma cells show substantial accumulation of araCTP from extracellular araC.</sentence>
<gene range="84-113">araCTP from extracellular araC</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="68-79" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="27-43">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au706" phase="p2">
<sentence pmid="11776599.s7">Increase in nitric oxide synthase activity might be related to the growth and malignant behavior of ovarian cancer.</sentence>
<gene range="12-32">nitric oxide synthase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-7" type="Positive_regulation">Increase</expression_change_keyword_2>
<cancer_term range="100-113">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au707" phase="p2">
<sentence pmid="9590136.s0">Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG.</sentence>
<gene range="131-158">insulin-like growth factor-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="114-126" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="75-88">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au708" phase="p2">
<sentence pmid="9590136.s9">Our findings suggest that LH/hCG influences the chemosensitivity of ovarian cancer cells through an apoptosis-inhibitory signal possibly via up-regulation of IGF-1 expression.</sentence>
<gene range="158-162">IGF-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="141-153" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="68-81">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au709" phase="p2">
<sentence pmid="18088084.s2">Mesothelin is a glycosyl-phosphatidyl inositol (GPI)-linked membrane protein of 40 kDa over-expressed in all pancreatic adenocarcinoma and mesothelioma, in &gt;70% of ovarian adenocarcinoma, and in non-small cell lung and colorectal cancers.</sentence>
<gene range="0-9">Mesothelin</gene>
<expression_change_keyword_1 range="87-100" type="Gene_expression">over-expressed</expression_change_keyword_1>
<expression_change_keyword_2 range="87-100" type="Positive_regulation">over-expressed</expression_change_keyword_2>
<cancer_term range="161-182">of ovarian adenocarcin</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au710" phase="p2">
<sentence pmid="11459464.s10">An in vitro internalization study showed that Av-G6Gd accumulated and was internalized into SHIN3 cells (a human ovarian cancer) 50- and 3.5-fold greater than Gd-DTPA (Magnevist) and G6-(1B4M-Gd)(256) (G6Gd).</sentence>
<gene range="46-52">Av-G6Gd</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="54-64" type="Positive_regulation">accumulated</expression_change_keyword_2>
<cancer_term range="113-126">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au711" phase="p2">
<sentence pmid="1464654.s0">Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1.</sentence>
<gene range="50-63">procathepsin D</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="10-19" type="Positive_regulation">stimulates</expression_change_keyword_2>
<cancer_term range="107-120">ovarian cancer</cancer_term>
<cancer_term range="132-135">BG-1</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au712" phase="p2">
<sentence pmid="15781636.s6">LPA increased COX-2 protein expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six ovarian cancer cell lines.</sentence>
<gene range="14-26">COX-2 protein</gene>
<expression_change_keyword_1 range="28-37" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-12" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="176-189">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au713" phase="p2">
<sentence pmid="15138597.s6">In patients with ovarian cancer, the increased leptin levels were associated with higher circulating follicle-stimulating hormone (FSH).</sentence>
<gene range="47-52">leptin</gene>
<expression_change_keyword_1 range="54-59" type="Gene_expression">levels</expression_change_keyword_1>
<expression_change_keyword_2 range="37-45" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="17-30">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au714" phase="p2">
<sentence pmid="16825507.s2">We previously reported that LTBP-1L is overexpressed in some patients with ovarian cancer.</sentence>
<gene range="28-34">LTBP-1L</gene>
<expression_change_keyword_1 range="39-51" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="39-51" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="75-88">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au715" phase="p2">
<sentence pmid="16825507.s7">Interestingly, ovarian cancer patients (n = 42) with G-A/G-A homozygous genotype had increased expression of LTBP-1 and apparently poorer survival than those with other genotypes (P = 0.02).</sentence>
<gene range="109-114">LTBP-1</gene>
<expression_change_keyword_1 range="95-104" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="85-93" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="15-28">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au716" phase="p2">
<sentence pmid="18632752.s4">Intriguingly, the loss of MKP3 protein was associated with ubiquitination/proteosome degradation mediated by high intracellular reactive oxygen species (ROS) accumulation such as hydrogen peroxide in ovarian cancer cells.</sentence>
<gene range="26-37">MKP3 protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="18-21" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="200-213">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au717" phase="p2">
<sentence pmid="18632752.s5">Functionally, short hairpin RNA knock down of endogenous MKP3 resulted in increased ERK1/2 activity, cell proliferation rate, anchorage-independent growth ability and resistance to cisplatin in ovarian cancer cells.</sentence>
<gene range="84-89">ERK1/2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="74-82" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="194-207">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au718" phase="p2">
<sentence pmid="18632752.s6">Conversely, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.</sentence>
<gene range="35-38">MKP3</gene>
<expression_change_keyword_1 range="21-30" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="12-19" type="Positive_regulation">enforced</expression_change_keyword_2>
<cancer_term range="58-71">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au719" phase="p2">
<sentence pmid="18632752.s6">Conversely, enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.</sentence>
<gene range="101-106">ERK1/2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="93-99" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="58-71">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au720" phase="p2">
<sentence pmid="17092940.s0">Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells.</sentence>
<gene range="116-120">ErbB2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="122-131" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="233-245">ovarian tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au721" phase="p2">
<sentence pmid="18070364.s0">Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.</sentence>
<gene range="28-33">TMEM97</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="11-23" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="173-186">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au722" phase="p2">
<sentence pmid="18070364.s0">Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.</sentence>
<gene range="39-68">cholesterol biosynthesis genes</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="11-23" type="Positive_regulation">up-regulation</expression_change_keyword_2>
<cancer_term range="173-186">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au723" phase="p2">
<sentence pmid="12174912.s9">Our findings indicate that: (I) VDR expression is increased in ovarian carcinomas as compared to normal ovarian tissue.</sentence>
<gene range="32-34">VDR</gene>
<expression_change_keyword_1 range="36-45" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="50-58" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="63-80">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au724" phase="p2">
<sentence pmid="12174912.s10">(II) Up-regulation of VDR in ovarian carcinomas is not exclusively induced by an increase of proliferation, but by different unknown mechanisms.</sentence>
<gene range="22-24">VDR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="5-17" type="Positive_regulation">Up-regulation</expression_change_keyword_2>
<cancer_term range="29-46">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au725" phase="p2">
<sentence pmid="17415999.s8">Transfection with GSK-3betaS9A to upregulate the GSK-3beta activity resulted in the increase of BrdU incorporation in SKOV3 cells compared with that in the control vector.</sentence>
<gene range="96-99">BrdU</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="84-91" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="118-122">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au726" phase="p2">
<sentence pmid="17415999.s8">Transfection with GSK-3betaS9A to upregulate the GSK-3beta activity resulted in the increase of BrdU incorporation in SKOV3 cells compared with that in the control vector.</sentence>
<gene range="49-57">GSK-3beta</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="34-43" type="Positive_regulation">upregulate</expression_change_keyword_2>
<cancer_term range="118-122">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au727" phase="p2">
<sentence pmid="17415999.s8">Transfection with GSK-3betaS9A to upregulate the GSK-3beta activity resulted in the increase of BrdU incorporation in SKOV3 cells compared with that in the control vector.</sentence>
<gene range="18-29">GSK-3betaS9A</gene>
<expression_change_keyword_1 range="0-11" type="Gene_expression">Transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Transfection</expression_change_keyword_2>
<cancer_term range="118-122">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au728" phase="p2">
<sentence pmid="17415999.s9">On the contrary, transfection with GID5-6 to downregulate GSK-3beta activity decreased the BrdU incorporation in SKOV3 cells, compared with that in GID5-6LP, which is a control vector of GID5-6.</sentence>
<gene range="35-40">GID5-6</gene>
<expression_change_keyword_1 range="17-28" type="Gene_expression">transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="17-28" type="Positive_regulation">transfection</expression_change_keyword_2>
<cancer_term range="113-117">SKOV3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au729" phase="p2">
<sentence pmid="21323863.s1">Targeting and down-regulation of ErbB2, a member of EGF receptor family, is regarded as one of the key aspect for cancer treatment because it is often overexpressed in breast and ovarian cancer cells.</sentence>
<gene range="33-37">ErbB2</gene>
<expression_change_keyword_1 range="151-163" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="151-163" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="179-192">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au730" phase="p2">
<sentence pmid="16093247.s8">Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer.</sentence>
<gene range="13-28">TRAIL receptor 4</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Negative_regulation">Knockdown</expression_change_keyword_2>
<cancer_term range="298-311">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au731" phase="p2">
<sentence pmid="16136053.s6">Quantitative PCR revealed decreased Notch 1 mRNA in ovarian adenocarcinomas compared with adenomas.</sentence>
<gene range="36-42">Notch 1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="26-34" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="52-74">ovarian adenocarcinomas</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au732" phase="p3">
<sentence pmid="18519708.s6">Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P &lt; 0.001 for all).</sentence>
<gene range="216-222">UGT2B17</gene>
<expression_change_keyword_1 range="157-166" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="144-155" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="22-36">prostate tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au733" phase="p3">
<sentence pmid="18519708.s6">Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P &lt; 0.001 for all).</sentence>
<gene range="257-262">SRD5A2</gene>
<expression_change_keyword_1 range="243-252" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="228-241" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="22-36">prostate tumors</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au734" phase="p3">
<sentence pmid="15735018.s3">Progression of benign prostate cancer to malignant metastasis is linked to increased production of basic fibroblast growth factor (bFGF), a powerful mitogen.</sentence>
<gene range="131-134">bFGF</gene>
<expression_change_keyword_1 range="85-94" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="75-83" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="22-36">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au735" phase="p3">
<sentence pmid="15735018.s4">In this study, using in vitro model system we show that DPPIV loss is associated with increased bFGF production in metastatic prostate cancer cells.</sentence>
<gene range="96-99">bFGF</gene>
<expression_change_keyword_1 range="101-110" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="86-94" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="115-140">metastatic prostate cancer</cancer_term>
<cancer_term range="126-140">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au736" phase="p3">
<sentence pmid="15735018.s5">DPPIV reexpression in prostate cancer cells blocks nuclear localization of bFGF, reduces bFGF levels, inhibits mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)1/2 activation, and decreases levels of urokinase-type plasminogen activator, known downstream effectors of bFGF signaling pathway.</sentence>
<gene range="89-92">bFGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="81-87" type="Negative_regulation">reduces</expression_change_keyword_2>
<cancer_term range="22-36">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au737" phase="p3">
<sentence pmid="15735018.s8">These results indicate that DPPIV inhibits the malignant phenotype of prostate cancer cells by blocking bFGF signaling pathway.</sentence>
<gene range="104-107">bFGF</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="95-102" type="Negative_regulation">blocking</expression_change_keyword_2>
<cancer_term range="70-84">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au738" phase="p3">
<sentence pmid="16818637.s8">Our findings suggest that blockage of osteopontin and/or COX-2 is a promising therapeutic approach for the inhibition of prostate tumor progression and angiogenesis.</sentence>
<gene range="38-48">osteopontin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="26-33" type="Negative_regulation">blockage</expression_change_keyword_2>
<cancer_term range="121-134">prostate tumor</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au739" phase="p3">
<sentence pmid="10590366.s2">Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid.</sentence>
<gene range="23-25">Met</gene>
<expression_change_keyword_1 range="9-18" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-7" type="Positive_regulation">Elevated</expression_change_keyword_2>
<cancer_term range="63-87">carcinoma of the prostate</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au740" phase="p3">
<sentence pmid="14676836.s0">Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.</sentence>
<gene range="18-22">Bcl-2</gene>
<expression_change_keyword_1 range="24-33" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="10-16" type="Negative_regulation">repress</expression_change_keyword_2>
<cancer_term range="88-102">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au741" phase="p3">
<sentence pmid="14676836.s1">The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.</sentence>
<gene range="105-109">Bcl-2</gene>
<expression_change_keyword_1 range="111-124" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="111-124" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="48-62">prostate tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au742" phase="p3">
<sentence pmid="14676836.s1">The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.</sentence>
<gene range="13-17">Bcl-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="22-32" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="48-62">prostate tumors</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au743" phase="p3">
<sentence pmid="14676836.s9">Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1.</sentence>
<gene range="138-144">p27KIP1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="43-53" type="Positive_regulation">upregulated</expression_change_keyword_2>
<cancer_term range="31-35">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au744" phase="p3">
<sentence pmid="22199300.s6">Prostate cancer cells transfected with EP4-siRNA and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt.</sentence>
<gene range="39-47">EP4-siRNA</gene>
<expression_change_keyword_1 range="22-32" type="Gene_expression">transfected</expression_change_keyword_1>
<expression_change_keyword_2 range="22-32" type="Positive_regulation">transfected</expression_change_keyword_2>
<cancer_term range="0-14">Prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au745" phase="p3">
<sentence pmid="18929692.s11">Combined blockade of RANK/RANKL axis and BMP pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic prostate cancer lesion in bone.</sentence>
<gene range="41-43">BMP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="9-16" type="Negative_regulation">blockade</expression_change_keyword_2>
<cancer_term range="182-196">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au746" phase="p3">
<sentence pmid="10067845.s0">Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.</sentence>
<gene range="13-29">androgen receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="103-117">prostate cancer</cancer_term>
<cancer_term range="91-95">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au747" phase="p3">
<sentence pmid="10067845.s10">This increased expression of AR was followed by 1,25-(OH)2D3-induced inhibition of growth in LNCaP cells.</sentence>
<gene range="29-30">AR</gene>
<expression_change_keyword_1 range="15-24" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="5-13" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="93-97">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au748" phase="p3">
<sentence pmid="10067845.s14">In conclusion, our results demonstrate that growth inhibition of LNCaP cells by 1,25-(OH)2D3 and 9-cis RA is mediated by an AR-dependent mechanism and preceded by the induction of AR gene expression.</sentence>
<gene range="180-186">AR gene</gene>
<expression_change_keyword_1 range="188-197" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="167-175" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="65-69">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au749" phase="p3">
<sentence pmid="18336887.s6">The decrease in survivin gene expression by transfection of siRNA was accompanied by the inhibition of cell proliferation of PCa cells (31% and 25% decreased in LNCaP and PC-3 cells, P &lt;0.01).</sentence>
<gene range="16-28">survivin gene</gene>
<expression_change_keyword_1 range="30-39" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="4-11" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="161-165">LNCaP</cancer_term>
<cancer_term range="171-174">PC-3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au750" phase="p3">
<sentence pmid="11410510.s10">Antisense oligodeoxynucleotides, designed to block production of epidermal-FABP (a marker for normal prostate cells), caused increased proliferation in DU 145 prostate cancer cells.</sentence>
<gene range="65-78">epidermal-FABP</gene>
<expression_change_keyword_1 range="51-60" type="Gene_expression">production</expression_change_keyword_1>
<expression_change_keyword_2 range="45-49" type="Negative_regulation">block</expression_change_keyword_2>
<cancer_term range="159-173">prostate cancer</cancer_term>
<cancer_term range="152-157">DU 145</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au751" phase="p3">
<sentence pmid="11410510.s11">In vivid contrast, antisense oligodeoxynucleotides to L-FABP (overexpressed in prostate cancer) decreased proliferation and caused apoptosis.</sentence>
<gene range="54-59">L-FABP</gene>
<expression_change_keyword_1 range="62-74" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="62-74" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="79-93">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au752" phase="p3">
<sentence pmid="16982748.s7">Furthermore, elevated [Ca2+]o triggered activation of the Akt signaling pathway and enhanced PC-3 cell attachment.</sentence>
<gene range="58-60">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="40-49" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="93-96">PC-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au753" phase="p3">
<sentence pmid="12507906.s0">The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.</sentence>
<gene range="168-184">androgen receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="123-130" type="Positive_regulation">enhances</expression_change_keyword_2>
<cancer_term range="103-117">prostate cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au754" phase="p3">
<sentence pmid="12507906.s5">In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val--&gt;met.</sentence>
<gene range="109-110">AR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="100-107" type="Positive_regulation">enhanced</expression_change_keyword_2>
<cancer_term range="3-17">prostate cancer</cancer_term>
<cancer_term range="19-24">DU-145</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au755" phase="p3">
<sentence pmid="14687488.s4">NP manifested no immunoreactivity, whereas Pca and BPH showed significantly increased HIF-1alpha protein expression.</sentence>
<gene range="86-103">HIF-1alpha protein</gene>
<expression_change_keyword_1 range="105-114" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="76-84" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="51-53">BPH</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au756" phase="p3">
<sentence pmid="14687488.s7">Our findings of increased HIF-1alpha protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.</sentence>
<gene range="26-43">HIF-1alpha protein</gene>
<expression_change_keyword_1 range="45-54" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="16-24" type="Positive_regulation">increased</expression_change_keyword_2>
<cancer_term range="59-61">BPH</cancer_term>
<cancer_term range="128-130">BPH</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au757" phase="p3">
<sentence pmid="8978405.s17">The same concentration of R1881 resulted in a decrease in intracellular glutathione concentrations and an increase in gamma-glutamyl transpeptidase activity in LNCaP cells.</sentence>
<gene range="118-146">gamma-glutamyl transpeptidase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="106-113" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="160-164">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au758" phase="p3">
<sentence pmid="8978405.s18">Treatment with the oxidizing agents H2O2 and menadione produced an increase in gamma-glutamyl transpeptidase activity in LNCaP cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.</sentence>
<gene range="79-107">gamma-glutamyl transpeptidase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="67-74" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="121-125">LNCaP</cancer_term>
<cancer_term range="246-250">LNCaP</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au759" phase="p3">
<sentence pmid="8978405.s18">Treatment with the oxidizing agents H2O2 and menadione produced an increase in gamma-glutamyl transpeptidase activity in LNCaP cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.</sentence>
<gene range="299-327">gamma-glutamyl transpeptidase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="287-293" type="Negative_regulation">blocked</expression_change_keyword_2>
<cancer_term range="121-125">LNCaP</cancer_term>
<cancer_term range="246-250">LNCaP</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au760" phase="p3">
<sentence pmid="9790546.s1">For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels.</sentence>
<gene range="127-142">androgen hormone</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="103-113" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="18-43">metastatic prostate cancer</cancer_term>
<cancer_term range="29-43">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="prostate" id="au761" phase="p3">
<sentence pmid="11571633.s0">Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.</sentence>
<gene range="78-81">VEGF</gene>
<expression_change_keyword_1 range="30-39" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="15-24" type="Negative_regulation">attenuates</expression_change_keyword_2>
<cancer_term range="86-100">prostate cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au762" phase="p3">
<sentence pmid="15958562.s8">These findings indicate that FoxM1 depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target breast cancer.</sentence>
<gene range="29-33">FoxM1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="35-43" type="Negative_regulation">depletion</expression_change_keyword_2>
<cancer_term range="160-172">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au763" phase="p3">
<sentence pmid="17616457.s3">Long-term culture of MCF-7 cells in estrogen deprived medium (LTED) mimics aromatase inhibition in patients.</sentence>
<gene range="75-83">aromatase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="85-94" type="Negative_regulation">inhibition</expression_change_keyword_2>
<cancer_term range="21-25">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au764" phase="p3">
<sentence pmid="20536410.s8">The findings of the present study suggest that COX-2 overexpression in lobular and ductal breast cancers, which correlates with traditional clinico-pathological parameters, may be considered as a negative prognostic marker.</sentence>
<gene range="47-51">COX-2</gene>
<expression_change_keyword_1 range="53-66" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="53-66" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="83-103">ductal breast cancers</cancer_term>
<cancer_term range="90-103">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au765" phase="p3">
<sentence pmid="21400218.s2">Its stimulation on breast cancer cell lines induces β1 integrin and promotes tumor invasiveness.</sentence>
<gene range="52-62">β1 integrin</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="44-50" type="Positive_regulation">induces</expression_change_keyword_2>
<cancer_term range="19-31">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au766" phase="p3">
<sentence pmid="11544097.s0">P1, a high mobility group-like protein is depressed in human breast adenocarcinoma.</sentence>
<gene range="6-37">high mobility group-like protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="42-50" type="Negative_regulation">depressed</expression_change_keyword_2>
<cancer_term range="61-81">breast adenocarcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au767" phase="p3">
<sentence pmid="18840527.s6">We showed, for the first time, that knockdown of PDI in MCF-7 human breast cancer cells with RNA interference down-regulates ERalpha protein but up-regulates ERbeta protein, resulting in a drastic increase in ERbeta/ERalpha ratio, which is a crucial determinant of different cellular responses to estrogens.</sentence>
<gene range="158-171">ERbeta protein</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="145-156" type="Positive_regulation">up-regulates</expression_change_keyword_2>
<cancer_term range="68-80">breast cancer</cancer_term>
<cancer_term range="56-60">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au768" phase="p3">
<sentence pmid="18655371.s4">A higher increase of the expression and maximal pixel intensity of ICAM-1, VCAM-1 and P-selectin was observed in endothelial cells cocultured with c-erbB2-positive breast carcinoma cells as compared to endothelial cells cocultured with c-erbB2-negative cell line.</sentence>
<gene range="67-72">ICAM-1</gene>
<expression_change_keyword_1 range="25-34" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="9-16" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="164-179">breast carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au769" phase="p3">
<sentence pmid="18713757.s7">In addition, even a transient, siRNA-mediated p21 suppression in fibroblasts sufficiently stimulates MCF7 and MDA-MB-231 growth in vivo.</sentence>
<gene range="46-48">p21</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="50-60" type="Negative_regulation">suppression</expression_change_keyword_2>
<cancer_term range="110-119">MDA-MB-231</cancer_term>
<cancer_term range="101-104">MCF7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au770" phase="p3">
<sentence pmid="8838861.s6">The butyrate-induced apoptosis in MCF-7 cells was closely linked with the down-regulation of expression of Bcl-2 mRNA and Bcl-2 protein, a gene product known to be involved in the regulation of apoptosis in mammalian cells.</sentence>
<gene range="107-116">Bcl-2 mRNA</gene>
<expression_change_keyword_1 range="93-102" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="74-88" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="34-38">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au771" phase="p3">
<sentence pmid="8838861.s7">The observed relationship between the down-regulation of Bcl-2 and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of MCF-7 cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells).</sentence>
<gene range="57-61">Bcl-2</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="38-52" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="170-174">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au772" phase="p3">
<sentence pmid="21923922.s3">The non-receptor PTK termed breast tumor kinase (Brk/PTK6) is overexpressed in approximately 86% of human breast tumors.</sentence>
<gene range="49-56">Brk/PTK6</gene>
<expression_change_keyword_1 range="62-74" type="Gene_expression">overexpressed</expression_change_keyword_1>
<expression_change_keyword_2 range="62-74" type="Positive_regulation">overexpressed</expression_change_keyword_2>
<cancer_term range="106-118">breast tumors</cancer_term>
<cancer_term range="28-39">breast tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au773" phase="p3">
<sentence pmid="21923922.s11">Brk-dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11 murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in breast cancer cells blocked EGF-stimulated p38 signaling.</sentence>
<gene range="57-59">Brk</gene>
<expression_change_keyword_1 range="61-74" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="61-74" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="169-181">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au774" phase="p3">
<sentence pmid="19995430.s13">We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation.</sentence>
<gene range="137-141">CUL4A</gene>
<expression_change_keyword_1 range="119-132" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="110-117" type="Positive_regulation">inducing</expression_change_keyword_2>
<cancer_term range="92-105">breast cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au775" phase="p3">
<sentence pmid="20217214.s6">
Intercellular adhesion molecule 1 (ICAM-1) was down-regulated in MCF10A cells using short hairpin RNA.</sentence>
<gene range="0-41">Intercellular adhesion molecule 1 (ICAM-1)</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="47-60" type="Negative_regulation">down-regulated</expression_change_keyword_2>
<cancer_term range="65-70">MCF10A</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au776" phase="p3">
<sentence pmid="20217214.s11">The down-regulation of ICAM-1 by short hairpin RNA in MCF10A cells led to the induction of psoriasin, calgranulin-A, calgranulin-B, and MUC1, and we demonstrated that these up-regulations were not ROS dependent.</sentence>
<gene range="102-114">calgranulin-A</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="78-86" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="54-59">MCF10A</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au777" phase="p3">
<sentence pmid="20217214.s11">The down-regulation of ICAM-1 by short hairpin RNA in MCF10A cells led to the induction of psoriasin, calgranulin-A, calgranulin-B, and MUC1, and we demonstrated that these up-regulations were not ROS dependent.</sentence>
<gene range="23-28">ICAM-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-18" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="54-59">MCF10A</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au778" phase="p3">
<sentence pmid="20217214.s14">Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade DCIS tumors and to the induction of MUC1.</sentence>
<gene range="200-203">MUC1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="187-195" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="164-167">DCIS</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au779" phase="p3">
<sentence pmid="20217214.s14">Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade DCIS tumors and to the induction of MUC1.</sentence>
<gene range="49-54">ICAM-1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="30-44" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="164-167">DCIS</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au780" phase="p3">
<sentence pmid="22228571.s10">RT-PCR and Western blot showed that the expressions of only c-Met and STAT3 decreased obviously in colon and breast cancer cells exposed to LS-7.</sentence>
<gene range="70-74">STAT3</gene>
<expression_change_keyword_1 range="40-50" type="Gene_expression">expressions</expression_change_keyword_1>
<expression_change_keyword_2 range="76-84" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="109-121">breast cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au781" phase="p3">
<sentence pmid="17986353.s8">These compounds decreased ERalpha in MCF-7 cells at both mRNA and protein levels, and suppressed estrogen-stimulated genes.</sentence>
<gene range="26-32">ERalpha</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="16-24" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="37-41">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au782" phase="p3">
<sentence pmid="11689445.s3">Oestradiol acutely increases PI3-kinase and Akt activities in MCF-7 cells.</sentence>
<gene range="44-46">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="19-27" type="Positive_regulation">increases</expression_change_keyword_2>
<cancer_term range="62-66">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au783" phase="p3">
<sentence pmid="11689445.s5">The Src inhibitor, PP1, prevents hormone stimulation of Akt and PI3-kinase activities in MCF-7 cells.</sentence>
<gene range="56-58">Akt</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="41-51" type="Positive_regulation">stimulation</expression_change_keyword_2>
<cancer_term range="89-93">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au784" phase="p3">
<sentence pmid="11689445.s6">In turn, stimulation of Src activity is abolished in ERalpha-expressing NIH 3T3 fibroblasts by co-transfection of the dominant-negative p85alpha and in MCF-7 cells by the PI3-kinase inhibitor, LY294002.</sentence>
<gene range="118-143">dominant-negative p85alpha</gene>
<expression_change_keyword_1 range="95-109" type="Gene_expression">co-transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="95-109" type="Positive_regulation">co-transfection</expression_change_keyword_2>
<cancer_term range="152-156">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au785" phase="p3">
<sentence pmid="10602481.s7">Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.</sentence>
<gene range="29-38">E-cadherin</gene>
<expression_change_keyword_1 range="40-49" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="21-24" type="Negative_regulation">loss</expression_change_keyword_2>
<cancer_term range="59-72">breast cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au786" phase="p3">
<sentence pmid="9815853.s0">Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.</sentence>
<gene range="142-145">p185</gene>
<expression_change_keyword_1 range="130-140" type="Gene_expression">overexpress</expression_change_keyword_1>
<expression_change_keyword_2 range="130-140" type="Positive_regulation">overexpress</expression_change_keyword_2>
<cancer_term range="105-117">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au787" phase="p3">
<sentence pmid="12942541.s0">PKC-zeta is required for angiotensin II-induced activation of ERK and synthesis of C-FOS in MCF-7 cells.</sentence>
<gene range="62-64">ERK</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="48-57" type="Positive_regulation">activation</expression_change_keyword_2>
<cancer_term range="92-96">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au788" phase="p3">
<sentence pmid="12942541.s6">When the epidermal growth factor-receptor (EGFR) tyrosine kinase activity was inhibited by the use of its inhibitor AG1478, Ang II was still able to induce ERK1/2 phosphorylation and c-fos expression, therefore proving that the transactivation of EGFR was not required for these Ang II effects in MCF-7 cells.</sentence>
<gene range="9-40">epidermal growth factor-receptor</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="78-86" type="Negative_regulation">inhibited</expression_change_keyword_2>
<cancer_term range="297-301">MCF-7</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au789" phase="p3">
<sentence pmid="12942541.s6">When the epidermal growth factor-receptor (EGFR) tyrosine kinase activity was inhibited by the use of its inhibitor AG1478, Ang II was still able to induce ERK1/2 phosphorylation and c-fos expression, therefore proving that the transactivation of EGFR was not required for these Ang II effects in MCF-7 cells.</sentence>
<gene range="183-187">c-fos</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="149-154" type="Positive_regulation">induce</expression_change_keyword_2>
<cancer_term range="297-301">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au790" phase="p3">
<sentence pmid="12942541.s8">Our results suggest that in MCF-7 cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of c-fos.</sentence>
<gene range="194-198">c-fos</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="181-189" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="28-32">MCF-7</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="breast" id="au791" phase="p3">
<sentence pmid="15868442.s7">In the former group, ErbB2 overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and breast cancer death (RR = 5.4; 95% CI, 2.3-12.6).</sentence>
<gene range="21-25">ErbB2</gene>
<expression_change_keyword_1 range="27-40" type="Gene_expression">overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="27-40" type="Positive_regulation">overexpression</expression_change_keyword_2>
<cancer_term range="133-145">breast cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au792" phase="p3">
<sentence pmid="16136053.s9">Transfecting A2780 cells with active Notch 1-IC resulted in a proliferative and colony formation advantage compared to mock transfected cells.</sentence>
<gene range="37-46">Notch 1-IC</gene>
<expression_change_keyword_1 range="0-11" type="Gene_expression">Transfecting</expression_change_keyword_1>
<expression_change_keyword_2 range="0-11" type="Positive_regulation">Transfecting</expression_change_keyword_2>
<cancer_term range="13-17">A2780</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="causality"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au793" phase="p3">
<sentence pmid="12149147.s6">Immunoblotting analysis demonstrated that PRB protein expression was markedly up-regulated in OVCAR-3, whereas the PRA and PRB isoforms both appeared to be increased in NOV-31.</sentence>
<gene range="42-52">PRB protein</gene>
<expression_change_keyword_1 range="54-63" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="78-89" type="Positive_regulation">up-regulated</expression_change_keyword_2>
<cancer_term range="94-100">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au794" phase="p3">
<sentence pmid="12149147.s7">These results suggest that down-regulation of PRA is associated with the development of ovarian epithelial carcinoma.</sentence>
<gene range="46-48">PRA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="27-41" type="Negative_regulation">down-regulation</expression_change_keyword_2>
<cancer_term range="88-115">ovarian epithelial carcinoma</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au795" phase="p3">
<sentence pmid="10728592.s8">Up-regulation of AR by 1,25(OH)2D3 and of VDR by DHT provides evidence of cross-talk between 2 signaling pathways in OVCAR-3 cells.</sentence>
<gene range="42-44">VDR</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-12" type="Positive_regulation">Up-regulation</expression_change_keyword_2>
<cancer_term range="117-123">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au796" phase="p3">
<sentence pmid="9815853.s1">Overexpression of p185(c-erbB2) (p185/NEU/HER2) by tumor cells is associated with a poor prognosis in many but not all studies of breast and ovarian cancer.</sentence>
<gene range="33-45">p185/NEU/HER2</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="141-154">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au797" phase="p3">
<sentence pmid="9815853.s13">Moreover, the poor prognosis of breast and ovarian cancers that overexpress p185(c-erbB2) could relate in part to enhanced invasiveness rather than to increased proliferative capacity.</sentence>
<gene range="76-79">p185</gene>
<expression_change_keyword_1 range="64-74" type="Gene_expression">overexpress</expression_change_keyword_1>
<expression_change_keyword_2 range="64-74" type="Positive_regulation">overexpress</expression_change_keyword_2>
<cancer_term range="43-57">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au798" phase="p3">
<sentence pmid="15528975.s8">Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.</sentence>
<gene range="359-362">TIMP</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="294-305" type="Positive_regulation">upregulation</expression_change_keyword_2>
<cancer_term range="98-114">ovarian carcinoma</cancer_term>
<cancer_term range="62-66">A2780</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au799" phase="p3">
<sentence pmid="15162825.s9">This study showed that IL-18 serum levels were elevated in ovarian cancer patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.</sentence>
<gene range="23-27">IL-18</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="47-54" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="59-72">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au800" phase="p3">
<sentence pmid="18497984.s3">Overexpression of TUBB3 protein was observed in 56 (85%) of the 66 ovarian cancers, and was significantly associated with aggressive tumor behavior (advanced stage, presence of ascites, suboptimal cytoreduction at surgery and presence of lymph node metastasis) (P&lt;0.05).</sentence>
<gene range="18-30">TUBB3 protein</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="67-81">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au801" phase="p3">
<sentence pmid="18497984.s5">In 2 cell lines with weak expression of TUBB3 protein (OVCAR-3 and JHOC-8), TUBB3 induction was independently induced by treatment with 5-Aza-CdR (JHOC-8) or PBA (OVCAR-3), while neither agent markedly altered TUBB3 mRNA/protein expression in a strongly TUBB3-expressing cell line (JHOC-5).</sentence>
<gene range="76-80">TUBB3</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="82-90" type="Positive_regulation">induction</expression_change_keyword_2>
<cancer_term range="55-61">OVCAR-3</cancer_term>
<cancer_term range="163-169">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au802" phase="p3">
<sentence pmid="18497984.s7">A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3.</sentence>
<gene range="118-122">TUBB3</gene>
<expression_change_keyword_1 range="124-133" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="139-145" type="Positive_regulation">induced</expression_change_keyword_2>
<cancer_term range="77-83">OVCAR-3</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au803" phase="p3">
<sentence pmid="8244317.s0">p53 accumulation in ovarian carcinomas and its prognostic implications.</sentence>
<gene range="0-2">p53</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="4-15" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="20-37">ovarian carcinomas</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au804" phase="p3">
<sentence pmid="8244317.s11">These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma.</sentence>
<gene range="27-29">p53</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="31-42" type="Positive_regulation">accumulation</expression_change_keyword_2>
<cancer_term range="195-211">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au805" phase="p3">
<sentence pmid="12174904.s0">Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.</sentence>
<gene range="13-21">MDR1-gene</gene>
<expression_change_keyword_1 range="23-32" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="62-75">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au806" phase="p3">
<sentence pmid="9114434.s0">Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.</sentence>
<gene range="13-46">gamma-glutamyl transpeptidase mRNA</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="0-8" type="Positive_regulation">Induction</expression_change_keyword_2>
<cancer_term range="81-97">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au807" phase="p3">
<sentence pmid="9114434.s2">Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2) [El-akawi et al., Cancer Lett. 105:5-14; 1966].</sentence>
<gene range="207-235">gamma-glutamyl transpeptidase</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="154-161" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="55-71">ovarian carcinoma</cancer_term>
<cancer_term range="83-87">A2780</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au808" phase="p3">
<sentence pmid="10498868.s6">Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.</sentence>
<gene range="86-89">ING1</gene>
<expression_change_keyword_1 range="91-100" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="72-81" type="Negative_regulation">repression</expression_change_keyword_2>
<cancer_term range="46-60">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au809" phase="p3">
<sentence pmid="3465487.s0">Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation.</sentence>
<gene range="70-75">CA-125</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="11-19" type="Positive_regulation">increases</expression_change_keyword_2>
<cancer_term range="48-60">ovarian tumor</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au810" phase="p3">
<sentence pmid="16552954.s0">[Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice].</sentence>
<gene range="55-64">TRAIL gene</gene>
<expression_change_keyword_1 range="66-77" type="Gene_expression">transfection</expression_change_keyword_1>
<expression_change_keyword_2 range="66-77" type="Positive_regulation">transfection</expression_change_keyword_2>
<cancer_term range="82-98">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au811" phase="p3">
<sentence pmid="22312289.s3">Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level.</sentence>
<gene range="88-95">cyclin A</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="33-40" type="Positive_regulation">increase</expression_change_keyword_2>
<cancer_term range="124-137">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au812" phase="p3">
<sentence pmid="22312289.s3">Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level.</sentence>
<gene range="230-232">p27</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="218-225" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="124-137">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au813" phase="p3">
<sentence pmid="12066248.s0">Abdominopelvic tuberculosis simulating disseminated ovarian carcinoma with elevated CA-125 level: report of two cases.</sentence>
<gene range="84-89">CA-125</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="75-82" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="52-68">ovarian carcinoma</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au814" phase="p3">
<sentence pmid="11104617.s10">Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis.</sentence>
<gene range="38-43">CA 125</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="29-36" type="Positive_regulation">elevated</expression_change_keyword_2>
<cancer_term range="0-13">Ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au815" phase="p3">
<sentence pmid="21740819.s7">The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.</sentence>
<gene range="72-94">VEGF-A protein and mRNA</gene>
<expression_change_keyword_1 range="96-105" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="62-70" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="145-158">ovarian cancer</cancer_term>
<cancer_term range="139-143">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au816" phase="p3">
<sentence pmid="21740819.s8">This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells.</sentence>
<gene range="75-80">VEGF-A</gene>
<expression_change_keyword_1 range="82-91" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="66-73" type="Negative_regulation">decrease</expression_change_keyword_2>
<cancer_term range="129-142">ovarian cancer</cancer_term>
<cancer_term range="123-127">SKOV3</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="cancerTOnormal"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au817" phase="p3">
<sentence pmid="10397458.s4">Patients with invasive ovarian cancer were found to have significantly higher median c-erbB-2 oncoprotein expression than patients with either benign ovarian cyst (P = 0.002) or control groups (P = 0.001).</sentence>
<gene range="85-104">c-erbB-2 oncoprotein</gene>
<expression_change_keyword_1 range="106-115" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="71-76" type="Positive_regulation">higher</expression_change_keyword_2>
<cancer_term range="23-36">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unidentifiable"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au818" phase="p3">
<sentence pmid="10397458.s5">Overexpression of c-erbB-2 oncoprotein was found in seven (21.9%) of 32 epithelial ovarian cancers.</sentence>
<gene range="18-37">c-erbB-2 oncoprotein</gene>
<expression_change_keyword_1 range="0-13" type="Gene_expression">Overexpression</expression_change_keyword_1>
<expression_change_keyword_2 range="0-13" type="Positive_regulation">Overexpression</expression_change_keyword_2>
<cancer_term range="72-97">epithelial ovarian cancers</cancer_term>
<cancer_term range="83-97">ovarian cancers</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au819" phase="p3">
<sentence pmid="14516936.s3">BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types.</sentence>
<gene range="0-4">BRCA1</gene>
<expression_change_keyword_1 range="6-15" type="Gene_expression">expression</expression_change_keyword_1>
<expression_change_keyword_2 range="20-28" type="Negative_regulation">decreased</expression_change_keyword_2>
<cancer_term range="91-105">ovarian cancers</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au820" phase="p3">
<sentence pmid="19935792.s5">CCBE1 is expressed in normal ovary, but is reduced in ovarian cancer cell lines and primary carcinomas.</sentence>
<gene range="0-4">CCBE1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="43-49" type="Negative_regulation">reduced</expression_change_keyword_2>
<cancer_term range="54-67">ovarian cancer</cancer_term>
<annotation>
<CGE value="decreased"/>
<CCS value="normalTOcancer"/>
<IGE value="unchanged"/>
<PT value="observation"/>
</annotation></annotation_unit>
<annotation_unit cancer_type="ovarian" id="au821" phase="p3">
<sentence pmid="19935792.s6">Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer.</sentence>
<gene range="84-88">CCBE1</gene>
<expression_change_keyword_1 range="None" type="None">
None
</expression_change_keyword_1>
<expression_change_keyword_2 range="73-82" type="Positive_regulation">re-induced</expression_change_keyword_2>
<cancer_term range="47-60">ovarian cancer</cancer_term>
<annotation>
<CGE value="increased"/>
<CCS value="unidentifiable"/>
<IGE value=""/>
<PT value=""/>
</annotation></annotation_unit>
</gene_cancer_corpus>
